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Abstract 
The receptor tyrosine kinases (RTKs) c-Kit and insulin receptor (IR) initiate similar 
intracellular signalling pathways in pancreatic beta cells to regulate beta cell 
proliferation, survival, and insulin secretion. Mice with a c-Kit overexpression 
specifically in beta cells (c-KitβTg) demonstrated improved beta cell proliferation and 
insulin secretion compared to control mice, and islets from c-KitβTg mice also 
demonstrated increased IR expression. The potential interplay between c-Kit and IR and 
their roles during ageing and metabolic stress are not currently known. This work reports 
the examination of c-Kit and IR signalling using in vitro and in vivo models to determine 
their effects on beta cell proliferation and insulin secretion.   
To examine the effects of prolonged c-Kit signalling, c-KitβTg mice were analyzed at 60 
weeks of age. The results from this section demonstrated that c-KitβTg mice developed 
impaired insulin release due to reduced soluble N-ethylmaleimide-sensitive factor 
attachment protein receptor (SNARE) expression. Increased IR and phosphorylated IRS-
1S612 and reduced insulin-induced Akt signalling were observed in islets from 60-week c-
KitβTg mice. The effect of IR deficiency was examined by knocking down beta cell IR at 
40 weeks in c-KitβTg mice and resulted in partial restoration of glucose tolerance. To 
determine the role of postnatal IR function on insulin secretion, a mouse model with beta 
cell-specific IR knockout (MIP-βIRKO) was generated and exposed to high-fat diet 
(HFD). MIP-βIRKO mice on HFD developed glucose intolerance due to reduced insulin 
secretion and SNARE expression. Islets from MIP-βIRKO HFD mice also demonstrated 
reduced Akt phosphorylation and GLUT2 levels. In vitro examination of INS-1 832/13 
cells showed that co-stimulation of c-Kit and IR with ligands stem cell factor (SCF) and 
insulin, respectively, did not lead to synergistic intracellular signalling or proliferation 
when compared to single ligand treatments. This may be due to negative feedback from 
IRS-1S612 phosphorylation, which can be inhibited with rapamycin.  
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In summary, this work presents a regulatory role for altered c-Kit and IR activity in 
maintaining beta cell intracellular signalling and insulin release. Results from these 
studies may be useful when considering RTK-based treatments to optimize islet function.   
Keywords 
Receptor tyrosine kinase, diabetes mellitus, beta cell, insulin release, c-Kit, insulin 
receptor, SNARE proteins, receptor interplay, tamoxifen-inducible Cre recombinase 
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Chapter 1  
1 Introduction1 
 
 
 
 
 
 
 
 
 
 
  
                                                 
1 Text and figures from this chapter have been adapted from the following manuscript: 
Oakie A and Wang R. -cell receptor tyrosine kinases in controlling insulin secretion and 
exocytotic machinery: c-Kit and insulin receptor. Endocrinology. 2018;159(11):3813-
3821 
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1.1 Significance of study 
Insulin production and exocytotic events from beta cells are necessary to avoid the 
development of hyperglycemia and diabetic complications. Various subfamilies of 
receptor tyrosine kinases (RTKs) are found on beta cells and on cells within the islet 
microenvironment. RTKs are required for normal pancreatic development and play a role 
in mature islet function. The receptors c-Kit and insulin receptor (IR) are present on beta 
cells and exploit similar intracellular signalling pathways to promote proliferation, 
survival, and insulin release. This study examines the role of c-Kit and IR activation on 
the regulation of beta cell function and insulin secretion using in vitro and in vivo models. 
The findings in this thesis provide new insights into the effects of RTK interplay on beta 
cell function and how RTK therapies can influence signalling pathways in islets and 
affect the long-term alleviation of hyperglycemia in diabetes. 
1.2 Islet cell biology 
1.2.1 General islet development and morphology 
The pancreas is an endoderm-derived organ that contributes to both digestive and 
endocrine functions through two distinct secretory cell types: [1] the exocrine acinar 
cells, which release digestive enzymes through the pancreatic ducts to the duodenum in 
order to aid in the breakdown of macronutrients; and [2] the endocrine cells comprising 
the islets of Langerhans, responsible for the release of hormones that regulate glucose 
availability and energy expenditure. The mature pancreas first emerges in the foregut at 
rodent embryonic day (e) 8.5 as dorsal and ventral buds that express early pancreatic 
transcription factors (TFs) pancreatic and duodenal homeobox-1 (PDX-1), SRY-box 9 
(SOX9), and pancreas associated transcription factor 1a (PTF1A) (1). By the time the two 
buds fuse at e12.5, the pancreas has formed an outer ‘tip’ layer, committed to acinar cell 
differentiation, and an inner ‘trunk’ region, where endocrine cells emerge from the early 
duct compartment (2,3). Neurogenin 3 (NGN3) TF expression in the duct promoted the 
migration of endocrine-committed cells through the mesenchyme to form initial islet 
clusters, which then undergo vascularization and TF-induced maturation to form the islet 
microenvironment (1,4,5).  
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The islets are composed of five distinct endocrine cell types that secrete specific 
hormones: alpha cells (glucagon), beta cells (insulin), delta cells (somatostatin), PP cells 
(pancreatic polypeptide), and epsilon cells (ghrelin). The ratio of each endocrine cell type 
within the islet varies drastically throughout species. However, beta cells compose the 
highest percentage of endocrine cells found in both rodent (~75-80%) and human (~55-
60%) islets (6,7). Insulin release can be regulated by hormone secretion from the other 
four cell types found in the islet. In turn, insulin exocytosis from the beta cell is able to 
prevent the release of glucagon (8,9). The islet microenvironment is therefore able to 
control insulin secretion through paracrine signalling. 
1.2.2 Beta cell transcription factors 
The temporal expression of beta cell TFs is required for beta cell commitment during 
development (1). NGN3 is the major TF that has been shown to drive the commitment of 
all endocrine cells within the islet population (10). Subsequent expression of neuronal 
differentiation 1 (NEUROD), paired box gene 4 (PAX4), NK-homeodomain factors 2.2 
and 6.1 (NKX2.2 and NKX6.1), and V-maf musculoaponeurotic fibrosarcoma oncogene 
homolog A (MAFA) during the second transition of pancreatic development (e12.5-18.5) 
are required for developing beta cells to reach a functionally mature state (11-15). Down-
regulation of beta cell-associated TFs has been shown to reduce postnatal beta cell mass 
and induce glucose intolerance in mice (16,17). The beta cell TFs examined in the 
following chapters are important for adult beta cell function and their roles in the 
postnatal beta cell are discussed in further detail below.  
Pancreatic and duodenal homeobox-1 (PDX-1) is a key TF in pancreatic development 
and is essential for maintaining Insulin (Ins) 1/2 transcription in the postnatal beta cell. 
Recent studies have identified that activation of specific enhancer regulatory areas in 
Pdx-1 were required during different stages of development and maturation, with area IV 
being key for postnatal function (18). Pdx-1 transcription was also deemed essential for 
maintaining insulin secretion in mature islets and for the expression of additional beta 
cell-associated TFs (18). 
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V-maf musculoaponeurotic fibrosarcoma oncogene homolog A (MAFA) is a beta cell-
specific TF that has been identified as an essential factor for the maintenance of beta cell 
mass and for insulin vesicle docking and release in mice following weaning (3 weeks of 
age) (15,19). Studies conducted using a beta cell-specific knockout of MAFA resulted in 
decreased beta cell mass and Cyclin D2 expression in adult islets, loss of beta cell 
identity due to dedifferentiation, and reduced glucose transporter 2 (GLUT2) expression 
in islets (17,20). Along with PDX-1 and NEUROD, MAFA has been identified as one of 
the essential TFs that interact with the insulin promoter to promote Ins1/2 transcription 
(21).   
 NK-homeodomain factor 6.1 (NKX6.1) has been identified as an essential TF for the 
maintenance of MAFA and GLUT2 expression and beta cell proliferation (16). The 
postnatal loss of NKX6.1 at approximately 4 weeks of age induced in the mature beta cell 
demonstrated a similar phenotype to mouse models with NKX6.1 lost during 
development (reduced insulin secretion and beta cell proliferation), indicating the 
importance of NKX6.1 in the maintenance of normal beta cell function (22).   
Forkhead box O1 (FOXO1) has been shown to down-regulate Pdx-1 gene expression. 
This has been reported to initiate the following: [1] inhibition of beta cell emergence 
during development; [2] decreased proliferation of mature beta cells; [3] reduced 
expression of the Insulin2 gene; and [4] induction of endoplasmic reticulum (ER) stress 
and subsequent beta cell apoptosis through binding to the Chop promoter (23-27). 
FOXO1 also inhibited peroxisome proliferator-activated receptor  (PPAR), which 
further contributed to impaired proliferation and compromised glucose tolerance (28). 
However, increased nuclear FOXO1 expression in beta cells during oxidative stress has 
been found to up-regulate beta cell MAFA expression, which led to improved glucose 
tolerance (29-31). These findings suggest that FOXO1 also maintains a protective role in 
diabetic islets until its eventual down-regulation in failing beta cells (29,32). 
1.2.3 Regulation of beta cell mass 
The endocrine cells that comprise adult islets first emerge during the second transition 
(e12.5) of murine pancreatic development and form islet clusters through beta cell 
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neogenesis from the trunk compartment (33). At postnatal day (p) 0, the neonatal rodent 
pancreas undergoes a period termed ‘beta cell remodeling’, where both high beta cell 
neogenesis and apoptosis are present and result in a maintained beta cell mass until 
weaning (p20) (33,34). A similar period of remodeling was identified in the developing 
human pancreas, where beta cell turnover occurred from 15 weeks of fetal age to 2 
months postnatal age after expansion of the beta cell mass from 8-21 weeks of fetal age 
(35,36). The remodeling phase can also exhibit high beta cell regeneration capacity as 
seen in studies utilizing streptozotocin (STZ)-induced destruction of beta cells (37,38). 
After the remodeling phase is complete, beta cell expansion is maintained through 
proliferation and is regulated by the expression of Cyclin D cell cycle proteins (39-41). 
The replication of existing beta cells is the most frequently reported mechanism of beta 
cell generation in the adult rodent islet (42). Rodent beta cells maintain their replicative 
expansion throughout their lifespan and undergo proliferation multiple times, although 
their observed frequency of replication has been shown to decrease with age (43). 
Reported beta cell proliferation rates are low (<1%) in adult (6-week) mice and have been 
observed to be lower than 0.1% in mice over 7 months of age (44,45). However, dietary 
stress and obesity in rodents have been shown to induce beta cell mass expansion due to 
the increased demand for insulin to overcome elevated glucose levels. Beta cell 
hyperplasia in high-fat diet (HFD) mouse models occurred within the first week of HFD 
initiation but was lost as cells underwent apoptosis with prolonged feeding (46-48). 7- to 
8-month old mice also did not demonstrate HFD-induced beta cell expansion, which 
demonstrates an age-dependent loss of beta cell compensatory proliferation (45).  
Although beta cell neogenesis has not been observed in unchallenged islets, it has been 
reported to occur with injury-induced pancreatic damage. Ductal ligation, a technique 
where 50-60% of the pancreas (gastric and splenic segments) is subjected to acinar 
destruction due to blocked ductal drainage, has been shown to contribute to islet 
neogenesis through ductal cell reprogramming (49,50). Regulation of the postnatal and 
ageing beta cell compartment can therefore be altered by metabolic challenges and 
injuries. 
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1.3 Mechanisms of insulin section in beta cells 
1.3.1 Glucose-stimulated insulin secretion 
The major physiological mechanism that induces insulin secretion is increased 
intracellular glucose levels. Glucose-stimulated insulin release is a biphasic response that 
has two distinct phases: first-phase insulin secretion, which peaks approximately 5 
minutes after glucose challenge and releases 0.15% of the total insulin content per minute 
per beta cell, and second-phase insulin secretion, which begins 10 minutes after glucose 
challenge and releases 0.05% of the total insulin content per minute per beta cell (51). 
Glucose stimulation induces a multiple step process, which is outlined in the following 
sections: 
1) Glucose entry and glycolysis 
Unstimulated beta cells have a resting membrane potential between -56 to -75 mV (52). 
Glucose initially enters the beta cell through the glucose transporter GLUT1 (human) or 
the lower affinity transporter GLUT2 (rodent) (53), located on the lateral membrane of 
beta cells (54). The expression of glucose transporters is essential for the rapid release of 
insulin associated with the first phase of exocytosis (55). Glucokinase primarily serves as 
a sensor for intracellular glucose levels in beta cells (56). The influx of glucose into beta 
cells initiates glycolysis, producing ATP and initiating membrane depolarization (57).  
2) Potassium channel –induced depolarization and calcium influx 
Beta cells express ATP-sensitive potassium (KATP) channels on their membrane 
composed of four sulfonylurea receptors (SUR1) and four inward rectifying potassium 
6.2 (Kir6.2) isoforms, with each SUR1 unit linked to one pore-forming Kir6.2 unit in 
order to create a functional channel (58,59). ATP binds to the Kir6.2 subunits and inhibits 
the potassium channel, preventing K+ efflux that promotes depolarization and Ca2+ influx 
(60). Maintaining the expression of both SUR1 and Kir6.2 in KATP channels is required 
for physiological control of insulin secretion under low and high glucose conditions as 
previously observed in knockout mouse models (61-63). Extracellular Ca2+ influx 
through channels located on the cell membrane increases cytosolic Ca2+ levels, priming 
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the beta cell for insulin exocytosis from docked vesicles close to Ca2+ channels (64-67). 
The ryanodine receptors (RyR) found on the endoplasmic reticulum (ER) can regulate 
Ca2+ levels in both the ER and cytosol, which affect insulin secretion and mitochondrial 
function (68).  
3) Cytoskeletal remodeling and exocytosis of insulin vesicles through SNARE machinery 
assembly 
Increased intracellular Ca2+ in beta cells induces phosphorylation of focal adhesion kinase 
(FAK) and paxillins, components of the focal adhesion complex, which leads to actin 
depolymerization and remodeling (69). Gelsolin is activated by calcium and is involved 
in the remodeling process for glucose-stimulated insulin secretion (70). Soluble N-
ethylmaleimide-sensitive factor attachment receptor (SNARE) protein assembly allows 
for vesicle tethering and is a necessary step involved in insulin release. The assembly of 
SNARE complexes at the beta cell membrane consists of two synaptosome-associated 
protein 25 (SNAP25), one syntaxin protein, and one vesicle-associated membrane protein 
(VAMP), with mammalian homologue of uncoordinated 18 (MUNC18) proteins serving 
to stabilize the formed complex (71). The first and second phases of insulin secretion 
involve specific SNARE isoforms (Table 1.1). Although SNARE proteins are found 
throughout the beta cell membrane, insulin vesicles are released on the vascular-facing 
side of the beta cell (72). Syntaxin 1A has also been shown to bind to and inhibit KATP 
channels, which demonstrates that SNARE proteins can play multiple roles during insulin 
secretion (73,74). Synaptotagmins found on the insulin vesicle are Ca2+ sensor proteins 
that facilitate SNARE complex-beta cell membrane contact and results in insulin 
exocytosis (71,75).  
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Table 1.1: SNARE protein isoform assembly during insulin secretion.  
 
  
	
 
Isoform Phase Key roles (associated SNAREs) Refs 
 
Munc18-1 
 
First 
 
Located on cell membrane and cytoplasm. Required for docking of 
granules during first-phase secretion (Syntaxin-1a, Syntaxin-4) 
 
(76) 
Munc18-2 Both Involved in vesicle fusion to beta cell membrane and to other 
insulin secretory granules (Syntaxin-2, Syntaxin-3) 
(77) 
Munc18-3 Second Required for docking of newcomer granules (Syntaxin-4) (78) 
 
Syntaxin-1a 
 
Both 
 
Responsible for granule docking of readily releasable pool and 
newcomer granule pool. Highly associated with first-phase insulin 
release (VAMP2, VAMP8, MUNC18-1, SNAP25) 
 
(79-
81) 
Syntaxin-2 Both Located on secretory insulin granules. Inhibitory: reduces fusion of 
readily releasable pool and newcomer granule docking (MUNC18-
2, SNAP23, SNAP25, VAMP2, VAMP8) 
(82) 
Syntaxin-3 Both Located on secretory granules. Fusion of newcomer granules to 
beta cell membrane and to other insulin granules (VAMP8) 
(83) 
Syntaxin-4 Both Released from gelsolin binding upon glucose stimulation. Granule 
docking of readily releasable pool and newcomer granule pool 
(VAMP2, VAMP8, MUNC18-3) 
(84,85) 
 
SNAP23 
 
First 
 
Inhibitory: reduces docking and fusion of the readily releasable 
pool granules by replacing SNAP25 in formation of SNARE 
complex (Syntaxin 1a, VAMP2) 
 
(86) 
SNAP25 Both Localized to the cell membrane. Involved in the docking of readily 
releasable insulin granules (Syntaxin-1a to 4, VAMP2 and 8, 
MUNC18-1-3) 
(87) 
 
VAMP2 
 
Both 
 
Present on insulin secretory granules. Tethers to syntaxin-SNAP 
complexes for vesicle docking (Syntaxin 1a, Syntaxin 2, Syntaxin 
4). 
 
(88,89) 
VAMP8 Both Interacts with SNARE proteins to initiate GLP-1 and glucose-
induced release of short-lived docked newcomer granules (Syntaxin 
1a) 
(79,90) 
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1.3.2 Intracellular signalling pathways in beta cell insulin secretion 
The activation of multiple signalling pathways can induce insulin secretion from beta 
cells. The phosphatidylinositol 3-kinase (PI3K)−Akt signalling axis has been shown to 
promote beta cell survival and increase proliferation through increased Cyclins D1 and 
D2 levels (40,91). Loss of class IA PI3Ks in beta cells reduced intracellular Ca2+ levels 
and SNARE proteins, which ablated insulin exocytosis (92). The α isoform of class II 
PI3Ks has also been linked to downstream Akt1 activation and glucose-stimulated insulin 
release (93). FAK-induced cytoskeletal remodeling and insulin vesicle trafficking has 
been shown to stimulate the phosphorylation of the Akt−AS160 complex, responsible for 
stimulating glucose-induced insulin release (94-96). Interestingly, the selective PI3K 
inhibitor LY294002 has been found to increase glucose-stimulated insulin release 
through KV channel inhibition in rat insulinoma line INS-1 832/12 cells (97,98), and 
inhibition of this pathway has been linked to increased insulin exocytosis (99). Further 
support for an inhibitory role of the PI3K−Akt pathway was found in experiments that 
suppressed the p85 regulatory subunit of PI3K, which resulted in enhanced insulin 
release (100). Taken together, the activation of the PI3K−Akt pathway appears to have 
differing effects on insulin secretion, yet it likely remains an important regulator of 
exocytosis in beta cells. 
The mitogen-activated protein kinase (MAPK) pathway is another signalling cascade 
linked to insulin secretion. Extracellular signal-regulated kinase (ERK), part of the 
MAPK pathway, has been shown to be required for glucose- and secretagogue-induced 
insulin release (101,102). Cytoskeletal remodeling, which is critical for exocytosis during 
the second-phase of insulin secretion, required signalling through the MAPK−ERK 
pathway (103). Phosphorylated FAK has been shown to stimulate ERK phosphorylation 
and induce the release of insulin (69). Interestingly, phosphorylated ERK proteins, 
triggered by chronic high glucose levels, led to reduced insulin secretion and was not 
restored by ERK inhibition despite normalized actin cytoskeletal dynamics (104). These 
studies are informative in understanding ERK signalling in relation to cytoskeletal 
remodeling and insulin release but further research is required to fully elucidate its role. 
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1.4 Etiology of diabetes mellitus 
Diabetes mellitus is a metabolic disorder that is characterized by high circulating glucose 
levels. Diabetes may be caused by either insufficient insulin production or a defect with 
insulin signalling, classified as Type 1 (T1DM) or Type 2 (T2DM), respectively. Both 
types of diabetes result in beta cell failure and apoptosis, resulting in a lack of 
endogenous insulin production (105). The predicted rate of global diabetes diagnoses in 
patients over 18 years was approximately 451 million people in 2017 and is currently 
predicted to reach 693 million people by the year 2045 (106). The estimated economic 
burden from this disease has also been predicted to reach approximately $2.5 trillion 
dollars by 2030 (107). In addition to the loss of normoglycemia and the development of 
metabolic dysregulation, diabetes can promote vascular disorders that result in 
cardiovascular complications and peripheral tissue damage (neuropathy, nephropathy, 
and retinopathy) (108). The two major types of diabetes mellitus, Type 1 and Type 2, are 
discussed in detail below. 
1.4.1 Type 1 diabetes mellitus 
T1DM develops from the autoimmune recognition and destruction of a patient’s beta 
cells. Up to 90% of the functional beta cell mass is lost and patients require an exogenous 
source of insulin to maintain normoglycemia. A genetic association between first-degree 
family members and the inheritance of the disease has been found to exist (109). 
Environmental factors have also been suggested to induce beta cell destruction (110). 
Islets in T1DM patients were found to be infiltrated by multiple immune cells including 
T-cells (CD4+ and CD8+), B-cells (CD20+), and macrophages (CD68+) (111). In the 
initial stages of T1DM, proteins that are produced by beta cells are recognized as 
autoantigens through antigen presentation (112). Examples of candidate autoantigens 
include a peptide sequence in the B chain of insulin, zinc transporter ZnT8, and 
chromogranin A (113-115). The inheritance of certain antigen presenting haplotypes, 
such as HLA-DQ8, have been shown to induce autoimmunity and present select C-
peptide epitopes to CD4+ cells (110,116). As autoantigens induce immune cell migration, 
the progressive islet infiltration with CD45+ (leukocyte) cells has been shown to destroy 
the surrounding islet basement membrane, which contributes to the progressive loss of 
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islets (117). Beta cells are then lost through the induction of apoptotic pathways, 
including CD8+-induced perforin and granzyme B release, increased Fas receptor-
induced Caspase 8 activation, and cleaved Caspase 3 activation (105). 
One study was able to identify INSULIN mRNA in the pancreatic tissue of T1DM 
patients even when there was an insufficient number of mature beta cells (118). Insulin 
secretion from the islets of T1DM patients followed a similar response when compared to 
control islets and normalized to total insulin content, indicating that the function of 
remaining beta cells in T1DM may not be damaged (119). Non-obese diabetic (NOD) 
mice also displayed an immature population of beta cells that are preserved from immune 
cell-mediated apoptosis (120). 
1.4.2 Type 2 diabetes mellitus 
Similar to T1DM, T2DM is associated with elevated circulating glucose levels. However, 
the pathogenesis of the disease is different from the autoimmune attack observed in 
T1DM. Genetic variants as well as nutritional and lifestyle conditions, resulting in 
obesity, are established links to the development of T2DM (51). T2DM patients develop 
insulin resistance in peripheral tissue sites, including the skeletal muscle, adipose tissue, 
and liver, that are important for the control of glucose reuptake (insulin-induced GLUT4 
up-regulation in adipocytes and skeletal muscle) and circulating glucose regulation (121). 
This results in increased beta cell mass and proliferation through the replication of pre-
existing beta cells (122,123). Unfortunately, it has been noted that many beta cell 
complications arise with prolonged exposure to hyperglycemia in insulin-resistant 
patients. Excess glucose and free fatty acids have been shown to induce oxidative and ER 
stresses in the beta cell, which resulted in misfolded proteins and the induction of 
apoptosis (124). Increased islet vasculature was also shown in obese and T2DM mouse 
models, which may facilitate infiltrating macrophages and the development of subsequent 
islet inflammation (125,126). One of the common histological markers exclusively 
associated with T2DM in humans is the accumulation of islet amyloid polypeptide 
(IAPP) plaques in the islet microenvironment, which has been reported to promote beta 
cell apoptosis through enhanced ER stress (127). Islets from T2DM patients also 
demonstrated a loss of essential SNARE proteins involved in insulin vesicle tethering and 
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exocytosis (128,129). Recent evidence confirmed that T2DM islets have reduced vesicle 
docking when stimulated with glucose (130). Although weight loss induced through 
nutritional and lifestyle interventions has been shown to improve the liver and pancreas 
fat content and return glucose-stimulated insulin secretion to some obese T2DM patients, 
a significant proportion of patients were unable to regain the same insulin secretory 
function, indicating that the alleviation of obesity-induced metabolic stresses may not be 
sufficient to rescue beta cell dysfunction in all patients (131). 
Diet-induced obesity mouse models have been used to examine the progression of beta 
cell compensation and failure in a T2DM-like model. It has been shown that feeding 
C57BL/6 mice a high-fat diet (HFD), in which 60% of total available kcal is derived from 
fat, for a 12 to 16-week duration induced multiple metabolic changes that manifested as 
glucose intolerance and peripheral insulin resistance (132). The accumulation of 
metabolic stresses in glucose-regulating peripheral tissues and reduced insulin sensitivity 
in HFD-fed mice resulted in hyperinsulinemia in order to maintain normal glycemic 
levels (133). The increased insulin demand induced in long-term HFD mice also led to 
the progressive loss of beta cell TFs and increased ER stress (134).   
1.4.3 Potential therapeutics for insulin restoration 
Diabetic patients that require an exogenous source of insulin to maintain normal glucose 
levels are required to monitor their blood glucose levels and regulate their insulin 
administration through injection or abdominal pump delivery. However, the optimal 
treatment would be the design of a user-independent system where patients would not be 
required to regulate their insulin input. The most promising form of endogenous insulin 
restoration is islet transplantation. This technique, known as the Edmonton Protocol, was 
first published in 2000 and involved the isolation of islets from two or more cadaveric 
donor pancreata and the infusion of these islets into the hepatic portal vein (135). Recent 
experiments have also examined the omentum, a peritoneal organ rich in vascularization, 
as an ideal site for islet transplantation since it is able to maintain insulin secretion while 
avoiding the toxic environment of the hepatic portal vein (136). Although there were 
promising results achieved with the Edmonton Protocol in the initial time following its 
publication, many limitations had developed at later time-points following 
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transplantation. A large pool of donor islets (minimum of 9000 islets per kilogram of 
body weight) was identified as a requirement for successful insulin independence in 
diabetic patients (137). Furthermore, the ability of transplanted islets to relieve patients of 
exogenous insulin has been shown to decrease over a 5-year period, with 90% of 
transplanted islet recipients requiring exogenous insulin delivery at 5 years (138). Other 
therapies are currently being researched to alleviate these limitations. The management of 
insulin deficiency in patients through the use of an ‘artificial pancreas’ has gained more 
traction in the past few years. Both single hormone (insulin only) and dual hormone 
(insulin and glucagon) artificial pancreas devices managed to achieve optimal glucose 
levels when compared to conventional insulin pump therapy (139). T1DM patients have 
also been treated with immunoglobulin therapy, which is aimed at targeting the T-cell 
autoimmune attack against beta cells. Although normoglycemia can be achieved by 
preventing the elimination of the patient’s beta cell mass, the frequent recurrence of T-
cell-mediated beta cell destruction has been noted with this treatment (140). When 
considering all available therapies, it is evident that maintaining beta cell mass and 
function is required to produce sufficient insulin in patients. The maintenance of islet 
function can be achieved under normal conditions through receptor activation and 
intracellular signalling, and examining the interplay of receptor activation and signalling 
in beta cells could provide information for the development of future therapies. 
1.5 Receptor tyrosine kinases 
1.5.1 General structure of RTKs 
RTKs are a class of cell membrane receptors that are subdivided into 20 distinct families. 
The structural composition of the extracellular region varies between each receptor class 
and can include repeats of a single type of molecule (e.g. class III/IV receptors with 
immunoglobulin-rich domains) or different molecular components (e.g. class II receptors 
with cysteine-rich domains, L domains, and fibronectin type III domains) (141,142). 
RTKs contain a single transmembrane region and an intracellular region consisting of 
tyrosine residues. RTKs exist as monomers and dimerize upon ligand binding, with the 
exception of class II receptors insulin receptor (IR) and insulin-like growth factor 1 
receptor (IGF-1R) that remain heterodimeric in the absence of ligands (141). In their 
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activated state, the intracellular region of RTKs undergo conformational changes and 
autophosphorylation of tyrosine kinase residues, which leads to the initiation of 
intracellular signalling through proteins containing regulatory phosphotyrosine-binding 
domain (PTB) or Src homology 2 (SH2) regions (e.g. the p85 regulatory unit of PI3K) 
(141,143-145). Activation of these signalling proteins can also be initiated through the 
binding of corresponding adaptor and scaffold proteins, which dock to the tyrosine 
residues and regulate multiple downstream signalling pathways (144). Adaptor and 
scaffold proteins that control intracellular signalling through RTK phosphorylation 
include Shc, the Growth factor receptor bound protein (Grb) family, Src homology-2 
domain containing protein B (SHB), adaptor protein with a PH and SH2 domain (APS), 
and insulin receptor substrates (IRS) (144,146). Many of these proteins regulate insulin 
secretion and insulin sensitivity (147-151), highlighting the importance of RTK-initiated 
signalling in the islet microenvironment. 
1.5.2 Expression of islet RTKs 
Cells in the islets express various RTKs that regulate beta cell proliferation, function, and 
insulin synthesis and secretion (Figure 1.1). Pancreatic development is one process that 
relies on the expression of multiple RTKs to achieve islet maturation. Epidermal growth 
factor receptor (EGFR) expression is required for embryonic beta cell maturation, islet 
migration, and maintenance of beta cell mass and proliferation (152,153). Other members 
of the ErbB receptor family are also present during murine pancreatic development (154). 
The receptor for nerve growth factor (NGF), tropomyosin receptor kinase-A (Trk-A), 
follows a specific pattern of expression within endocrine cells that is dependent on the 
stage of embryonic development (155). Discoidin domain receptor tyrosine kinase 1 
(DDR1) has recently been identified during early pancreatic development in emerging 
endocrine cells and in injury-induced ductal ligated pancreata (156). Platelet-derived 
growth factor receptor (PDGFR), which shares structural homology to c-Kit, 
demonstrated islet proliferation with activation (157). The contributions of c-Kit and IR 
to beta cell development and postnatal function are discussed in subsequent sections.   
The current literature regarding RTK expression on the non-beta islet endocrine cells is 
limited. Unlike the receptor for insulin, the receptors for other islet hormones belong to 
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the G protein-coupled receptor (GPCR) family (158,159). The presence of IR has been 
confirmed on alpha cells and is required for cell proliferation and glucagon secretion 
regulation through the Akt/P70S6K1 axis (160,161). IR expression is also found in 
isolated single delta cells from human islets and in the somatostatin-secreting TGP52 cell 
line (162,163). Recent findings have identified that glucagon release from alpha cells can 
be manipulated through the erythropoietin-producing hepatoma A (EphA) receptor, a 
RTK class that is unique due to ‘forward’ and ‘reverse’ signalling through beta cell-beta 
cell and beta cell-alpha cell receptor-ligand interactions (164,165). However, the 
presence of RTKs and their activity in non-beta cell endocrine cells requires further 
investigation. 
RTKs are also implicated in integrin-extracellular matrix (ECM) communication and islet 
vascularization. One study identified that beta cell fibroblast growth factor receptor 1 
(FGFR1) increased ERK phosphorylation in beta cells, but its activation depended on the 
binding of 61 integrin to specific ECM ligands produced by endothelial cells (166). 
This coordinated activity enhanced both islet-microvasculature remodeling and beta cell 
insulin secretion and survival (167). Vascular endothelial growth factor (VEGF) has also 
been shown to be released by beta cells and to bind to its receptor (VEGFR) on islet 
endothelial cells to promote angiogenesis. Reduced islet vascularization, decreased beta 
cell mass, and impaired insulin and glucagon secretion were noted in mice with beta cell 
VEGF-A loss during embryonic development (168-170). While VEGF-A inactivation in 
the postnatal adult beta cell also lowered islet vascularization after 3 months, these mice 
developed mild glucose intolerance and had unchanged beta cell mass (169). These 
results indicate that islet endothelial cell regulation of beta cell mass occurred during 
select developmental time-points. Hypervascularization of the islets through enhanced 
VEGFR expression can also detrimentally affect beta cell survival and lead to the 
development of hyperglycemia. Overexpression of VEGF-A during islet development or 
induced in adult beta cells led to enhanced endothelial cell density, but this expansion 
impaired the formation of islet clusters and decreased beta cell proliferation and mass in 
both mouse models (171,172). NOD mice also demonstrated increased VEGF-A 
production from beta cells, which increased the expression of VEGFR on endothelial 
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cells and subsequently led to islet inflammation and T-cell-mediated beta cell destruction 
(173).  
In addition to controlling overall islet function, the activation of certain RTKs can 
directly regulate insulin release. NGF signalling has been shown to promote Trk-A 
internalization, F-actin reorganization, and insulin exocytosis, which maintained glucose-
stimulated insulin secretion in mouse islets (174-176). Signalling through the c-Met 
receptor has also been observed to regulate secretion. Its disruption in murine beta cells 
resulted in impaired insulin release with minimal effect on islet morphology (177). IGF-
1R, which shares structural homology with IR, is required for glucose-stimulated insulin 
release and glucose sensing through the maintenance of GLUT2 expression (178,179). 
FGF-21, through binding to its receptor, stimulated insulin release from isolated islets of 
diabetic rodent models under high glucose conditions (180). RTKs have further been 
found to play a role in the negative feedback of insulin release, as observed with 
bidirectional signalling through EphA (164,181). Examining the role of RTKs signalling 
in insulin secretion is therefore important when determining their contribution towards 
maintaining glucose homeostasis.   
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Figure 1.1: Summary of reported RTKs in the islet microenvironment. 
The mature murine islet is composed of insulin-secreting beta cells in the core of the islet 
(blue) and other endocrine hormone–secreting cells along the islet’s periphery (red). Beta 
cells express multiple RTKs that influence their growth and development. The direct 
effect of specific RTK activation on insulin secretion has been previously demonstrated. 
Beta cells regulate and are also influenced by RTKs expressed on islet vasculature.  
  
  
 
18 
1.6 c-Kit receptor 
1.6.1 Receptor structure and activation 
The c-Kit (CD117 or Kit) receptor is a 21-exon class III RTK located on the Kit/W locus 
of chromosome 5 in mice (chromosome 4 in humans) (182). The extracellular portion of 
the receptor is composed of five immunoglobulin (Ig)-like domains (183). c-Kit interacts 
with the ligand stem cell factor (SCF), a 9-exon growth factor expressed from the Steel 
locus (chromosome 10 in mice and 12 in humans) (184,185). SCF is produced as a cell 
membrane-bound ligand with two different isoforms: one that contains exon 6 and one 
that is lacking exon 6 (185). SCF isoforms containing exon 6 have a proteolytic cleavage 
site that is susceptible to cleavage by proteases, producing a soluble form of the ligand, 
while SCF lacking exon 6 would be a solely membrane-bound ligand (185,186). These 
forms of SCF have been found to have differing functions in vitro, where the membrane-
bound form of SCF promoted sustained c-Kit phosphorylation while the soluble form 
promoted receptor internalization (187-189). In order to stimulate c-Kit dimerization, 
SCF itself must form a homodimer (190). SCF dimers interact with the first 3 Ig-like 
domains (N-terminal) of the extracellular portion of c-Kit to allow for receptor 
dimerization of the remaining two Ig-like domain regions (183). Once SCF-induced c-Kit 
dimerization has been initiated, the intracellular region tyrosine residues Y568 and Y570 
are phosphorylated and initiate intracellular signalling through multiple subsequent 
tyrosine residues (141,185). c-Kit phosphorylation promotes downstream intracellular 
signalling through different pathways, including PI3K−Akt, MAPK−ERK, and 
phospholipase C-1 (PLC-) pathways, in various cell types (191-194).   
Early studies tracing the expression of c-Kit during murine organogenesis using LacZ 
labeling identified multiple cell types, including hematopoietic cells, germ cells, 
melanocytes, and intestinal cells (195,196). Various mutations in the intracellular region 
of c-Kit have been well-characterized, with missense loss-of-function mutations at select 
sites leading to death shortly after birth in mice (182). In contrast, mutations in the 
intracellular region that are associated with constitutive activity are associated with the 
development of neoplasia (197). 
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1.6.2 c-Kit activity in the islet 
c-Kit is expressed in human and murine beta cells and is also present in pancreatic 
carcinoma-derived cell lines (195,198-200). Similar to the islet RTKs discussed above, c-
Kit expression is high in embryonic and developing endocrine cells, yet expression of the 
receptor is reduced to a small subpopulation (10-20%) of beta cells in postnatal and adult 
rodents (195,200,201). The role of c-Kit signalling in maintaining beta cell survival and 
function has been studied in both in vitro and in vivo models (Figure 1.2). SCF treatment 
increased insulin expression in the human pancreatic ductal carcinoma PANC-1 cell line, 
implicating its role in beta cell development (195,198). Silencing of the c-Kit receptor 
using in vitro siRNA administration has also demonstrated that it is required to maintain 
both PDX-1+ and insulin+ cell expression, cell proliferation, and cell survival in human 
fetal islet-epithelial cell clusters (200). c-Kit activity in islet function and insulin 
secretion have been further examined in vivo using mouse models with either a point 
mutation or an over-expression of c-Kit. The c-KitWv/Wv mouse line has been previously 
used as a global c-Kit-deficient mouse model since a point mutation located in the 
intracellular site of the receptor produced mice with almost no functional receptor activity 
(182). Interestingly, c-KitWv/+ mice displayed reduced islet insulin content and glucose-
stimulated insulin secretion (202). This impaired insulin release was associated with 
reduced signalling through the c-Kit−Akt−glycogen synthase kinase-3 (GSK3) 
pathway, reduced mature beta cell transcription factors, and increased apoptosis through 
Fas receptor−p53−caspase-3 activation (203,204). In contrast to the c-KitWv/+ model, mice 
with a beta cell-specific overexpression of the human c-KIT receptor (c-KitβTg) had 
markedly improved islet mass, proliferation, and insulin release as well as increased 
phosphorylation of Akt at serine 473 when compared to wild-type controls (205). 
Increased vascularization was also noted in the islets of c-KitβTg mice with increased 
beta cell VEGF-A production, which promoted insulin secretion in control diet mice. 
However, inflammation-induced beta cell apoptosis and islet dysfunction were observed 
when these mice were subjected to 22 weeks of HFD feeding (199,205). In summary, 
information gathered through in vivo studies has demonstrated that c-Kit signalling is 
required for beta cell development, survival, and function, but that prolonged activation 
of the receptor may promote detrimental effects under metabolic stresses.   
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Figure 1.2: Summary of established c-Kit signalling pathways in the beta cell. 
c-Kit has been shown to induce multiple intracellular signalling pathways, including 
MAPK−ERK, Akt, and PLC-. The Akt signalling pathway is of interest to this thesis due 
to its previously determined role in beta cell function. A schematic illustrating the main 
findings from our laboratory is provided above (206). Numbers within brackets indicate 
the position of the residue that is phosphorylated. [Y, tyrosine; S, serine].  
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1.6.3 The role of c-Kit on insulin release 
c-Kit activation in beta cells has been established to increase insulin production and 
release, but the exact role of c-Kit signalling on the exocytosis of insulin is unknown 
(205). The secretory control of granules from mast cells through c-Kit activation has been 
extensively assessed, where histamine and interleukin 6 (IL-6) release were shown to be 
stimulated with SCF administration (207,208). In mast cells, c-Kit stimulated PI3K 
pathway signalling and cytoskeletal remodeling to promote granule secretion (209,210). 
Mice with a mutation that rendered c-Kit inactive exhibited reduced downstream 
PI3K−Akt signalling and decreased granule release response from mast cells (211). 
Although the direct role of c-Kit signalling on the regulation of beta cell insulin granule 
exocytosis has not yet been documented, our group has previously found increased 
insulin release in c-KitβTg mice (203,205). In light of these results, additional research is 
warranted to determine whether c-Kit directly regulates vesicle release in beta cells or 
requires the assistance of additional beta cell RTKs. 
1.7 Insulin receptor 
1.7.1 Receptor structure and activation 
Insulin receptor (IR, CD220) is a heterodimeric receptor that is 22 exons long and is 
located on chromosome 8 in mice and chromosome 19 in humans (212,213). IR is a 
dimer made up of two alpha chains (extracellular domain) and two beta chains 
(extracellular, transmembrane, and intracellular domains) linked by disulfide bonds 
(214). The extracellular domain of the receptor is composed of two leucine-rich repeat 
domains surrounding one cysteine-rich region towards the N-terminal, type III 
fibronectin domains, and insert domains where the alpha and beta chains are bound (214). 
IR in its non-stimulated state is inhibited by the activation loop of the intracellular region 
of the receptor (141). The binding of insulin to IR leads to phosphorylation of Y1146, 
Y1150, and Y1151 residues in the kinase regulatory region and activates the intracellular 
portion of the receptor (215). The two functional isoforms of IR found in the islet are IR-
A and IR-B. The difference in the isoforms is the inclusion (IR-B) or exclusion (IR-A) of 
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exon 11 (216). IR-B has been reported to be the dominant IR isoform in beta cells, while 
IR-A is expressed in alpha cells and a smaller percentage of beta cells (163). 
The insulin gene is located on chromosome 11 in humans. However, mice have two 
nonallelic insulin genes lying on chromosomes 19 and 7 (217,218). These two genes 
encode for Insulin 1 and Insulin 2, with Insulin 2 displaying higher expression in the beta 
cell and detectable expression in the hypothalamus (219,220). Insulin mRNA is translated 
to preproinsulin before proinsulin formation in the rough ER (disulfide bonds directly 
joining A and B chains with a C chain located between the two), and is processed to its 
mature monomer form in the Golgi apparatus through C chain removal (C-peptide) via 
prohormone convertase 1/3 (221). The affinity of insulin for its receptor is low 
(approximately 18.4 pmol/L for human IR-A and 22.7 pmol/L for human IR-B) (222). 
Insulin-like growth factors (IGF-1 and -2) are also able to bind to IR-A due to the lack of 
exon 11 in this isoform (approximately 863 pmol/L for IGF-1 and 95.3 pmol/L for IGF-
2) (222,223). 
1.7.2 IR signalling on glucose regulation 
IR knockout in murine models has demonstrated drastically different effects based on the 
severity of its loss. Mice homozygous for a mutation in the IR intracellular kinase region 
died shortly after birth due to hyperglycemia and ketoacidosis but heterozygous mice 
displayed a lifespan and glucose tolerance similar to wild-type litter-mates, although this 
may be due in part to high insulin levels in heterozygous mice (224,225). The IR−insulin 
pathway is required for normal and controlled islet cell development, and mouse models 
with either a loss of insulin (Ins1-/-, Ins2-/-) or a loss of beta cell IR (MIP-βIRKO) 
demonstrated islet hyperplasia and vascularization by the end of embryonic development 
(e18.5-e20.5) (226,227). The earliest study of mice with a beta cell-specific IR knockout 
(βIRKO) demonstrated that mice suffered from the loss of beta cell mass, beta cell 
GLUT2 expression, and first-phase insulin secretion, leading to the development of 
glucose intolerance and overt diabetes in 7-month old βIRKO mice (228,229). The 
expression of IR on peripheral tissue types can also influence the maintenance of 
normoglycemia due to the lack of IR-induced glucose reuptake. Hepatocyte IR knockout 
mice displayed an insulin resistance-like phenotype with increased glucose intolerance 
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(230). In contrast, mice with a skeletal muscle cell-specific IR knockout were able to 
maintain normoglycemia (231). The knockout of IR specifically on adipocytes of 8-week 
old mice promoted a compensatory increase in islet mass and hyperinsulinemia following 
a brief period of glucose intolerance (232). 
The capacity to affect glucose tolerance, beta cell survival, and insulin secretion is also 
shared with IGF-1R−IGF-1 signalling. However, manipulations to the IGF-1R−IGF-1 
pathway did not affect beta cell mass, unlike that observed with IR−insulin signalling 
(178,233). Signalling through the IGF-1R axis may partially compensate for the loss of 
IR as mice with a loss of both receptors on the beta cells showed severe glucose 
intolerance compared to mice with a loss of either IR or IGF-1R alone (234).  
1.7.3 Insulin receptor substrates 
Insulin receptor substrates (IRS) are a class of docking proteins that bind to the 
phosphorylated intracellular region of IR, inducing interactions with SH2-containing 
proteins (235). To date, a total of six IRS proteins have been identified in rodents and 
humans, yet IRS-1 and IRS-2 are the only major substrates currently shown to play a 
major role in beta cell function (236). Beta cell IRS-1 loss (Irs-1-/-) in mice was linked to 
a mild change in pancreatic beta cell mass and stunted insulin secretion due to reduced 
sarco-endoplasmic reticulum Ca2+ ATPase (SERCA) expression (237,238). IRS-2 was 
found to be important for maintaining beta cell mass and proliferation and for promoting 
compensatory beta cell hyperplasia in HFD-treated mice (239,240). In addition, inducing 
IRS-2 expression exclusively in the beta cells of Irs-2-/- mice maintained normoglycemia 
even with global IRS-2 loss, highlighting the importance of these insulin substrates in 
maintaining the insulin−IR−IRS axis in islets (241).  
Docking of IRS-1 to the phosphorylated region of IR resulted in the tyrosine (Y) 
phosphorylation of the substrate, which then interacted with the p85 subunit of PI3K and 
promoted downstream phosphorylation of Akt, mTOR, GSK3β, and P70S6K1 (235,242). 
Interestingly, downstream signalling from phosphorylated IRS tyrosine sites resulted in 
negative feedback phosphorylation of serine (S) and threonine (T) sites on IRS-1, which 
has been shown to cause signalling disruption of phosphorylated tyrosine IRS residues 
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and down-regulate their association with PI3K (243,244). This negative feedback on IRS 
is hypothesized to be initially initiated through maintained PI3K−Akt−mTOR pathway 
signalling and can be prevented with the mTOR inhibitor rapamycin (151,245). The over-
activation of the IR−IRS pathway and signalling through the PI3K−Akt pathway 
demonstrated a reduction of both IRS-1 and IRS-2 and compromised insulin−IR−IRS 
signalling (246,247).  
1.7.4 The role of IR signalling on insulin secretion 
In contrast to c-Kit, numerous studies have examined the capacity of IR activation to 
stimulate insulin release. There is little consensus on the role of insulin-stimulated insulin 
secretion since multiple studies have presented both stimulatory and inhibitory roles 
(summarized in Figure 1.3). Findings from both in vitro cell models and in vivo rodent 
studies indicate that maintenance of the insulin−IR−IRS signalling axis is important for 
biphasic insulin signalling and insulin granule exoytotic machinery. Transfection of 
mouse insulinoma cell line βTC6-F7 cells with a kinase-inactivating mutation in IR was 
shown to impair glucose-stimulated insulin secretion (248). βIRKO mice demonstrated 
that reducing the presence of IR interferes with first-phase insulin secretion (229). More 
recently, the adaptor protein APPL1, a regulator of Akt and an anchor between IR and 
IRS-1 (249), was identified as a potential upstream factor for insulin granule exocytotic 
SNARE protein (Syntaxin 1A, SNAP25, and VAMP2) up-regulation in murine beta cells 
(250). Isolated single murine beta cells also demonstrated increased exocytotic events 
when stimulated with high doses of insulin (100 nmol/L) and impaired secretion when 
pretreated with IR neutralization antibody (251).  
A review of the literature suggests that IR−IRS activity differentially affects intracellular 
Ca2+ influx from the cell membrane and ER, which may explain the contrasting effects of 
autocrine insulin action during insulin release. It has been shown that IR signalling does 
not affect membrane depolarization-induced secretion but is required for mobilizing Ca2+ 
from intracellular stores (251). Insulin stimulation of isolated murine beta cells 
demonstrated hyperpolarization of the cell and mitochondrial membranes through 
activated KATP channels, which subsequently reduced the levels of intracellular Ca
2+ 
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necessary for insulin exocytosis (252). However, another report showed that treating 
murine beta cells with 100 nmol/L of insulin heightened intracellular Ca2+ release from 
the ER, resulting in enhanced insulin secretion (253). This pathway relied on activation 
through the IR−IRS-1−Akt axis and was independent of KATP-induced depolarization. 
IRS-1 co-localized with SERCA3b in βTC6-F7 cells, which inhibited Ca2+ re-uptake into 
the ER and increased insulin secretion (254). Irs-1-/- mice also displayed reduced insulin 
granule exocytosis due to a shortened transient period of high intracellular Ca2+ levels 
following glucose stimulation (238), indicating that the IR−IRS-1 signalling axis is 
important for ER-regulated Ca2+ release. It has also been reported that isolated rat islets 
increased insulin release when IRS-1 was inhibited in a high glucose level environment 
(255), which suggests that IRS-1-induced insulin secretion can also be affected by 
glycemic levels. This indicates that additional research is required to determine the 
contrasting effects of insulin stimulation on intracellular Ca2+ levels and the downstream 
signalling pathways that connect receptor activation to granule exocytosis. 
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Figure 1.3: Summary of the role of IR activation on insulin secretion. 
Autocrine insulin stimulation of beta cells can induce positive or negative feedback on 
insulin release. Positive feedback (right, green arrowheads): activation of the IR−IRS-1 
pathway induced Akt phosphorylation, which increased intracellular Ca2+ release from 
the ER and SNARE protein levels, which led to enhanced insulin release from beta cells. 
Negative feedback (left, red arrowheads): insulin stimulation activated the IR−IRS−PI3K 
pathway, which resulted in hyperpolarization of membrane KATP channel and a reduction 
in Ca2+-stimulated insulin release.  
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1.7.5 Interplay between c-Kit and IR signalling on insulin exocytosis 
Mice with beta cell-specific c-Kit overexpression (c-KitβTg) exhibited increased 
expression of Ir and Irs-1 in isolated islets at 8-weeks of age (205). Enhanced insulin 
release was also initially observed in 8-week c-KitβTg mice and continued to 28 weeks of 
age (199). This up-regulation of the IR signalling axis in islets of mice with c-Kit 
overexpression established a link between the c-Kit and IR−IRS pathways. Therefore, the 
improved insulin secretion and increased beta cell mass and proliferation observed in 8-
week c-KitβTg mice may be due to intact and enhanced signalling through the IR 
pathway. The previous findings from this mouse model resulted in two suggested 
mechanisms where c-Kit signalling in beta cells led to IR−IRS signalling up-regulation: 
[1] a direct interaction that affects the activity of the IR−IRS pathway (previously 
proposed in reference (206)); and/or [2] indirect IR activation through increased insulin 
secretion from c-Kit signalling (Figure 1.4). The focus of the work included in this thesis 
was to examine if signalling through both c-Kit and IR were required for maintaining 
beta cell function and insulin release. 
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Figure 1.4: Proposed c-Kit – IR interplay within the beta cell. 
c-Kit and IR both promote PI3K−Akt signalling, which is required for beta cell 
proliferation and the maintenance of factors that control insulin secretion. c-Kit receptor 
activation is proposed to increase IR−IRS signalling (via phosphorylation of tyrosine 
sites, green) through the following: [1] direct activation, and [2] indirect activation 
through increased insulin secretion. Y, tyrosine; S, serine. 
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1.8 Rationale and hypothesis 
1.8.1 General hypothesis of project 
The main objective of the work in the following chapters was to determine the role of c-
Kit and IR interplay using in vitro and in vivo models. I hypothesized that the regulation 
of c-Kit and IR signalling in beta cells under normal and diabetic stresses affects beta cell 
function, proliferation, and insulin release.  
1.8.2 Beta cell function in 60-week c-KitβTg mice 
RTKs in beta cells are essential to maintain beta cell mass and insulin secretion. 8-week 
old c-KitβTg mice have been shown to increase the expression of IR−IRS-1 in islets 
(205). However, the prolonged expression of RTKs in islets has not been well 
characterized. Mice with beta cell overexpression of platelet-derived growth factor 
receptor (PDGFR), a RTK found in the same family as c-Kit, developed improved 
glucose tolerance and increased beta cell mass at 60-weeks of age (157). However, it was 
not known if c-Kit signalling would display a similar phenotype and maintain the 
enhanced beta cell proliferation and insulin secretion seen in younger mice. In addition, 
while the increase in IR expression and insulin secretion may be beneficial under 
transient conditions, chronic insulin signalling may result in complications including 
insulin resistance and reduced lifespan in mice (256,257). The examination of prolonged 
c-Kit overexpression in mouse beta cells is therefore important. In Chapter 3, 60-week 
c-KitβTg and c-KitβTg;βIRKO mice were examined to determine the effect of chronic c-
Kit overexpression on insulin release, beta cell mass and transcription factor expression, 
intracellular signalling, and regulation of the IR axis. I hypothesized that prolonged c-Kit 
signalling would produce glucose intolerance and beta cell defects due to c-Kit-induced 
over-activation of the IR−IRS-1 pathway, and that reducing the expression of IR on beta 
cells of c-KitβTg mice would restore glucose tolerance. 
1.8.3 Postnatal IR loss in beta cells under normal and high-fat diet 
conditions 
IR expression on beta cells can influence beta cell mass, proliferation, and insulin 
transcription. The presence of IR on beta cells throughout development ensures that 
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normal beta cell mass and function is maintained. The loss of beta cell IR during 
development (βIRKO) produced adult mice that displayed reduced beta cell mass and 
first-phase insulin secretion, leading to the development of glucose intolerance (228,229). 
These mice are also unable to compensate for high-fat diet (HFD)-induced beta cell mass 
expansion (258). Previous research from our laboratory has shown that mice with a 
tamoxifen-inducible loss of beta cell IR (MIP-βIRKO; MIP, mouse insulin promoter) 
induced at e13.5 had compensatory beta cell expansion induced through IGF-1R−IGF-2 
signalling, which indicates that the stage at which IR loss is induced may produce 
differing effects on islet mass and function (227). Preliminary studies from our group also 
found that postnatal beta cell IR loss (4-week) did not alter glucose tolerance or beta cell 
morphology and proliferation in mice fed a short-term HFD for 6 weeks. However, long-
term (12-16 weeks) administration of HFD feeding in C57BL/6 mice has been shown to 
promote multiple metabolic changes not present on short-term HFD, including peripheral 
insulin resistance and the progressive loss of beta cell transcription factors and increased 
ER stresses (132-134). In Chapter 4, MIP-βIRKO mice with postnatal beta cell IR loss 
induced at 4 weeks of age were exposed to long-term (18-week) HFD feeding to examine 
the effects on glucose tolerance, insulin secretion, and beta cell mass and intracellular 
signalling pathways. I hypothesized that the loss of postnatal beta cell IR signalling in 
mice exposed to a prolonged HFD would produce beta cell dysfunction and loss of beta 
cell mass that resulted in the development of hyperglycemia. 
1.8.4 In vitro c-Kit and IR interplay 
Co-stimulation of RTKs has been shown to lead to synergistic effects in cells (259,260). 
Both c-Kit and IR have been shown to individually activate the PI3K−Akt signalling 
pathway in beta cells (205,261). However, it is not currently known if co-activation 
enhances signalling along this pathway. Since c-Kit overexpression initiated increased 
islet IR expression, there is the potential that the enhanced proliferation and signalling 
observed in c-KitβTg mice is due to activity from both receptors (205). Chapter 5 of this 
thesis used the INS-1 832/13 cell line to examine the effects of c-Kit and IR co-
stimulation on the activation of intracellular signalling pathways and cell proliferation at 
various time-points (15 minutes, 1 hour and 24 hours). I hypothesized that c-Kit and IR 
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co-stimulation would produce a synergistic effect on intracellular signalling and 
proliferation that is greater than single receptor stimulation alone. 
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Chapter 2  
2 General materials and methods for Chapters 3, 4, and 5 
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2.1 Experimental mouse models 
2.1.1 General maintenance of mouse models 
Experimental male mice utilized in Chapters 3 and 4 were housed with their control 
male littermates, with a minimum of 2 mice per cage and a maximum of 5 mice per cage. 
Mice were maintained on a 12-hour light/ 12-hour dark cycle. All mice were fed their 
assigned diet ad libitum. Weekly health checks were performed on all mice, and mice that 
developed health complications were excluded from experimental studies. Tamoxifen 
(>99%, Sigma-Aldrich, Saint Louis, MO; product #T5648) was prepared at a 
concentration of 30 mg/mL in corn oil vehicle (Sigma-Aldrich) and delivered using 
intraperitoneal injection or oral gavage (1,2). All animal work was conducted after 
protocols were approved by the University of Western Ontario Animal User 
Subcommittee in accordance with the Canadian Council of Animal Care guidelines 
(Appendix A). Biosafety permits were also approved prior to mouse experiments 
(Appendix B). 
2.1.2 Mouse models in Chapter 3 
Generation of the c-KitβTg mouse model: The c-KitβTg mouse line was generated with 
the injection of a pKS/RIP plasmid containing human c-KIT (2.9 kbp), with IRES2-linked 
enhanced green fluorescence protein (eGFP), into the pronuclei of one-cell C57BL/6J 
embryos as described previously (3). Mice that were positive for c-Kit expression and did 
not demonstrate any phenotypic abnormalities were used as founder mice and crossed 
with wild-type C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME). Genotyping 
primers c-Kit/Globin5 and eGFP/Globin3 were used to confirm c-Kit expression in mice 
(Figure 2.1a). Sequences can be found in Table 2.1. Male wild-type and c-KitβTg mice 
were aged to 60 weeks for analysis. All mice were maintained on a normal chow diet 
(Harlan Teklad, product #2919, Indianapolis, IN, USA) ad libitum throughout the study. 
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Figure 2.1: Representative PCR product from genotyping of c-KitβTg, c-
KitβTg;MIP-CreER;IR, and MIP-CreER;IRfl/+mouse lines. 
Representative images for (a) eGFP, (b) IRfl/fl, and (c) MIP-CreERT bands from PCR gel 
electrophoresis. Base pair (bp) length is listed for each band of interest. 
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Table 2.1: Primers for PCR genotyping of c-KitTg, c-KitTg;IRKO, and MIP-
IRKO mice featured in Chapters 3 and 4. 
 
WT, wild-type; KO, knockout 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Primer sequence 5’-3’ Fragment Annealing Temp  
 
eGFP 
Globin3 
 
Globin5 
c-Kit 
 
5’-CAG TCC GCC CTG AGC AAA GAC C-3’ 
5’-GGT ATT TGT GAG CCA GGG CAT TG-3’ 
 
5’-GCT CCT GGG CAA CGT GCT GG-3’ 
5’-GTG AGA GGA CAG CGG ACC AGC-3’ 
 
303bp 
 
 
481bp 
 
 
57oC 
 
 
57oC 
 
 
oIMR6765 
oIMR6766 
 
MIP 
CreER 
 
 
5’-GAT GTG CAC CCC ATG TCT G-3’ 
5’-CTG AAT AGC TGA GAC CAC AG-3’ 
 
5’-CCT GGC GAT CCC TGA ACA TGT CCT-3’ 
5’-TGG ACT ATA AAG CTG GTG GGC AT-3’ 
 
KO 313bp 
WT 279bp 
 
268bp 
 
60oC 
 
 
57oC 
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Generation of c-KitβTg;βIRKO mouse model: Tg(Ins1-Cre/ERT)1Lphi mice (MIP-CreERT) 
were obtained from Dr. Louis Philipson at the University of Chicago (Chicago, IL). The 
verification of Insulin 1 (MIP) promoter-driven Cre recombinase expression in pancreatic 
beta cells was performed by crossing MIP-CreERT mice with the B6.Cg-
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter strain (stock number: 007909; The Jackson 
Laboratories) as previously reported (4). MIP-CreERT mice were crossed to 
B6.129S4(FVB)-Insrtm1Khn/J mice (IRfl/fl) from Jackson Laboratories (stock number: 
006955) to produce a beta cell-specific Cre recombinase IR knockout model that was 
induced with tamoxifen administration (MIP-CreER+/-;IRfl/+) (Figure 2.2) (4). PCR 
genotyping was performed using primers oIMR6765 and oIMR6766 for floxed IR 
detection and primers MIP and Cre-ERT for MIP-driven Cre recombinase detection 
(Table 2.1 and Figure 2.1bc). The MIP-CreER;IRfl/+line was crossed to c-KitβTg mice 
to generate the following experimental groups: control (WT;MIP-CreER+;IR+/+ or 
WT;MIP-CreER-;IRfl/fl to increase the number of control mice available), c-KitβTg (c-
KitβTg;MIP-CreER+;IR+/+), and c-KitβTg;βIRKO mice (c-KitβTg;MIP-CreER+;IRfl/fl) 
(Figure 2.3). In order to induce beta cell IR knockout at 40 weeks of age, 4 mg/ 20 g 
bodyweight of tamoxifen was administered daily to male mice from all three 
experimental groups via oral gavage for three consecutive days (Figure 2.4a) (5). Mice 
were maintained on ad libitum normal chow diet and examined at 60 weeks of age. 
2.1.3 Mouse model in Chapter 4 
The MIP-CreER;IRfl/+mouse line described above was used to generate male control 
(MIP-CreER+;IR+/+or MIP-CreER-;IRfl/fl) and MIP-βIRKO (MIP-CreER+;IRfl/fl) mice 
(Figure 2.2). Genotyping using the IR and MIP Cre-ERT primers was used to confirm 
floxed IR or MIP-CreERT expression (Table 2.1 and Figure 2.1bc). Control and MIP-
βIRKO mice at 4 weeks of age received daily intraperitoneal tamoxifen injections (4 mg/ 
20 g bodyweight) for three days (Figure 2.4b) (5). At six weeks of age, control and MIP-
βIRKO mice were placed either on ad libitum normal chow (23% protein, 22% fat, 55% 
carbohydrate, 3.3 kcal/g; product #2919; Harlan Teklad) or high-fat diet (20% protein, 
60% fat, 20% carbohydrates, 5.21 kcal/g; product # D12492; Research Diets Inc, New 
Brunswick, NJ, USA) for 18 weeks. Mice were analyzed at 24 weeks of age. 
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Figure 2.2: Breeding schematic for the MIP-CreER;IRfl/+mouse line. 
Tg(Ins1-Cre/ERT)1Lphi and B6.129S4(FVB)-Insrtm1Khn/J lines were crossed to generate 
heterozygous MIP-CreER+/-;IRfl/+ breeding mouse pairs. The offspring from MIP-
CreER+/-;IRfl/+ mouse breeding pairs are listed with the percentage for potential 
generation of each genotype. Mice used for the control group (MIP-CreER+;IR+/+or MIP-
CreER-;IRfl/fl) are outlined in green, while MIP-βIRKO mice (MIP-CreER+;IRfl/fl) are 
outlined in red.
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Figure 2.3: Breeding schematic for the c-KitβTg;βIRKO mouse line. 
Established mice from c-KitβTg and MIP-CreER+/-;IRfl/+ mouse lines were crossed to 
produce c-KitβTg;MIP-CreER+/-;IRfl/+ breeding pairs. Control (green, WT;MIP-
CreER+;IR+/+ or WT;MIP-CreER-;IRfl/fl), c-KitβTg (blue, c-KitβTg;MIP-CreER+;IR+/+), 
and c-KitβTg;βIRKO mice (red, c-KitβTg;MIP-CreER+;IRfl/fl) were generated from the 
breeding pairs. The percentage of offspring that are predicted to result from each crossing 
are listed beside each genotype.  
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Figure 2.4: Timeline design for studies involving the c-KitβTg;MIP-CreER;IR and 
MIP-CreER;IR mouse lines. 
Timelines showing the week of tamoxifen administration, HFD feeding initiation, and 
end-point analysis of (a) c-KitβTg;βIRKO and (b) MIP-βIRKO mouse cohorts discussed 
in Chapters 3 and 4 of this work, respectively. 
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2.2 Genotyping of mouse models 
In order to identify mouse genotypes for experimental groups in Chapters 3 and 4, tail 
snips (1-2 mm) were obtained at postnatal day 21 and dissolved in base solution (25 
mmol/L NaOH and 0.2 mmol/L EDTA) at 95oC for 30 minutes. Tail samples were 
incubated at room temperature for 1 hour and then immersed in 40 mmol/L Tris HCl (pH 
5.0). Primers (Table 2.1) and tail samples were added to 2x Taq FroggaMix (FroggaBio 
Inc., Toronto, ON) and amplified using a thermocycler. Annealing temperatures were 
dependent on the primers utilized. PCR samples were run on a 2% ethidium bromide 
(Invitrogen, Burlington, ON) agarose gel and imaged on the GeneGenius BioImaging 
System (Syngene, Frederick, MD) (Figure 2.1).  
2.3 Metabolic studies of mouse models 
Experimental mouse models used in Chapters 3 and 4 had their body weight measured at 
experimental end-points. Food intake was monitored in individual 60-week wild-type and 
c-KitβTg mice every 24 hours for a 72-hour period. Overnight fasting (16-hour) blood 
glucose measurements were taken in all experimental mouse models. All blood glucose 
readings were taken from tail vein samples and were read on a FreeStyle Lite glucometer 
(Abbott, Mississauga, ON, Canada). 
Intraperitoneal glucose tolerance tests (IPGTT), which bypass incretin-induced insulin 
release, were performed in all mouse models after 16-hour fasting using a 2 mg/g 
bodyweight injection of D-(+)-glucose (Dextrose; Sigma, Saint Louis, MO) (6). Glucose 
levels were measured at baseline (0 minutes) and at 15, 30, 60, 90, and 120 minutes 
following administration. Intraperitoneal insulin tolerance tests (IPITT) were performed 
in 4-hour fasted mice using 1 U/kg bodyweight of insulin (Humulin, Eli Lilly, Toronto, 
ON), and glucose levels were measured at baseline and 15, 30, 60, and 120 minutes 
following administration. Differences between control and experimental groups were 
determined using the area under the curve (AUC), which represented glucose levels over 
a period of 120 minutes (mmol/L x min) or percentage of baseline glucose over a period 
of 120 minutes (% x min) (7,8). In vivo glucose-stimulated insulin secretion (GSIS) was 
conducted after 16 hours of fasting by injecting 2 mg/g bodyweight glucose. Plasma 
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insulin was collected at baseline (0 mins), 5, and 35 minutes following glucose injection 
and blood glucose measurements were taken in parallel. Samples were centrifuged and 
serum was stored at -20oC for insulin measurement using ELISA.   
2.4 Islet isolation 
The islet isolation protocol described below was used for islet purification for ex vivo 
GSIS, ex vivo insulin stimulation experiments, and protein analyses. Mouse pancreata 
were saturated with collagenase V (1 mg/mL, Sigma-Aldrich) through ductal injection 
and digested at 37oC for 30 minutes in dissociation buffer (Hank’s Balanced Salt Solution 
and HEPES; 0.6% g/mL). Islets were separated from exocrine tissue by Ficoll density 
gradient followed by hand picking, as previously described (9,10).  
2.5 Ex vivo glucose-stimulated insulin secretion and insulin-
treated stimulation of isolated islets 
For ex vivo GSIS experiments, 10 islets from wild-type and c-KitβTg mice (Chapter 3) 
and from control and MIP-βIRKO mice (Chapter 4) were picked and recovered 
overnight in RPMI-1640 media (FBS; Gibco) supplemented with 10% fetal bovine serum 
(Gibco), 2 g/L sodium bicarbonate, 10 mmol/L HEPES, and 1 mmol/L sodium pyruvate. 
Low and high glucose stimulation was initiated by incubating islets for 1 hour in RPMI-
1640 supplemented with 0.5% bovine serum albumin (BSA; Sigma-Aldrich) and 
containing either 2.2 mmol/L or 22 mmol/L glucose, respectively (3,11). Media from the 
low and high glucose conditions were collected for insulin measurement. Ex vivo GSIS 
measurements were completed in technical duplicates.  
For insulin stimulation of islets from wild-type and c-KitβTg mice (Chapter 3), islets 
from each mouse were divided into two separate wells in a 12-well plate and incubated in 
RPMI-1640 supplemented with 1% BSA media for 3 hours. Islets were either stimulated 
with 2 nmol/L insulin (Sigma-Aldrich) or were left unstimulated (12). Cells were 
harvested 24 hours after insulin stimulation for protein lysis analysis. 
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2.6 ELISA analysis of in vivo and ex vivo insulin secretion and 
islet insulin content 
Fed plasma insulin levels were measured from cardiac serum withdrawal following 
mouse euthanasia. Islet insulin content was measured by extracting insulin from fresh 
islets using Acid-Ethanol extraction (165 mmol/L HCl in 70% ethanol). Insulin release 
and content was detected using the ALPCO (Salem, NH) ultrasensitive insulin mouse 
ELISA kit (0.15 ng/mL sensitivity) (3). Insulin levels in plasma and media were reported 
as ng/mL. Islet insulin content was normalised to total islet protein content, measured 
using a Bradford Assay (Bio-Rad Dye; Bio-Rad Laboratories Inc, Mississauga, ON), and 
expressed as g/mg. 
2.7 In vitro cell culture and treatment 
INS-1 cell line culture: The INS-1 832/13 cell line provided by Dr. C. Newgard (Duke 
University, Durham, North Carolina) was maintained in RPMI-1640 media (Gibco) 
supplemented with 10% FBS (Gibco), 2 g/L sodium bicarbonate, 10 mmol/L HEPES, 1 
mmol/L sodium pyruvate, and 0.05 mmol/L 2-merpathoethanol (Sigma-Aldrich). Cells 
were incubated at 37oC in 5% CO2. Experiments involving the INS-1 cell line (Chapters 
4 and 5) were performed when cell growth reached 80-90% confluency. Treated INS-1 
cells were harvested for western blot and immunofluorescence staining at the designated 
time-points. The use of the INS-1 832/13 cell line was approved and can be found on the 
Biosafety protocol (Appendix B). 
Insulin-stimulated SNARE protein analysis: For Chapter 4, INS-1 cells were serum-
starved in RPMI-1640 supplemented with 1% BSA media overnight (16-24 hours) before 
treatment. Cell wells were either left untreated (control) or received 100 nmol/L insulin 
(Sigma-Aldrich) for 1 hour. Cells were harvested, fixed, and embedded in 2% agarose gel 
for paraffin-embedded immunofluorescence staining. 
SCF and insulin time-dependent co-stimulation studies: For Chapter 5, INS-1 cells were 
serum-starved in RPMI-1640 with 1% BSA media overnight (for 15-minute and 1-hour 
stimulation) or for 3 hours (for 24-hour stimulation) before treatment. Experimental wells 
received no treatment (control), SCF only (50 ng/mL; ID Labs, London, ON), insulin 
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only (0.2 nmol/L; Sigma), or a combination of SCF (50 ng/mL) and insulin (0.2 nmol/L) 
for a 15-minute, 1-hour, or a 24-hour period (3,13). Cells were either harvested and lysed 
in a Nonidet-P40 (NP40)-containing lysis buffer for western blot analysis or were fixed 
and embedded in 2% agarose gel for paraffin-embedded immunofluorescence analysis. 
Rapamycin treatment of INS-1 cells: For Chapter 5, cells were incubated in RPMI-1640 
with 1% BSA media overnight once they had reached 80-90% confluency. 100 nmol/L of 
rapamycin (LC Laboratories, Woburn, MA) was used as a 1-hour pre-treatment before 
SCF (50 ng/mL) and insulin (0.2 nmol/L) co-stimulation was initiated for 1 hour (7). 
Experimental groups were as follows: [1] no treatment (control), [2] 1-hour SCF and 
insulin co-stimulation, [3] 1-hour rapamycin pre-treatment, [4] 1-hour rapamycin pre-
treatment with subsequent 1-hour SCF and insulin co-stimulation. Cells were harvested 
and lysed in NP40 lysis buffer for western blot analysis. 
2.8 Histological staining and morphometric analyses 
2.8.1 Immunofluorescence and immunohistochemical staining 
Pancreata from mice and treated INS-1 cells were fixed overnight (4oC) in 4% 
paraformaldehyde. INS-1 cell pellets were embedded in 2% agarose gel. Fixed cells and 
pancreata were dehydrated and embedded in paraffin wax then sectioned at 4 m and 
placed on slides. Cell and pancreatic sections were probed with the primary antibodies 
listed in Table 2.2 for single immunohistochemical or double immunofluorescence 
staining. Sections were treated with heat-induced antigen retrieval solution (citrate pH 
6.0 or Tris-EDTA pH 9.0) to improve antibody detection (indicated in Table 2.2). 
Double immunofluorescence staining was performed using fluorescein isothiocyanate 
(FITC)- and tetramethyl rhodamine isothiocyanate (TRITC)-conjugated secondary 
antibodies (Jackson Immunoresearch, West Grove, PA) and nuclear counterstaining was 
conducted with 4’-6’-diamidino-2-phenylindole (DAPI) (1:1000 dilution; Sigma-
Aldrich). Immunohistochemical detection of a single antigen was achieved using the 
Zymed Histostain Plus IHC kit and aminoethyl carbazole (AEC) substrate kit 
(Invitrogen) with hematoxylin counterstaining (Invitrogen). Negative control slides were 
prepared by adding secondary antibody alone to rule out non-specific binding. 
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Antibodies, which were used for both histological and western blot analyses, were 
validated in prior publications (4,7,14). Islet sections and cultured cells were captured 
using the Leica DMIRE2 fluorescent microscope and analyzed using Image Pro Plus 
software version 7.0.1 (MediaCybernetics, Rockville, MD). Representative double 
immunofluorescence images in this thesis were imaged using the Nikon Eclipse Ti2 
confocal microscope (Nikon, Melville, NY). 
2.8.2 Histological analysis and islet quantification 
Islet morphology was measured using area measurement software in Image Pro Plus. 
Alpha and beta cell mass were calculated using the following previously described 
formula (15,16):  
alpha, beta cell mass [mg] = (alpha, beta cell area x pancreas mass [mg]) / pancreas 
section area 
Islet density was calculated by dividing the total number of islets per section by the total 
pancreatic area. Quantification of beta cell proliferation (Ki67), beta cell transcription 
factors (PDX-1, NKX6.1, MAFA, FOXO1), and beta cell SNARE proteins (Syntaxin 
1A, VAMP2, SNAP25, MUNC18-1) was conducted using manual cell counting of 
marker positive beta cells (marker+/insulin+ cells) divided by the total number of beta 
cells in each islet (11,16). Immunohistochemistry of phosphorylated (p-) AktS473 staining 
in islets was performed by dividing the number of p-AktS473 + cells over the total number 
of islet cells. Islet capillary morphology was measured using the capillary marker 
PECAM-1 and calculated using the following formulas: Islet capillary area was 
calculated by dividing the total islet capillary area over the total islet area; islet capillary 
density was quantified by dividing the number of islet capillaries over total islet area; 
islet capillary diameter was measured by dividing capillary diameter by the number of 
islet capillaries (7). A minimum of ten islets per section were used for marker-positive 
quantifications. 
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2.9 Protein isolation and western blot analyses 
Isolated mouse islets and INS-1 cells were lysed in Nonidet-P40 (NP40; Sigma-Aldrich) 
lysis buffer (100 mmol/L sodium othovanadate; 100 mmol/L phenylmethylsulfonyl 
fluoride; complete Protease Inhibitor Cocktail Tablet, Roche) for 20 minutes on ice and 
sonicated. Protein samples were separated by centrifugation (15,800 rcf) for 20 minutes 
at 4oC. To determine the protein concentration of each sample, a Bradford assay with 
Bio-Rad Dye (Bio-Rad Laboratories Inc.) was run in parallel with a BSA standard curve 
(0-0.5 mg/mL BSA). All protein samples were normalised to 15-20 g before loading 
on to a western blot gel.    
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) ranging from 
5-12% was used to separate bands of a targeted kDa size. After the samples had run 
through and separated, gel bands were transferred to a nitrocellulose membrane and run 
on ice for 120 minutes at 250 mA. Ponceau S dye (Sigma-Aldrich) was used to confirm 
successful protein transfer. After washing in Tris buffered saline containing 0.1% 
Tween-20 (TBST), membranes were blocked in in 5% non-fat dry milk (2.5 mL TBS, 
50 L NP-40 in 50 mL double distilled water with pH adjusted to 7.4) at room 
temperature for 1 hour before overnight primary antibody incubation at 4oC (Table 2.2). 
Anti-rabbit and anti-mouse IgG secondary antibodies were conjugated with horseradish 
peroxidase and used to detect primary antibodies (Cell Signalling Technology, Whitby, 
ON). Chemiluminescence detection (PerkinElmer, Waltham, MA) was used to visualize 
proteins of interest and membranes were imaged on the Versadoc imaging system, 
version 4.6.9 (Bio-Rad Laboratories Inc.). Reference proteins (-tubulin, -actin) and 
total proteins were used to normalise protein bands of interest. The probing for total 
protein bands of signalling proteins was completed after immersing the membrane in 
membrane stripping buffer (3.5 mL 2-mercaptoethanol, 3.79 g Tris base, 10 g SDS in 
500 mL double distilled water with pH adjusted to 6.7) at 55oC and blocking in milk 
blocking solution for 1 hour at room temperature. Densitometry analysis of bands was 
completed with the Bio-Rad Image Lab program, version 5.2 (Bio-Rad Laboratories 
Inc.). 
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2.10 Statistical analyses 
All data presented are represented as mean  SEM and were generated using GraphPad 
Prism, version 5.0 (GraphPad Software, Inc.). An unpaired Student’s t-test was used 
when examining two groups, while a one-way ANOVA with a Tukey’s post hoc test was 
used when comparing groups of three or more. Statistical significance was obtained when 
p < 0.05.   
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Table 2.2: Antibodies for immunohistochemistry/immunofluorescence and western 
blot analysis. 
  
Primary Antibody   Dilution Source 
Mouse anti--tubulin 
Mouse anti--Actin 
Mouse anti-p-AktS473 
Rabbit anti-p-AktS473 
Rabbit anti-p-AktT308 
Rabbit anti-Akt 
Rabbit anti-c-KitY719 
Rabbit anti-C-peptide 
Mouse anti-Cyclin D1 
Rabbit anti-p-ERK1/2T202/Y204 
Rabbit anti-ERK1/2  
Rabbit anti-FOXO1 
Rabbit anti-glucagon 
Rabbit anti-glucagon 
Rabbit anti-GLUT2 
Mouse anti-insulin 
Rabbit anti-insulin 
Rabbit anti-IR 
Rabbit anti-p-IRY1146 
Rabbit anti-p-IRS-1/2Y608 
Rabbit anti-p-IRS-1S612 
Rabbit anti-IRS-1 
1:2000W 
1:5000W 
1:1000W 
1:100B/ 1:1000W 
1:1000W 
1:1000W 
1:500W 
1:200 
1:1000W 
1:1000W 
1:1000W 
1:800A 
1:50 
1:100 
1:200A 
1:1500 
1:50 
1:50A/1:1000W 
1:1000W 
1:1000W 
1:1000W 
1:50 
DSHB, Iowa City, IA, USA 
Sigma, Saint Louis, MO, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
Linco Research, St. Charles, MO, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
H. Dong, University of Pittsburgh, PA, USA 
Santa Cruz Biotechnology Inc, Dallas, TX, USA 
Sigma, Saint Louis, MO, USA 
Abcam Inc., Cambridge, MA, USA 
Sigma, Saint Louis, MO, USA 
Santa Cruz Biotechnology Inc, Dallas, TX, USA 
Santa Cruz Biotechnology Inc, Dallas, TX, USA 
Cell Signaling Technology, Boston, MA, USA 
Santa Cruz Biotechnology Inc, Dallas, TX, USA 
Cell Signaling Technology, Boston, MA, USA 
Santa Cruz Biotechnology Inc, Dallas, TX, USA 
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Rabbit anti-Ki67 
Rabbit anti-MAFA 
1:200A 
1:100A 
Abcam Inc. Cambridge, MA, USA 
Bethyl Laboratories, Inc., Montgomery, TX, USA 
Rabbit anti-MAFA 
Rabbit anti-MUNC18-1 
Mouse anti-NKX6.1 
Rabbit anti-PARP 
Mouse anti-PCNA 
Rabbit anti-PECAM-1 
1:400A 
1:100/1:1000W 
1:100A 
1:1000W 
1:200A 
1:200A 
Cell Signaling Technology, Boston, MA, USA 
Abcam Inc. Cambridge, MA, USA 
DSHB, Iowa City, IA, USA 
Cell Signaling Technology, Boston, MA, USA 
Lab Vision., Fremont, CA, USA 
Santa Cruz Biotechnology Inc, Dallas, TX, USA 
Rabbit anti-PDX-1  
Mouse anti-p-P70S6K1T389 
Rabbit anti-P70S6K1 
Mouse anti-SNAP25 
Mouse anti-Syntaxin 1A 
Rabbit anti-VAMP2 
1:800A 
1:2000W 
1:1000W 
1:50/1:1000W 
1:50/1:1000W 
1:200/1:1000W 
C. Wright, University of Vanderbilt, USA 
Cell Signaling Technology, Boston, MA, USA 
Cell Signaling Technology, Boston, MA, USA 
Santa Cruz Biotechnology Inc. Dallas, TX, USA 
Santa Cruz Biotechnology Inc. Dallas, TX, USA 
Abcam Inc. Cambridge, MA, USA 
W Dilution selected for optimal western blot probing 
A Citrate (pH 6.0) antigen retrieval used 
B Tris-EDTA (pH 9.0) antigen retrieval used 
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Chapter 3  
3 Long-term c-Kit overexpression in beta cells compromised 
their function2  
                                                 
2 Text and figures from this chapter have been adapted from the following manuscript: 
Oakie A, Feng Z-C, Li J, Silverstein J, Yee S-P, and Wang R. Long-term c-Kit 
overexpression in beta cells compromises their function in ageing mice. Accepted to 
Diabetologia (in press). Manuscript number: Diab-18-1549 ** 
** Partial data from Figures 3.1, 3.2, and 3.3 were collected and analyzed by Z-C Feng 
(co-author in the manuscript above) 
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3.1 Introduction 
The receptor tyrosine kinase (RTK) c-Kit, expressed during pancreatic development and 
in a subset of adult beta cells, has been shown to activate the PI3K/Akt signalling 
pathway to regulate beta cell mass, increase beta cell proliferation, and enhance insulin 
secretion (1-6). c-Kit activation also improved islet cell viability and vascularization 
through suppression of Fas receptor-induced apoptosis and up-regulated VEGF-A 
production, respectively (7,8). Importantly, mice with beta cell-specific c-Kit 
overexpression (c-KitβTg) had increased expression of insulin receptor (IR) and insulin 
receptor substrate-1 (IRS-1) at 8 weeks (4). Although c-KitβTg mice demonstrated 
improved beta cell function up to 28 weeks on control chow diet, feeding c-KitβTg mice 
a high-fat diet for 22 weeks resulted in islet vessel dilation and subsequent infiltration of 
inflammatory cells, which led to beta cell apoptosis and reduced insulin release (7). 
These results highlighted the importance of controlled c-Kit activation in beta cells to 
maintain beta cell function and insulin secretion.  
Ageing has been shown to deleteriously impact the islet microenvironment through the 
development of insulin secretion defects and decreased Ins1/Ins2 and Glut-2 mRNA 
expression in beta cells (9,10). Islets from ageing mice were found to be more susceptible 
to Fas-induced apoptosis and showed reduced PDX-1 expression, which indicated beta 
cell dysfunction in older mice (11). Beta cell proliferation was also lower in ageing mice. 
However, some studies have found that beta cells in older mice were able to replicate in 
response to beta cell damage (12-17). The induction of beta cell senescence in the islets 
of ageing mice has also been reported to enhance insulin secretion, emphasizing that the 
effects of ageing on islets are not well established (18).  
We have recently shown that enhanced c-Kit signalling can improve pancreatic 
transcription factor expression and beta cell proliferation, viability, and insulin secretion 
during the age-dependent decline of beta cell function (4,8). However, the effects of long-
term c-Kit overexpression on beta cells are currently not known. This chapter examined 
c-KitβTg mice at 60 weeks of age to determine the effects of chronic c-Kit 
overexpression towards the maintenance of beta cell mass and insulin release. In this 
study, we also used a mouse model generated through crossing tamoxifen-inducible, beta 
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cell-specific insulin receptor (IR) knockout mice with c-KitβTg mice (c-KitβTg;βIRKO) 
in order to determine the role of insulin receptor signalling in 60-week c-KitβTg mice. 
3.2 Materials and methods 
Generation of c-KitβTg and c-KitβTg;βIRKO mice: Male wild-type (WT) and c-KitβTg 
mice were generated from established in-house breeding colonies. c-KitβTg mice were 
aged to 60 weeks and subjected to metabolic studies and islet morphology and protein 
expression analyses. c-KitβTg;βIRKO mice (with littermate control and c-KitβTg mice) 
were generated by crossing c-KitβTg mice with MIP-CreER;IRfl/+ mice from the MIP-
βIRKO colony. c-KitβTg;βIRKO mice and littermate controls were treated with 
tamoxifen (4 mg/ 20 g bodyweight, i.p.) at 40 weeks to induce beta cell IR knockout and 
analyzed at 60 weeks of age. More information on these mouse models can be found in 
Section 2.1.2.  
Metabolic experiments: c-KitβTg mouse groups had body weight and overnight (16-hour) 
fasting blood glucose measured at 40 and 60 weeks of age. c-KitβTg;βIRKO groups had 
body weight and overnight blood glucose levels measured at 60 weeks. IPGTT, IPITT, 
and in vivo and ex vivo GSIS assays were performed and analyzed as detailed in Sections 
2.3 and 2.5. 
Western blot analyses: Islets from 60-week WT and c-KitβTg mice were probed for 
Syntaxin 1a, MUNC18-1, IR, and phosphorylated (p-) IRS-1S612 and normalised to the 
loading protein control -actin (Table 2.2). Signalling and cleaved proteins (p-AktS473, p-
ERKT202/Y204, cleaved PARP) were normalised to respective total proteins. Additional 
information can be found in Section 2.9. For insulin stimulation, islets from 60-week WT 
and c-KitβTg mice were either untreated or treated for 24 hours with 2 nmol/L insulin 
and harvested for western blot analysis of p-AktS473 (Section 2.5). 
Immunostaining: Pancreata from the 60-week c-KitβTg group (WT and c-KitβTg) and c-
KitβTg;βIRKO group (control, c-KitβTg, and c-KitβTg;βIRKO) were stained with select 
primary antibodies listed in Table 2.2. Immunofluorescence analysis was completed with 
fluorophore-labeled secondary antibodies (Jackson Immunoresearch) and DAPI (Sigma-
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Aldrich). For immunohistochemical studies, the Zymed Histostain Plus kit and AEC 
substrate kit (Invitrogen) with hematoxylin counterstain (Invitrogen) were used. Islet 
morphology (islet density, beta cell mass, alpha cell mass), co-staining (marker+/insulin+ 
cells), or single label staining (marker+ islet cells) quantification was completed as 
described in Section 2.8. Sample sizes reflected pancreata sections analyzed from 
different biological replicates, with a minimum of 10 islets analyzed from each sample.  
Statistical analysis: All data presented are represented as mean  SEM and were analyzed 
using either an unpaired Student’s t-test (2 groups) or a one-way ANOVA test with a 
Tukey’s post hoc test (3 or more groups). Statistical significance was obtained when p < 
0.05. 
3.3 Results 
3.3.1 c-Kit overexpression impaired glucose tolerance in c-KitβTg mice 
after prolonged expression 
Previous studies demonstrated no change in body weight between WT and c-KitβTg mice 
at 8 and 28 weeks of age (4,7). During the current study, there was no change in body 
weight observed in mice at 40 weeks of age, but c-KitβTg mice exhibited increased body 
weight compared to WT littermates at 60 weeks of age (Figure 3.1a). Also in contrast to 
prior studies demonstrating reduced fasting blood glucose in young c-KitβTg mice (4,7), 
the current study found similar blood glucose levels in WT and c-KitβTg mice at 40 
weeks of age and significantly elevated levels in c-KitβTg mice at 60 weeks (Figure 
3.1b). Examination of pancreas and fat pad mass in 60-week old mice revealed no 
significant changes between WT and c-KitβTg mice (Figure 3.1cd). The average 24-hour 
food intake over a 3-day period at 60 weeks did not change between the two groups 
(Figure 3.1e).  
Although improved glucose tolerance was previously observed in young c-KitβTg mice 
(4,7), 60-week c-KitβTg mice demonstrated impaired glucose tolerance compared to their 
WT counterparts and did not return to basal levels at 120 minutes (Figure 3.2a). IPITT 
tests also revealed similar insulin sensitivity between WT and c-KitβTg mice (Figure 
3.2b), suggesting that the poor glucose tolerance observed in older c-KitβTg mice may be 
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due to impaired insulin release by beta cells. Therefore, insulin release was assayed to 
measure beta cell insulin secretion in response to a glucose challenge. Ex vivo GSIS 
demonstrated similar insulin release from islets between 60-week WT and c-KitβTg mice 
at 2.2 mmol/L of glucose stimulation but low insulin secretion from islets of 60-week c-
KitβTg mice when incubated in 22 mmol/L glucose (Figure 3.2c). Insulin content from 
isolated islets of 60-week c-KitβTg mice did not differ from WT mice (Figure 3.2d).  
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Figure 3.1: c-KitβTg mice had increased body weight and fasted glucose levels at 60 
weeks of age. 
(a) Body weight measurements at 40 (n=13 WT and n=30 c-KitβTg) and 60 (n=20 WT 
and n=22 c-KitβTg) weeks of age, and (b) overnight (16 hours) fasting blood glucose at 
40 (n=13 WT and n=30 c-KitβTg) and 60 (n=15 WT and n=20 c-KitβTg) weeks of age 
for WT and c-KitβTg mice demonstrated the progressive increase in weight gain and 
blood glucose levels. Body weight and fasting blood glucose levels were compared to 
mice previously analyzed at 8 and 28 weeks of age (4,7). (c) Pancreatic (n= 9 for WT, n= 
14 for c-KitβTg) and (d) fat pad weights (n= 11 for WT, n= 15 for c-KitβTg) measured at 
60 weeks of age in WT and c-KitβTg mice revealed similar weights between the groups. 
(e) Average 24-hour food intake measurements (in grams) over a 72-hour duration in WT 
(n=3) and c-KitβTg (n=6) mice. Closed circles: WT group; open circles: c-KitβTg group. 
Data are expressed as mean ± SEM. *p < 0.05, **p < 0.01; analyzed using unpaired 
Student’s t-test. 
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Figure 3.2: Decreased insulin release was linked to impaired glucose tolerance in 60-
week old c-KitβTg mice. 
(a) IPGTT with area under curve (AUC), and (b) IPITT with AUC for 60-week WT and 
c-KitβTg mice demonstrated impaired glucose tolerance in 60-week c-KitβTg mice and 
unchanged insulin resistance (n=13 WT and n=19 c-KitβTg for IPGTT; n=10 WT and 
n=13 c-KitβTg for IPITT). (c) Ex vivo GSIS (ng/mL) from 10 isolated islets per 
biological replicate exposed to low (2.2 mmol/L) and high glucose (22 mmol/L) 
demonstrated that islets from c-KitβTg mice had reduced insulin release under high 
glucose conditions (n=5). (d) Total insulin content (g/mg) from isolated islets of 60-
week WT and c-KitβTg mice (n=4). Closed circles: WT group; open circles: c-KitβTg 
group. Data are expressed as mean ± SEM. *p < 0.05; analyzed using unpaired Student’s 
t-test. 
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3.3.2 c-KitβTg mice demonstrated increased beta cell mass and proliferation 
and nuclear FOXO1 expression at 60 weeks of age 
Histological analyses of pancreata from 60-week c-KitβTg mice showed an increase in 
beta cell mass with no discernable changes in islet number or alpha cell mass (Figure 
3.3a-d). The increased beta cell mass in 60-week c-KitβTg mice was not due to changes 
in beta cell size (Figure 3.3e) but was accompanied by higher beta cell proliferation as 
shown using Ki67 co-staining with insulin (Figure 3.3f). When analyzing the subcellular 
localisation of transcription factors in beta cells, it was found that nuclear PDX-1 
immunoreactivity was similar between 60-week WT and c-KitβTg mice (Figure 3.4a). In 
contrast, islets from 60-week c-KitβTg mice showed increased FOXO1 localisation in the 
nucleus (Figure 3.4b). No changes were observed between mouse groups for the nuclear 
expression of beta cell maturation factors NKX6.1 and MAFA. GLUT2 staining in beta 
cells was also similar between the groups (Figure 3.5). Vascularization was analyzed in 
the islets of 60-week WT and c-KitβTg mice and showed similar capillary density, area, 
and vessel diameter (Figure 3.6).  
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Figure 3.3: Beta cell mass and proliferation were increased in 60-week c-KitβTg 
mice. 
(a) Representative immunofluorescence images of islet morphology in 60-week WT and 
c-KitβTg pancreata, showing insulin staining (red) with DAPI counterstained nuclei 
(blue). Scale bar: 200 m. Quantification of (b) islet density (no./mm2), (c) beta cell mass 
(mg), and (d) alpha cell mass (mg), and (e) individual beta cell size (m2) in 60-week 
WT and c-KitβTg mice showed significantly increased beta cell mass in c-KitβTg mice 
(n=5). (f) Proliferation of beta cells, quantified using cell cycle marker Ki67 co-
localisation with insulin+ cells, was increased in 60-week c-KitβTg mice (n=4). Closed 
circles: WT group; open circles: c-KitβTg group. Data are expressed as mean ± SEM. *p 
< 0.05; analyzed using unpaired Student’s t-test.  
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Figure 3.4: FOXO1 nuclear localisation was increased in islets of c-KitβTg mice at 
60 weeks of age. 
Representative double immunofluorescence images and quantification of nuclear (a) 
PDX-1 and (b) FOXO1 (green) co-localised with insulin+ (red) and DAPI (blue) stained 
pancreas sections. Quantification of nuclear PDX-1 (n=5 WT and n=6 c-KitβTg) and 
FOXO1 (n=4 WT and n=5 c-KitβTg) in insulin+ cells of 60-week mice revealed 
increased FOXO1+ beta cells in 60-week c-KitβTg mice. Nuclei are stained with DAPI 
(blue). White asterisk marks red blood cell autofluorescence in vessel lumens. Scale bar: 
50 m. Closed circles: WT group; open circles: c-KitβTg group. Data are expressed as 
mean ± SEM. **p < 0.01; analyzed using unpaired Student’s t-test. 
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Figure 3.5: NKX6.1, MAFA, and GLUT2 expression was similar between islets from 
60-week WT and c-KitβTg mice. 
(a) Representative immunofluorescence photomicrographs for the beta cell transcription 
factors NKX6.1 (green), co-stained with insulin (red), and MAFA (red) IHC staining 
from pancreatic sections of 60-week WT and c-KitβTg mice demonstrated unaltered 
immunoreactivity. Nuclei were labeled with DAPI (blue) for IF staining, hematoxylin 
(blue) for IHC staining. (b) Representative immunofluorescence images of GLUT2 
(green) co-localisation in insulin+ (red) cells showed similar membrane reactivity 
between 60-week mouse groups. DAPI, blue. White asterisk marks red blood cell 
autofluorescence in vessel lumens. Scale bar: 50 μm. 
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Figure 3.6: Islet vascularization was similar in islets from 60-week WT and c-
KitβTg mice.  
(a) Representative immunofluorescence photomicrographs of islet vascularization 
detected using PECAM-1 (green) in 60-week WT and c-KitβTg pancreas section co-
stained for insulin (red) and DAPI (blue). Scale bar: 50 μm. (b) Blood vessel density, (c) 
area, and (d) diameter of 60-week WT (n=6) and c-KitβTg (n=5) pancreas sections 
revealed similar vessel characteristics. Closed circles: WT group; open circles: c-KitβTg 
group. Data are expressed as mean ± SEM.   
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3.3.3 Levels of exocytosis-regulating SNARE proteins were reduced in 60-
week c-KitβTg mice 
The soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) 
complex, required for insulin vesicle tethering and fusion to the membrane, was 
examined by western blot and immunofluorescence microscopy to determine their 
changes in expression. Significantly reduced levels of Syntaxin 1A (Figure 3.7ab) and 
the associated chaperone protein MUNC18-1 (Figure 3.7cd) were observed in islets from 
60-week c-KitβTg mice. Immunofluorescence imaging found unchanged 
immunoreactivity for SNAP25 between WT and c-KitβTg mice (Figure 3.7e) and 
relatively low detection of VAMP2 in islets of 60-week c-KitβTg mice (Figure 3.7e). 
These data implicated that chronic c-Kit overexpression may impair insulin release 
kinetics in 60-week c-KitβTg beta cells due to significantly reduced levels of SNARE 
proteins. 
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Figure 3.7: 60-week c-KitβTg mice demonstrated reduced levels of islet SNARE 
proteins. 
Representative western blot (above) and densitometry (below) for (a) Syntaxin 1A and 
(c) MUNC18-1 in islets showed decreased levels in 60-week c-KitβTg mice (n=4). 
Representative immunofluorescence images of (b) Syntaxin 1A and (d) MUNC18-1; (e) 
SNAP25 (left) and VAMP2 (right) staining in islets of 60-week WT and c-KitβTg mice. 
SNARE proteins (green) were shown in insulin+ cells (red) labeled with DAPI (blue). 
Scale bar: 50 m. White asterisk, red blood cell autofluorescence in vessel lumens. 
Closed circles: WT group; open circles: c-KitβTg group. Data are expressed as mean ± 
SEM. *p < 0.05, **p < 0.01; analyzed using unpaired Student’s t-test. 
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3.3.4 Increased IR and phosphorylated IRS-1S612 levels resulted in an impaired 
response to insulin in 60-week c-KitβTg mice 
Although c-KitβTg mice at 8-28 weeks of age showed increased insulin release and 
enhanced IR–IRS1/2Y608–AktS473 signalling (4,7), islets from 60-week c-KitβTg mice 
demonstrated increased levels of IR and phosphorylated IRS-1S612 (Figure 3.8a). 
Immunofluorescence analysis for total IRS-1 in pancreata also demonstrated significantly 
reduced levels in beta cells of 60-week c-KitβTg mice (Figure 3.8b). Increased AktS473 
phosphorylation observed in prior studies of 8-week c-KitβTg mice (4) was abolished in 
60-week c-KitβTg mice (Figure 3.9a). Similar levels of phosphorylated ERK1/2 was 
found in islets of 60-week WT and c-KitβTg mice (Figure 3.9a). The apoptosis marker 
cleaved poly (ADP-ribose) polymerase (PARP) was increased in the islets of c-KitβTg 
mice at 60 weeks (Figure 3.9a). 
To determine whether impaired IR–IRS-1–Akt signalling in islets of 60-week c-KitβTg 
mice impacted insulin responses, islets were isolated and treated with exogenous insulin 
at a concentration of 2 nmol/L for 24 hours. Western blot analyses of the lysates revealed 
that islets from WT mice had increased AktS473 phosphorylation in response to insulin 
stimulation compared to untreated control islets (Figure 3.9b). However, islets from 60-
week c-KitβTg mice treated with 2 nmol/L insulin showed no increase in AktS473 
phosphorylation when compared to untreated controls (Figure 3.9b).  
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Figure 3.8: Islets from 60-week c-KitβTg mice demonstrated increased IR and 
phosphorylated IRS-1S612 levels but reduced total IRS-1 levels. 
(a) Western blot and densitometry for total IR and phosphorylated IRS-1S612 expression 
in islets from WT (n=3) and c-KitβTg (n=4) mice showed increased levels of both 
proteins. (b) Representative images (left) and quantification (right) of IRS-1 (green) in 
insulin+ (red) cells in 60-week mice (n=4 WT and n=7 c-KitβTg) co-stained with DAPI 
(blue). Scale bar: 50 m. Closed circles: WT group; open circles: c-KitβTg group. Data 
are expressed as mean ± SEM. *p < 0.05; analyzed using unpaired Student’s t-test.  
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Figure 3.9: Islets from 60-week c-KitβTg mice exhibited reduced insulin-induced 
signalling. 
(a) Western blot and densitometry for AktS473 and ERK1/2 phosphorylation (n=4), and 
cleaved PARP levels (n=4 WT and n=3 c-KitβTg) in islets from 60-week c-KitβTg mice 
demonstrated a loss of Akt signalling with increased islet apoptosis. Data were 
normalised to total signalling protein (Akt, ERK, PARP) from islets. Closed circles, WT 
group; open circles, c-KitβTg group. (b) Western blot and densitometry for AktS473 
phosphorylation in isolated islets from WT (left) and c-KitβTg (right) mice in response to 
insulin stimulation for 24 hours showed increased insulin-induced Akt phosphorylation in 
WT, but not in c-KitβTg, mice (n=4). Closed circles: control with 0 nmol/L insulin; open 
circles: 24-hour treatment with 2 nmol/L insulin. Data are expressed as mean ± SEM. *p 
< 0.05; analyzed using unpaired Student’s t-test. 
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3.3.5 IR knockout protected against glucose intolerance in 60-week c-KitβTg 
mice 
As islets from c-KitβTg mice showed impaired IR–IRS-1 signalling and decreased 
response to insulin stimulation, we crossed c-KitβTg mice with the MIP-βIRKO mouse 
line to generate a model with tamoxifen-inducible loss of beta cell IR in c-KitβTg mice 
(c-KitβTg;βIRKO) (19). At 40 weeks of age, western blot and immunofluorescence 
analyses of IR levels in islets from MIP-βIRKO mice showed an approximately 40% 
reduction (Figure 3.10). The body weight of 60-week c-KitβTg and c-KitβTg;βIRKO 
mice was significantly increased compared to control littermates (Figure 3.11a). 
Increased fasting blood glucose levels in 60-week c-KitβTg mice were not found in c-
KitβTg;βIRKO mice (Figure 3.11b). IPGTT in 60-week c-KitβTg;βIRKO mice showed 
similar glucose tolerance compared to control littermates (Figure 3.11c). Fed plasma 
samples revealed that 60-week c-KitβTg mice had significantly elevated insulin levels 
compared to control and c-KitβTg;βIRKO mice, indicating high circulating insulin levels 
(Figure 3.11d). No differences were found in in vivo GSIS assays between 60-week c-
KitβTg;βIRKO mice and c-KitβTg mice (Figure 3.11e).  
Islet morphology from c-KitβTg;βIRKO mice revealed that beta cell mass was decreased 
compared to 60-week c-KitβTg mice (Figure 3.12a). Alpha cell mass and islet density 
was unchanged between all three groups (Figure 3.12bc). Beta cell proliferation was 
modestly increased in islets from 60-week c-KitβTg mice compared to control mice but 
was not different when compared to c-KitβTg;βIRKO mice (Figure 3.12d). Furthermore, 
no differences were found in the levels of phosphorylated AktS473 (Figure 3.12e) or 
syntaxin 1A+ beta cells from 60-week mice (Figure 3.12f). Nuclear PDX-1 expression 
was also unchanged between the three groups (Figure 3.13a). Nuclear FOXO1 in 60-
week c-KitβTg mouse islets was increased compared to control mice (Figure 3.13b). 
FOXO1 nuclear localisation in c-KitβTg;βIRKO mice was not statistically different 
compared to control mice (Figure 3.13b). Interestingly, nuclear MAFA levels were 
increased in islets from 60-week c-KitβTg;βIRKO mice compared to both control and c-
KitβTg mice (Figure 3.13c). Overall, these results demonstrated that reduced IR 
signalling in c-Kit-overexpressing beta cells decreased glucose levels and beta cell mass.  
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Figure 3.10: Confirmation of IR knockdown was observed after tamoxifen 
administration in c-KitβTg;βIRKO mice. 
(a) Western blot and densitometry of IR expression in islets from control and MIP-
βIRKO mice after oral gavage tamoxifen administration (n=3). (b) Representative 
immunofluorescence images of control and MIP-βIRKO pancreas sections for IR (green) 
and insulin+ cells (red), co-stained with DAPI (blue). Scale bar: 25 m. Closed circles: 
control; open circles: MIP-βIRKO. Data are expressed as mean ± SEM. *p < 0.05; 
analyzed using unpaired Student’s t-test. 
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Figure 3.11: 60-week c-KitβTg;βIRKO mice demonstrated improved glucose 
tolerance and insulin release compared to c-KitβTg mice. 
(a) Fasting body weight and (b) blood glucose levels were increased in c-KitβTg mice 
compared to control littermates at 60 weeks of age (20 weeks post-tamoxifen), but only 
fasting body weight was increased in c-KitβTg;βIRKO mice (n=9 control, n=8 c-KitβTg, 
and n=7 c-KitβTg;βIRKO). (c) c-KitβTg mice showed impaired glucose tolerance 
compared to littermate controls (n=9 control, n=8 c-KitβTg, and n=7 c-KitβTg;βIRKO). 
(d) Fed plasma insulin was increased in c-KitβTg mice compared to control littermates. 
c-KitβTg;βIRKO mice showed no change compared to controls (n=5 control, n=4 c-
KitβTg, and n=4 c-KitβTg;βIRKO). (e) In vivo GSIS (ng/mL) at baseline (0 min), 5 min, 
and 35 min after glucose challenge (n=5 control, n=3 c-KitβTg, and n=4 c-
KitβTg;βIRKO). Closed circles: control group; open circles: c-KitβTg group; closed 
squares: c-KitβTg;βIRKO group. Data are expressed as mean ± SEM. *p < 0.05, **p < 
0.01, ***p < 0.001; analyzed using one-way ANOVA with Tukey’s post hoc test. 
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Figure 3.12: Beta cell mass was increased in 60-week c-KitβTg mice and reduced in 
c-KitβTg;βIRKO mice. 
Morphometric analysis for (a) beta cell mass, (b) alpha cell mass, and (c) islet density 
(n=4 control, n=5 c-KitβTg, and n=4 c-KitβTg;βIRKO) in control, c-KitβTg, and c-
KitβTg;βIRKO mice demonstrated increased beta cell mass in c-KitβTg mice compared 
to control and c-KitβTg;βIRKO. (d) Beta cell proliferation measured using Ki67 staining 
in beta cells of 60-week control, c-KitβTg, and c-KitβTg;βIRKO mice (n=6 control, n=6 
c-KitβTg, and n=5 c-KitβTg;βIRKO). (e) Representative immunohistochemical images 
(left) and quantification (right) of p-AktS473 (red) staining in control, c-KitβTg, and c-
KitβTg;βIRKO mice (n=4 control, n=3 c-KitβTg, and n=3 c-KitβTg;βIRKO). 
Hematoxylin, blue; scale bar: 50 m. (f) Immunofluorescence images (right) and 
quantification (left) for SNARE protein Syntaxin 1A (green) in insulin+ (red) cells of 60-
week control, c-KitβTg, and c-KitβTg;βIRKO mice were similar between the three 
groups (n= 4). DAPI, blue; scale bar: 50 m. White asterisk, red blood cell 
autofluorescence. Closed circles: control; open circles: c-KitβTg; closed squares: c-
KitβTg;βIRKO. Data are expressed as mean ± SEM. *p < 0.05; analyzed using one-way 
ANOVA with Tukey’s post hoc test. 
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Figure 3.13: Nuclear transcription factor expression in 60-week c-KitβTg;βIRKO 
mice demonstrated increased MAFA levels when compared to littermates. 
Representative double immunofluorescence images (left) and quantification (right) for 
nuclear (a) PDX-1 (n=3 control, n=5 c-KitβTg, and n=3 c-KitβTg;βIRKO), (b) FOXO1 
(n=5 control, n=5 c-KitβTg, and n=4 c-KitβTg;βIRKO), and (c) MAFA (n=4 control, n=4 
c-KitβTg, and n=3 c-KitβTg;βIRKO) (green) in insulin+ (red) cells of 60-week mice. The 
findings indicate that 60-week c-KitβTg;βIRKO mice have lowered nuclear FOXO1 and 
increased nuclear MAFA in beta cells compared to c-KitβTg mice. DAPI, blue, scale bar: 
50 m. White asterisk, red blood cell autofluorescence. Closed circles: control; open 
circles: c-KitβTg; closed squares: c-KitβTg;βIRKO. Data are expressed as mean ± SEM. 
*p < 0.05 and analyzed using one-way ANOVA with Tukey’s post hoc test. 
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3.4 Discussion 
The studies presented characterized the long-term effects of chronic c-Kit receptor 
expression in murine beta cells. Results from this section demonstrated that 60-week c-
KitβTg mice lost their capacity to regulate glucose levels due to reduced insulin 
secretion. Although beta cell mass and proliferation were maintained in c-KitβTg mice, 
high levels of apoptosis and decreased insulin exocytosis were observed in islets from 60-
week c-KitβTg mice. 60-week islets from c-KitβTg mice also showed increased IR 
signalling and phosphorylated IRS-1S612, potentially resulting in negative feedback on the 
PI3K–Akt pathway and increased shuttling of FOXO1 to the nucleus. Decreased response 
to insulin stimulation in islets of c-KitβTg mice manifested the development of impaired 
IR–insulin signalling due to c-Kit overexpression (Figure 3.14) (20). Reducing beta cell 
IR expression in c-KitβTg mice led to partially restored glucose tolerance and improved 
insulin secretion through up-regulation of MAFA. This study demonstrates that 
prolonged overexpression of the c-Kit receptor, although able to improve glucose 
tolerance and insulin release with short-term activity, can induce beta cell dysfunction 
and insulin secretory defects through chronic activation of the IR-insulin signalling 
pathway. 
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Figure 3.14: Schematic for working model summarizing the effects of c-Kit 
overexpression on insulin secretion in beta cells. 
Initial c-Kit activation, as seen in 8-28 week old c-KitβTg mice, led to improved beta cell 
function and insulin secretion though enhanced Akt signalling, nuclear localisation of 
PDX-1, and increased expression of IR and IRS (4). When c-Kit overexpression was 
maintained for prolonged periods (60 weeks in our current study), c-KitβTg mice 
developed impaired glucose tolerance linked to phosphorylation of IRS-1S612 from long-
term c-Kit and IR signalling (dashed arrows) (20). Islets from c-KitβTg mice 
demonstrated reduced Akt signalling that was associated with nuclear FOXO1 (to signal 
apoptosis) and defects in insulin release due to reduced SNARE proteins. Impaired IR–
IRS-1–Akt pathway in 60-week c-KitβTg mice was partially rescued by reducing the 
expression of beta cell IR in tandem with c-Kit overexpression, which restored insulin 
secretion and glucose tolerance. This figure was assembled using the Inkscape software 
(version 0.92). Y: phosphorylated tyrosine site; S: phosphorylated serine site. 
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Previous studies established that c-Kit overexpression in 8-week-old c-KitβTg mice 
resulted in improved insulin release under normal diet and short-term HFD challenge (4). 
The current study demonstrated that long-term beta cell c-Kit overexpression in mice 
resulted in glucose intolerance due to reduced insulin release, which is similar to the 
findings of long-term HFD challenge in c-KitβTg mice (7). Although beta cell 
proliferation has been reported to decrease in older mice (12), 60-week c-KitβTg mice 
maintained their high beta cell proliferation rate and beta cell mass seen in the 8-week 
model. c-KitβTg mice also demonstrated increased body weight at 60 weeks of age. This 
increased body weight may have contributed to the development of glucose intolerance 
and defects in insulin release despite enhanced beta cell mass and proliferation, which is 
a common phenotype observed C57BL/6 mice fed a high-fat diet (21). These studies have 
also demonstrated that 60-week c-KitβTg mice lacked the increased Akt phosphorylation 
seen in young c-KitβTg mice (4). Islet cell survival, which was decreased in 60-week c-
KitβTg mice as indicated by increased levels of cleaved PARP, has also been shown to be 
regulated through Akt signalling (24). Previous studies have also shown that the 
percentage of apoptotic beta cells cultured in high glucose was increased when PI3K–Akt 
signalling was inhibited but was unchanged after ERK inhibition (25). Collectively these 
findings indicate that chronic c-Kit activation can cause intracellular signalling changes 
that can impact islet survival rate and proliferation. 
The altered expression of SNARE proteins in islets of 60-week c-KitβTg mice may have 
contributed to decreased insulin release and glucose intolerance. The PI3K–Akt 
signalling pathway has been linked to regulation of SNARE levels in beta cells and has 
been shown to affect insulin secretion. Mice with a total PI3K deficiency (βDKO mice) 
had decreased mRNA and protein levels of exocytotic molecules, including Syntaxin 1A, 
SNAP25 and VAMP2, and were restored upon introduction of constitutive Akt signalling 
(26). Similar to 60-week c-KitβTg mice, βDKO mice also showed increased nuclear 
FOXO1 and ERK signalling (26). Akt phosphorylation regulated the cytoplasmic 
sequestering of FOXO1 and transcription of Pdx-1 in beta cells, which is important in 
order to avoid FOXO1-induced apoptosis (27,28). Reductions in SNARE protein levels 
have been noted in db/db mouse and fa/fa rat models and in individuals with type 2 
diabetes (29-31). The high fed plasma insulin secretion and glucose intolerance in c-
  
 
106 
KitβTg mice at 60 weeks may reflect this defect, where loss of SNARE proteins due to 
reduced levels of phosphorylated Akt led to FOXO1 nuclear localisation and 
dysfunctional insulin release. 
Our previous study determined that c-KitβTg mice at 8–28 weeks of age had increased 
insulin release and enhanced IR–IRS1/2–AktS473 signalling (4). However, while 60-week 
c-KitβTg mice in the current study displayed increased IR protein levels in islets, these 
islets also had a significant increase in IRS-1S612 phosphorylation. Serine phosphorylation 
of IRS-1 has been shown to negatively feed back to the PI3K–Akt pathway, resulting in 
downregulation of its activity, promotion of IRS-1 protein degradation, and insulin 
resistance (32,33). Maintenance of the IR–IRS signalling axis has also been implicated in 
glucose-induced FOXO1 nuclear exclusion and insulin resistant ob/ob mouse islets 
demonstrated both increased nuclear FOXO1 expression along with reduced levels of 
SNARE proteins SNAP25 and VAMP2 (28,34). Inhibiting the Akt–mechanistic target of 
rapamycin kinase (mTOR) signalling axis prevents serine phosphorylation and prolongs 
tyrosine phosphorylation of IRS-1, which led to maintained IRS-1 signalling (33). Insulin 
resistance has recently been implicated in the enhanced presence of beta cell senescence 
markers, as seen in mice with induced hyperinsulinaemia through the IR antagonist S961 
(35). The high fed plasma insulin levels found in 60-week c-KitβTg mice in this study 
may indicate the development of beta cell insulin resistance and may contribute to the 
dysfunction seen in c-KitβTg beta cells. Inhibiting the development of insulin resistance 
in islets by reducing IR signalling, which was the aim of the IR knockdown in ageing c-
KitβTg;βIRKO mice, may serve as a potential mechanism to alleviate beta cell 
dysfunction.  
The knockdown of IR in c-KitβTg mice at 40 weeks partially restored glucose tolerance. 
This reduction in beta cell insulin signalling can be beneficial since prolonged circulating 
insulin has been shown to affect glucose tolerance and insulin sensitivity in mice (36,37). 
The enhanced proliferation and reduced Syntaxin 1A protein expression found in 60-
week c-KitβTg mice was not seen in the MIP-CreER-crossed mouse model, where the 
cohort of 60-week c-KitβTg mice demonstrated only mild glucose intolerance and similar 
levels of Ki67-positive and Syntaxin 1A-positive beta cell when compared with control 
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and c-KitβTg;βIRKO mice. This may be due to confounding effects attributed to both the 
MIP-CreER mouse model and the tamoxifen administration used in the second part of 
this study. The growth hormone minigene found within the MIP-CreER mouse model is 
transcribed and has been shown to produce increased beta cell mass and proliferation 
(38,39), while tamoxifen can blunt beta cell proliferation when administered to mice (40). 
Another limitation to consider is the incomplete IR knockdown achieved in 60-week c-
KitβTg;βIRKO mice administered tamoxifen at 40 weeks (40% reduction). Previous 
knockout mouse models from our laboratory that were crossed with the MIP-CreERT line 
achieved a 40–70% protein reduction (19,41). One change that was consistently observed 
was increased nuclear MAFA levels in c-KitβTg;βIRKO mice. Nuclear FOXO1 can 
increase MAFA expression under metabolic stresses as seen in hyperglycaemia and high-
fat diet feeding (42,43), and MAFA up-regulation was required for insulin secretion (44-
46). These results may indicate that nuclear FOXO1 expression in c-KitβTg mice 
develops initially as a response to metabolic stress but results in glucose intolerance due 
to reduced insulin signalling; reduction of IR expression in ageing c-KitβTg;βIRKO mice 
may delay the progression of glucose intolerance through MAFA up-regulation. 
The present study demonstrated that long-term overexpression of c-Kit in beta cells does 
not maintain the improved glucose tolerance seen in mice with short-term c-Kit activation 
and resulted in altered beta cell function that reduced glucose-induced insulin exocytosis. 
Examining the long-term activation of c-Kit in a mouse model has identified that 
transient signalling through the receptor can improve beta cell function and the expansion 
of the beta cell compartment, yet chronic activation of this pathway can result in the 
development of beta cell dysfunction that led to compromised blood glucose control. The 
use of RTK-based therapies to enhance beta cell function in transplanted murine, primate, 
and human islets has been previously studied (47,48). However, the long-term effects of 
chronic RTK signalling must be examined to determine their lasting efficacy and any 
potential complications. Regulating the duration of c-Kit overexpression to prevent the 
development of negative feedback in beta cells needs to be considered when examining 
the potential use of RTK-based therapies for the treatment of diabetes in order to ensure 
optimal beta cell function.  
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Chapter 4  
4 Postnatal knockout of beta cell insulin receptor impaired 
insulin secretion in mice exposed to high-fat diet stress3 
 
  
                                                 
3
 Text and figures from this chapter have been adapted from the following manuscript: 
Oakie A, Zhou L, Rivers S, Cheung C, Li J, and Wang R. Postnatal deletion of beta cell 
insulin receptor affects insulin secretion in mice exposed to high-fat diet stress. 
Submitted to American Journal of Physiology- Endocrinology and Metabolism, April 
2019. Manuscript number: E-00165-2019 ** 
 
** Results from ND mice in Figures 4.1, 4.2, 4.3, and 4.4 were analyzed and previously 
presented by L. Zhou (featured in the manuscript above) 
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4.1 Introduction 
Optimal beta cell function requires activation of signalling pathways activated through 
different membrane receptor tyrosine kinases (RTKs). The RTK insulin receptor (IR) has 
high affinity for insulin and insulin binding leads to the activation of multiple signalling 
pathways in beta cells (1-3). The first report utilizing a beta cell-specific IR knockdown 
mouse model (βIRKO) demonstrated reduced first-phase insulin release, age-dependent 
loss of beta cell mass, and decreased GLUT2 expression, all of which contributed to the 
loss of glycemic control and development of diabetes (4). Subsequent studies have 
determined that phosphorylation of IR is associated with activation of the PI3K−Akt 
pathway, and that signalling through this axis is important for insulin synthesis and 
maintenance of functional beta cell mass through PDX-1 nuclear expression (1,5,6). 
However, the role of autocrine insulin stimulation on insulin granule release from beta 
cells is unclear due to reports that have found both positive and negative regulatory roles 
for insulin signalling on insulin release (7-10). One pathway proposed to contribute to 
beta cell-specific insulin resistance is dysfunctional IR−IRS−Akt axis signalling (11).  
The high-fat diet (HFD) mouse model exhibits peripheral insulin resistance and glucose 
intolerance, and promotes rapid weight gain and a steady increase in serum insulin levels 
(12). HFD-challenged mice demonstrated hyperinsulinemia after 8 weeks and a parallel 
decrease in beta cell PDX-1 and GLUT2 expression (13). HFD mice have also been 
shown to undergo a period of proliferative beta cell expansion in the weeks initially 
following the start of HFD as an adaptation to the abnormal glucose tolerance that 
developed (14,15). The βIRKO mouse line has been previously used to determine the role 
of beta cell IR signalling under HFD-induced metabolic stress (16). Unlike control HFD 
fed littermates that demonstrated a proliferative increase in beta cell mass, beta cell mass 
of βIRKO mice fed a HFD did not show compensatory proliferation and did not increase 
beta cell mass. This indicates that maintenance of IR signalling was required for beta cell 
response to HFD challenge. 
Although the βIRKO mouse model, in which IR was deleted in beta cells from the onset 
of fetal islet development, has shown reduced beta cell mass and function postnatally 
  
 
114 
(4,17), the loss of IR in developed beta cells has not been examined. In order to 
determine if IR signalling is required for beta cell maintenance and function postnatally, 
this study investigated the effects of postnatal beta cell IR loss in mice fed a normal diet 
(ND) and HFD diet (18-week duration).    
4.2 Materials and methods 
Generation and maintenance of MIP-βIRKO mice: MIP-CreER+/-;IRfl/+ mice were 
generated as previously described (Section 2.1.3) and bred to acquire control (MIP-
CreER+;IR+/+or MIP-CreER-;IRfl/fl) and MIP-βIRKO (MIP-CreER+;IRfl/fl) mice. Male 
mice were used for all experiments. Tamoxifen was administered to all mice at 4 weeks 
of age (4 mg/ 20 g bodyweight, i.p.) for 3 days. Control and MIP-βIRKO littermates were 
divided into normal diet (ND) or high-fat diet (HFD; 20% protein, 60% fat, 20% 
carbohydrates, 5.21 kcal/g; product # D12492; Research Diets Inc, New Brunswick, NJ) 
groups at 6 weeks of age and maintained for 18 weeks (analysis at 24 weeks of age).   
In vitro INS-1 cell experiments: INS-1 832/13 cells were serum-starved in RPMI 1640 
with 1% BSA media overnight at 90% confluency. Cells were then treated with insulin 
(100 nmol/L; Sigma-Aldrich) for 1 hour and harvested for immunofluorescence analysis 
of SNARE proteins. Additional information can be found in Section 2.7.  
Metabolic experiments: Control and MIP-βIRKO mice fed ND or HFD had their body 
weights, fasting blood glucose levels, and fasting plasma insulin levels measured at 24 
weeks of age. IPGTT, IPITT, and ex vivo GSIS were performed at this time-point using 
the methods described in Sections 2.3 and 2.5. Islet insulin content was measured and 
normalised to total islet protein (g/mg). 
Immunohistochemical staining: Pancreata from control and MIP-βIRKO mice and 
harvested INS-1 cells were stained with select primary antibodies listed in Table 2.2 
(from Chapter 2). Detection was performed using fluorophore- or peroxidase-linked 
secondary antibodies. For chromagen staining, AEC substrate was used. Details are 
presented in Section 2.8. 
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Western blot analyses: Islets from control and MIP-βIRKO mice were isolated and lysed 
as described in Section 2.4. Proteins were analyzed by western blot using primary 
antibodies (Table 2.2 from Chapter 2) for proteins of interest (IR, Cyclin D1, VAMP2, 
SNAP25, Syntaxin 1A, MUNC18-1) and normalised to a loading control (-actin), or 
respective total protein for signalling proteins (p-AktS473, p-AktT308, p-P70S6K1T389, p-
ERKT202/Y204) (Section 2.9). 
Statistical analysis: All data presented are represented as mean  SEM and were analyzed 
using unpaired Student’s t-tests. Statistical significance was obtained when p < 0.05. 
4.3 Results 
4.3.1 IR knockout demonstrated glucose intolerance when challenged with 
HFD 
Islets isolated from MIP-βIRKO ND mice showed that the deletion efficiency of IR 
expression was approximately 50% compared to islets from control ND mice (Figure 
4.1a). Knockout of IR was also confirmed using immunofluorescence staining of islets 
from control ND and MIP-βIRKO ND mice (Figure 4.1b). Under ND conditions, MIP-
βIRKO mice examined at 24 weeks of age did not demonstrate a change in body weight 
or fasted blood glucose levels when compared to control littermates (Figure 4.2a). 
Following 18 weeks of HFD feeding (24 weeks of age), MIP-βIRKO mice still did not 
display a change in either body weight or fasted blood glucose when compared to control 
HFD mice (Figure 4.2b). However, both body weights and fasting glucose levels were 
increased in HFD mice groups compared to ND groups (Figure 4.2ab), indicating that 
HFD stress increased body weight and blood glucose levels in both control and MIP-
βIRKO mice.  
IPGTT results from MIP-βIRKO ND mice demonstrated similar glucose tolerance as 
control ND mice (Figure 4.2c). However, unlike MIP-βIRKO ND mice, MIP-βIRKO 
HFD mice displayed impaired glucose tolerance when compared to their control HFD 
counterparts (Figure 4.2d). To examine if increased glucose intolerance in MIP-βIRKO 
HFD mice was due to the development of peripheral insulin resistance, insulin tolerance 
tests were performed. IPITT results from both ND and HFD mice revealed that insulin 
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sensitivity was similar between control and MIP-βIRKO mice (Figure 4.3ab). Fasting 
plasma insulin was collected from both ND and HFD groups to examine basal insulin 
release. Although no change was detected between control and MIP-βIRKO ND mice, 
MIP-βIRKO HFD mice demonstrated a reduction in fasting plasma insulin levels when 
compared to control HFD mice (Figure 4.3c). Ex vivo GSIS results from ND mice 
revealed similar levels of insulin release under low and high glucose conditions, although 
variability was noted between groups (Figure 4.3d). Ex vivo GSIS performed on isolated 
HFD islets showed that MIP-βIRKO HFD mice had significantly reduced insulin release 
when exposed to low glucose, with no statistical significance in insulin release in 
response to high glucose (Figure 4.3e). The insulin content of islets from control and 
MIP-βIRKO HFD mice following GSIS was unchanged (Figure 4.3f). These results 
indicate that normal postnatal IR expression on beta cells is required for maintaining 
adult beta cell function in response to HFD-induced cell stress.   
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Figure 4.1: Confirmation of postnatal IR knockout in MIP-βIRKO mice revealed a 
reduction of IR expression in beta cells. 
(a) Representative western blot and quantification of IR expression in isolated islets from 
control and MIP-βIRKO normal diet (ND) mice demonstrated a 50% reduction in IR with 
knockout (n= 6). (b) Representative immunofluorescence images of IR (green) in insulin+ 
cells (red) showed reduced IR expression in islets from MIP-βIRKO ND mice. Nuclei 
were stained with DAPI (blue). Scale bar: 50 m. Closed square, control ND; open 
square, MIP-βIRKO ND. Data are expressed as mean ± SEM. **p < 0.01 vs control; 
analyzed using unpaired Student’s t-test. 
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Figure 4.2: MIP-βIRKO mice on ND maintained a similar response to glucose 
challenge as diet-matched controls, but MIP-βIRKO mice developed glucose 
intolerance after HFD challenge. 
(a) Body weight (n= 9 control ND and n=11 MIP-βIRKO ND) and fasted blood glucose 
(n= 8 control ND and n=10 MIP-βIRKO ND) measurements were similar for control and 
MIP-βIRKO mice at 24 weeks of age on ND. (b) Body weight and fasted blood glucose 
for 24-week control and MIP-βIRKO mice revealed no change after 18 weeks of high-fat 
diet (HFD) feeding (n= 11). (c) IPGTT (n=7 control ND and n=6 MIP-βIRKO ND) in 
control ND and MIP-βIRKO ND mice with corresponding area under curve (AUC) 
results demonstrated similar glucose tolerance levels. (d) IPGTT (n=7 control HFD and 
n=6 MIP-βIRKO HFD) for control HFD and MIP-βIRKO HFD mice with corresponding 
AUC showed increased glucose intolerance in MIP-βIRKO mice. Closed square, control 
ND; open square, MIP-βIRKO ND; Closed circle, control HFD; open circle, MIP-βIRKO 
HFD. Data are expressed as mean ± SEM. **p < 0.01 vs control; analyzed using unpaired 
Student’s t-test. 
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Figure 4.3: MIP-βIRKO HFD mice demonstrated decreased insulin release when 
compared to diet-matched controls. 
(a) IPITT results in control ND and MIP-βIRKO ND mice with corresponding area under 
curve (AUC) results were unchanged between ND groups (n= 5). (b) Similar IPITT 
results for control HFD and MIP-βIRKO HFD mice were found when comparing the 
corresponding AUC (n=6 control HFD and n=8 MIP-βIRKO HFD). (c) Fasting (16-hour) 
plasma insulin levels from ND (n=4) and HFD (n=5) control and MIP-βIRKO mice 
revealed reduced insulin release in MIP-βIRKO HFD mice. (d) Ex vivo GSIS results from 
isolated islets of control ND and MIP-βIRKO ND mice were comparable when 
stimulated at low (2 mmol/L) and high (22 mmol/L) glucose (n= 3). (e) Ex vivo GSIS in 
islets from control HFD and MIP-βIRKO HFD mice demonstrated reduced insulin 
secretion at low glucose levels in MIP-βIRKO HFD mice. (f) Insulin content normalised 
to total islet protein in control HFD and MIP-βIRKO HFD mice (n= 4). Closed square, 
control ND; open square, MIP-βIRKO ND; Closed circle, control HFD; open circle, 
MIP-βIRKO HFD. Data are expressed as mean ± SEM. *p < 0.05 vs control; analyzed 
using unpaired Student’s t-test. 
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4.3.2 IR deficiency does not alter islet morphology or the expression of 
exocytotic proteins under normal diet 
Histological examination of pancreata from control and MIP-βIRKO ND mice was 
performed in order to determine whether postnatal loss of IR affected islet morphology. 
Islet density, alpha cell and beta cell mass, and beta cell proliferation were unchanged 
between control and MIP-βIRKO ND mice (Figure 4.4a-d). Synaptosome-associated 
protein of 25 kDa (SNAP25) and Vesicle-associated membrane protein 2 (VAMP2) are 
two proteins involved in the exocytotic complex, referred to as the soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. Both 
SNAP25 and VAMP2 were expressed at similar levels in islets when comparing control 
and MIP-βIRKO ND mice (Figure 4.4e). These findings implicate that the postnatal 
partial loss of beta cell IR does not influence beta cell morphology or exocytotic proteins 
in adult mice maintained under normal conditions.  
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Figure 4.4: Islet morphology and exocytotic protein expression were unaltered in 
MIP-βIRKO ND mice. 
(a) Islet density, (b) alpha cell mass, and (c) beta cell mass measurements from control 
ND and MIP-βIRKO ND mice did not show any alterations (n= 4). (d) Quantification of 
the beta cell proliferation marker Ki67 in insulin+ cells was similar between control ND 
and MIP-βIRKO ND mice (n= 3). (e) Representative immunofluorescence images of 
VAMP2 and SNAP25 (green) in insulin+ cells (red) of islets from control ND and MIP-
βIRKO ND mice demonstrated similar levels of expression. Nuclei were labeled with 
DAPI (blue). White asterisk, red blood cell autofluorescence. Scale bar: 50 m. Closed 
square, control ND; open square, MIP-βIRKO ND. Data are expressed as mean ± SEM; 
analyzed using unpaired Student’s t-test.  
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4.3.3 HFD decreased exocytotic SNARE protein expression in IR knockout 
mice 
Since lower levels of insulin secretion were detected in islets from MIP-βIRKO HFD 
mice, proteins that comprise the SNARE complex involved in vesicle exocytosis were 
analyzed using immunofluorescence analyses. VAMP2, SNAP25, and MUNC18-1 
immunoreactivity was significantly decreased in islets of MIP-βIRKO HFD mice 
compared to control HFD mice, indicating dysfunction in insulin vesicle tethering and 
exocytosis (Figure 4.5). The expression of exocytotic SNARE proteins was also 
quantified by western blot analysis and islets from MIP-βIRKO HFD mice demonstrated 
a significant decrease in Syntaxin 1A and VAMP2 levels with modestly lowered 
SNAP25 expression (p = 0.0667) compared to control HFD mice (Figure 4.6).  
To verify if beta cell IR activity modulated SNARE protein expression, the INS-1 cell 
line was treated with 100 nmol/L insulin for 1 hour and examined by 
immunofluorescence. INS-1 cells showed increased SNAP25 expression after insulin 
stimulation, but levels of VAMP2 and MUNC18-1 were not induced (Figure 4.7). These 
results implicate that IR signalling may be required to maintain SNARE protein 
expression in beta cells exposed to HFD stress.  
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Figure 4.5: SNARE exocytotic protein expression was reduced in the islets of MIP-
βIRKO HFD mice. 
(a) Representative double immunofluorescence images for SNARE exocytotic proteins 
(green) and insulin (red), and (b) quantification of exocytotic proteins VAMP2 (n=5 
control HFD and n=4 MIP-βIRKO HFD), SNAP25 (n=4), and MUNC18-1 (n=5 control 
HFD and n=3 MIP-βIRKO HFD) demonstrated a consistent decrease in insulin+ cells 
from islets of MIP-βIRKO HFD mice compared to control HFD mice. DAPI, blue 
labeled nuclei. White asterisk mark red blood cell autofluorescence in vasculature. Scale 
bar: 50 m. Closed circle: control HFD; open circle: MIP-βIRKO HFD. Data are 
expressed as mean ± SEM. *p < 0.05, **p < 0.01 vs control; analyzed using unpaired 
Student’s t-test. 
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Figure 4.6: SNARE exocytotic protein levels in islets from MIP-βIRKO HFD mice 
demonstrated reduced expression of Syntaxin 1A and VAMP2. 
Representative western blot images and densitometry quantification of VAMP2, 
SNAP25, MUNC18-1, and Syntaxin 1A in isolated islets from control HFD and MIP-
βIRKO HFD mice (n=4). VAMP2 and Syntaxin 1A expression were decreased in islets 
from MIP-βIRKO HFD mice compared to control HFD mice. Closed circle: control 
HFD; open circle: MIP-βIRKO HFD. Data are expressed as mean ± SEM. *p < 0.05, **p 
< 0.01 vs control; analyzed using unpaired Student’s t-test.  
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Figure 4.7: Insulin treatment of INS-1 cells led to increased expression of SNAP25. 
Representative images of SNARE protein expression (green) with quantification of (a) 
VAMP2 (n=4 for 0 mins and n=3 for 60 mins), (b) SNAP25 (n=5), and (c) MUNC18-1 
(n=3) in INS-1 cells before and after stimulation with 100 nmol/L insulin. SNAP25 
expression was significantly increased after insulin treatment. Scale bar: 25 μm. DAPI, 
blue. Closed triangle: 0 mins; open triangle: 60 mins. Data are expressed as mean ± SEM. 
*p < 0.05 vs control; analyzed using unpaired Student’s t-test.  
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4.3.4 IR deficiency reduced Akt−P70S6K1 signalling after long-term HFD 
stress 
To examine if Akt signalling was affected in islets of MIP-βIRKO HFD mice, pancreatic 
histological sections and isolated islets were examined. AktS473 phosphorylation was 
reduced in islets of MIP-βIRKO HFD mice as evident through immunohistochemistry 
staining (Figure 4.8a) and western blot analysis (Figure 4.8b). In contrast, levels of 
AktT308 phosphorylation was unchanged in MIP-βIRKO HFD mice compared to control 
HFD mice (Figure 4.8c). P70S6K1T389 phosphorylation, which is downstream of the 
Akt−mTOR signalling axis, was also reduced in MIP-βIRKO HFD mice compared to 
control HFD mice (Figure 4.8d). Examination of the phosphorylated ERK showed 
unchanged signalling in islets of MIP-βIRKO HFD mice (Figure 4.8e). These results 
demonstrate that islets from MIP-βIRKO mice fed a HFD develop reduced 
Akt−P70S6K1 intracellular signalling. 
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Figure 4.8: Reduced levels of Akt and P70S6K1 phosphorylation in islets of MIP-
βIRKO HFD mice.  
(a) Representative immunohistochemistry image (left) and quantification (right) of 
AktS473 phosphorylation shown in red (n= 4), with hematoxylin co-staining shown in 
blue, demonstrated reduced islet levels in MIP-βIRKO HFD mice. Scale bar: 50 m. 
Representative western blot images and densitometry quantification of (b) AktS473, (c) 
AktT308, (d) P70S6K1T389, and (e) ERKT202/Y204 phosphorylation in isolated islets of 
control and MIP-βIRKO HFD mice (n= 4). MIP-βIRKO HFD mice demonstrated 
decreased AktS473 and P70S6K1T389 phosphorylation. Closed circle: control HFD; open 
circle: MIP-βIRKO HFD. Data are expressed as mean ± SEM. *p < 0.05 vs control; 
analyzed using unpaired Student’s t-test. 
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4.3.5 IR deficient mice demonstrated reduced GLUT2 expression with no 
change in beta cell mass, proliferation, and transcription factor 
expression upon HFD challenge 
Immunofluorescence analyses was performed on pancreata collected from control HFD 
and MIP-βIRKO HFD mice to examine if postnatal loss of IR affected HFD-induced 
compensatory increase in islet mass. No morphological differences were found in islets 
of control HFD and MIP-βIRKO HFD mice (Figure 4.9a). Islet density and alpha cell 
and beta cell mass were similar between control and MIP-βIRKO HFD mice (Figure 
4.9b-d). Beta cell replication was also found to be similar between control HFD and 
MIP-βIRKO HFD mice as determined by Ki67+/insulin+ double immunofluorescence 
staining (Figure 4.10a) and Cyclin D1 levels from western blot (Figure 4.10b). Beta cell 
expression of the glucose-sensing channel GLUT2 in MIP-βIRKO HFD mouse islets was 
significantly decreased when compared to control HFD mouse islets (Figure 4.11a). Beta 
cell expression of PDX-1 was modestly decreased in MIP-βIRKO HFD mouse islets 
compared to controls, although this difference was not statistically significant (p = 
0.0960) (Figure 4.11b). Similar expression levels for NKX6.1 and MAFA were observed 
in islets from control HFD and MIP-βIRKO HFD mice (Figure 4.11cd). Collectively, 
these data indicate that postnatal IR signalling was required to maintain beta cell GLUT2 
expression but was dispensable for pancreatic transcription factor expression.  
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Figure 4.9: Islet morphology was unchanged in islets of MIP-βIRKO mice 
maintained on HFD. 
(a) Representative images of glucagon+ (green) and insulin+ (red) staining in islets from 
control HFD and MIP-βIRKO HFD mice. Nuclei were stained with DAPI (blue). Scale 
bar: 100 m. (b) Islet density, (c) alpha cell mass, and (d) beta cell mass were similar in 
islets from control HFD and MIP-βIRKO HFD mice (n=5). Closed circle: control HFD; 
open circle: MIP-βIRKO HFD. Data are expressed as mean ± SEM and analyzed using 
unpaired Student’s t-test. 
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Figure 4.10: MIP-βIRKO HFD mice did not demonstrate a change in beta cell 
proliferation. 
(a) Representative image (left) and quantification (right) of the proliferation marker Ki67 
(green) in insulin+ cells (red). DAPI, blue. White arrows, proliferating beta cells; white 
asterisk, red blood cells (n=5). Scale bar: 50 m. The frequency of proliferating beta cells 
was similar between islets from control HFD and MIP-βIRKO HFD mice. (b) 
Representative western blot (left) and densitometry analysis (right) showed similar 
expression of cell cycle protein Cyclin D1 in control HFD and MIP-βIRKO HFD mice 
(n=4). Closed circle: control HFD; open circle: MIP-βIRKO HFD. Data are expressed as 
mean ± SEM and analyzed using unpaired Student’s t-test. 
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Figure 4.11: Islet GLUT2 expression was decreased in MIP-βIRKO HFD mice. 
Representative images (left) and quantification (right) of (a) glucose sensor GLUT2 and 
beta cell transcription factors (b) PDX-1, (c) NKX6.1, and (d) MAFA (n= 4). GLUT2 
expression was decreased in islets from MIP-βIRKO HFD mice, but similar expression of 
beta cell transcription factors was found between control HFD and MIP-βIRKO HFD 
mice. GLUT2, PDX-1, NKX6.1: green; insulin: red; DAPI, blue. Scale bar: 50 m. 
MAFA was stained using AEC (red) and counterstained with hematoxylin (blue). White 
asterisks mark red blood cells. Scale bar: 50 m. Closed circle, control HFD; open circle, 
MIP-βIRKO HFD. Data are expressed as mean ± SEM. *p < 0.05 vs control; analyzed 
using unpaired Student’s t-test. 
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4.4 Discussion 
This study used an inducible beta cell IR knockout mouse model to determine the role of 
IR signalling in adult beta cells. Under ND condition, MIP-βIRKO mice did not 
demonstrate metabolic or islet morphological changes. However, under long-term HFD 
stress, MIP-βIRKO mice demonstrated impaired glucose tolerance with reduced basal 
insulin release and exocytotic SNARE protein expression. Decreased expression of 
GLUT2 and phosphorylation of proteins in the Akt−mTOR−P70S6K1 pathway was also 
observed in islets from MIP-βIRKO HFD mice. The results from this study establish that 
beta cell IR signalling is required for maintaining adult beta cells function in response to 
HFD-induced metabolic challenge (Figure 4.12). 
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Figure 4.12: Summary of islet characterization using βIRKO and MIP-βIRKO 
mouse models. 
A schematic summarizing previously reported studies on the βIRKO and MIP-βIRKO 
mouse models, as well as the findings from this chapter (4,17,18). The effects of beta cell 
IR loss on beta cell mass and function are dependent on the temporal time-window when 
IR deficit is created (black timeline, above). Solid green lines indicate the duration of 
beta cell IR knockout in mice under normal metabolic conditions. Broken red lines 
indicate beta cell IR knockout in mice subjected to HFD. In brief, βIRKO mice, which 
had beta cell IR knockout present when insulin+ cells first emerged during development, 
had reduced beta cell mass and defective insulin secretion in adult life that was 
exacerbated after HFD challenge (4,16,17). MIP-βIRKO mice with induced beta cell IR 
knockout at e13.5 showed increased beta cell mass and proliferation and islet 
vascularization due to compensatory signalling through the IGF-1R/ IGF-2 signalling 
axis (18). MIP-βIRKO mice with beta cell IR knockout induced at 4 weeks postnatally 
demonstrated unchanged beta cell mass and proliferation under ND; however, MIP-
βIRKO HFD mice developed insulin secretory defects due to impaired Akt signalling and 
reduced GLUT2 and SNARE protein expression in beta cells. 
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Postnatal IR knockout in beta cells did not influence glucose tolerance or islet 
architecture in ND mice, which is in contrast to the loss of first-phase insulin secretion 
and the reduction in beta cell mass and functional transcription factors previously 
reported in the βIRKO model (4,17). In the βIRKO mouse model, IR was deficient 
throughout embryonic development, postnatal remodelling, and in the adult beta cell 
compartment. Our laboratory’s previous study, which utilized the MIP-βIRKO model to 
examine the loss of beta cell IR during the second transition of murine pancreatic 
development, demonstrated that fetal MIP-βIRKO mice at embryonic day (e) 19.5 
showed increased beta cell proliferation and vascularization linked to increased insulin-
like growth factor-1 receptor (IGF-1R) and IGF-2 signalling in islets (18). These data, 
and the data collected in adult mice, suggest that the role of IR signalling in beta cells 
was dependent on the temporal window when IR knockout is initiated (Figure 4.12). It 
must also be taken into consideration that the incomplete knockout observed in this 
study’s inducible MIP-βIRKO model (approximately 50% islet reduction) was not 
sufficient to induce the development of glucose intolerance. It has been observed that 
using the MIP-CreERT mouse model to knock out GLI-similar 3 (Glis3) led to a 66%  
reduction in Glis3 mRNA in isolated islets, yet the Pdx1-CreERT model demonstrated a 
90% reduction in Glis3 mRNA with the same treatment (19). Furthermore, the authors 
reported that while Pdx1-CreERT;Glis3fl/fl mice developed glucose intolerance, MIP-
CreERT;Glis3fl/fl mice maintained normoglycemia, indicating that a high percentage of 
beta cell Glis3 knockout was required to produce a diabetic phenotype (19). This may 
reflect the results found in MIP-βIRKO ND mice and suggests that a partial loss of beta 
cell IR is able to maintain glucose homeostasis under the normal diet condition.  
The current study also demonstrated that reduced IR signalling in adult mice affected 
postnatal beta cell function in MIP-βIRKO mice fed a long-term HFD. HFD feeding in 
C57BL/6 mice induced glucose intolerance, hyperinsulinemia, and the progressive loss of 
beta cell transcription factors expression (20,21). The maintenance of beta cell IR−insulin 
signalling is now identified as a critical factor in the prevention of beta cell insulin 
resistance. Sprague Dawley rats on a 60% HFD demonstrated increased islet expression 
of protein tyrosine phosphatase 1B (PTP1B), which decreased IR signalling, and 
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increased insulin secretion when PTP1B was silenced in isolated islets (22). These data 
parallel results in the MIP-βIRKO HFD mouse, where the reduction of IR signalling 
under HFD-induced stress produced insulin secretory defects. The results from these 
studies demonstrate that while the partial loss of postnatal beta cell IR signalling was not 
detrimental when mice were fed a normal diet, the maintenance of beta cell IR expression 
was required to prevent defects in beta cell insulin secretion when challenged with 
metabolic stresses.  
MIP-βIRKO HFD mice displayed impaired fasting plasma insulin levels and ex vivo 
GSIS. The reduced insulin secretion in MIP-βIRKO HFD mice was linked to the 
decreased expression of the exocytotic proteins that compose the SNARE complex. The 
reduction of SNARE proteins was previously reported in both obese rodent models and in 
islets from patients with type 2 diabetes (23,24). Decreased SNARE protein expression in 
MIP-βIRKO HFD mice indicated that beta cell IR signalling may be required to recruit 
SNARE complex proteins, as observed in our in vitro study. Although the factors that 
regulate beta cell SNARE expression are not fully understood, mouse models have shown 
a link between reduced beta cell Akt phosphorylation and decreased SNARE protein 
expression (25,26), indicating that the Akt−P70S6K1 signalling axis may be responsible 
for the up-regulation of exocytotic proteins. 
MIP-βIRKO HFD mice displayed decreased Akt−P70S6K1 signalling. Both βIRKO mice 
and IR knockout in the MIN6 cell line have previously demonstrated a loss of Akt 
phosphorylation (27-29), indicating that IR signalling is responsible for partially 
maintaining Akt−P70S6K1 signalling. Although phosphorylated AktT308 was unchanged 
between control and MIP-βIRKO HFD mice, phosphorylation of both AktT308 and AktS473 
sites was shown to be required for maximum Akt signalling activity (30). Inhibition of 
phosphorylated Akt activity in beta cells has been shown to decrease first- and second-
phase insulin secretion without affecting beta cell mass even after long-term (14 weeks) 
HFD feeding (31,32), which demonstrated that Akt signalling is important for 
maintaining insulin secretion but may be dispensable for regulating beta cell mass. Beta 
cell-specific mTOR knockout mice studies also demonstrated reduced insulin secretion, 
PDX-1 expression, and AktS473 phosphorylation with unchanged beta cell mass (32). It 
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should be noted that mice fed a long-term HFD developed chronic mTOR−P70S6K1 
activation that resulted in reduced Akt phosphorylation, IRS-1 and IRS-2 expression, and 
GSIS (33,34), indicating that signalling through the IR−Akt−P70S6K1 pathway requires 
balanced regulation to maintain insulin release. 
MIP-βIRKO ND and HFD mice did not show changes in beta cell mass or proliferation 
when compared to their control diet counterparts. One limitation that should be taken into 
consideration is the translation of the human growth hormone (hGH) transgene observed 
in MIP-Cre mouse models (35,36). Its production has been observed to affect beta cell 
proliferation. Interestingly, MIP-βIRKO HFD mice do demonstrate the decreased 
GLUT2 expression that has been previously reported in the βIRKO mouse model. 
Maintaining an appropriate level of beta cell GLUT2 has been reported to correct 
abnormal GSIS in mice with low beta cell GLUT2 expression (37,38), which, along with 
reduced SNARE expression, may account for the reduced insulin release in MIP-βIRKO 
HFD mice. The beta cell factors NKX6.1 and MAFA were unchanged in islets of MIP-
βIRKO HFD mice when compared to control mice, indicating that beta cell identity was 
not altered with the partial loss of IR signalling. However, relatively lower PDX-1 levels 
were observed in islets of MIP-βIRKO HFD mice, linking the loss of IR with reduced 
PDX-1 and GLUT2 expression under HFD stress. Beta cell-specific PDX-1 knockout 
mouse models have demonstrated a loss of GLUT2 expression (39,40), which supports 
that PDX-1 expression is required to regulate GLUT2 in beta cells. Mice with the loss of 
both beta cell IR and IGF-1R also demonstrated a loss of PDX-1 and GLUT2 at 4 weeks 
of age (41). Taken together, these results suggest that IR signalling was required to 
maintain the glucose-sensing transporter GLUT2 through nuclear PDX-1 expression.  
Overall, our findings propose that postnatal preservation of beta cell IR activity under 
HFD stress was required in order to maintain insulin secretion through activation of 
IR−Akt−P70S6K1 signalling and up-regulation of GLUT2 and SNARE proteins. These 
results determined a previously reported potential regulatory axis where reduced IR 
activation of Akt signalling contributes to decreased SNARE protein expression and 
defective insulin release (25,26). The loss of beta cell IR signalling under stress 
conditions that promote the development of insulin insensitivity (22) represent factors 
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that must be considered when examining beta cell dysfunction and developing potential 
therapeutics to restore IR signalling.  
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Chapter 5  
5 c-Kit and IR co-stimulation does not enhance Akt signalling 
and pancreatic beta cell proliferation4 
  
                                                 
4
 Text and figures from this chapter are currently in preparation for the following 
manuscript: 
Oakie A, Li J, and Wang R. c-Kit and IR co-stimulation does not produce synergistic 
signalling or increase proliferation in the INS-1 cell line. Manuscript in preparation 
(2019). 
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5.1 Introduction 
The activity of RTKs in the beta cell can regulate proliferation, survival, and insulin 
secretion. c-Kit and IR have been shown to activate overlapping signalling pathways to 
control beta cell function. Our group has previously demonstrated that SCF stimulation of 
INS-1 cells for 24 hours increased Akt signalling and up-regulated IR (1). IR activation 
in beta cell lines increased PI3K−Akt−P70S6K1 signalling and Insulin transcription, and 
the presence of IR on beta cells was required for glucose-stimulated Akt phosphorylation 
(2,3). The IR family member IGF-1R also increased proliferation of rat islet cells through 
the activation of the mTOR−P70S6K1 signalling pathway (4). c-Kit overexpression in 
beta cells of the 8-week c-KitβTg mouse model demonstrated an up-regulation of IR and 
IRS-1 and increased Akt phosphorylation when compared to wild-type mice (1). These 
findings indicate that combined c-Kit and IR signalling may be responsible for 
synergistic signalling through the PI3K−Akt pathway (5). However, the activation of the 
PI3K−Akt pathway has also been reported to induce negative regulation on IR−IRS 
signalling through inhibited phosphorylation of IRS-1 tyrosine sites and degradation of 
the IRS protein (6,7). The potential for negative feedback with increased PI3K−Akt 
activation must therefore be considered when examining co-activation of c-Kit and IR. 
Co-activation of RTKs has been reported in various cell types and has demonstrated that 
receptor co-stimulation can be required to achieve synergistic intracellular signalling 
(8,9). FGFR2B has been shown to up-regulate c-Kit during salivary gland organogenesis, 
and cumulative Akt and MAPK signalling through the activation of both receptors was 
required for the initiation of transcriptional activity (10). In both MIN6 and INS-1 cell 
lines, the co-stimulation of growth hormone receptor (GHR) and IGF-1R demonstrated a 
synergistic increase in Akt phosphorylation 15 minutes after ligand stimulation and 
increased proliferation after 24 hours (11). Although these studies demonstrated 
synergistic signalling with receptor co-stimulation, it has not been established whether c-
Kit and IR co-activation can achieve this effect through overlapping 
PI3K−Akt−P70S6K1 signalling. In this study, c-Kit and IR co-stimulation was examined 
in vitro to determine whether activation of both receptors produced a synergistic effect on 
beta cell PI3K−Akt−P70S6K1 signalling compared to single receptor activation. 
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5.2 Materials and methods 
INS-1 cell line culture and ligand treatments: INS-1 832/13 cells were plated in 12-well 
plates and treated with ligands at 80-90% confluency. Before ligands were administered, 
cells were serum-starved in RPMI-1640 supplemented with 1% BSA media for either 16-
24 hours (for short-term 15-minute or 1-hour stimulation time-points) or 3 hours (for 
long-term 24-hour stimulation time-points). Four experimental groups were examined in 
this study: [1] control with no ligand treatment; [2] stem cell factor alone (SCF, 50 
ng/mL); [3] insulin alone (Ins, 0.2 nmol/L); and [4] SCF plus insulin (SCF+Ins) co-
stimulation treatments. Three time-points were examined in this study: 15 minutes, 1 
hour, and 24 hours. At the end of experiments, cells were processed for western blot 
analysis or were fixed for immunocytochemical labeling.  
Rapamycin treatment: INS-1 cells were starved in RPMI-1640 with 1% BSA media 
overnight (16-24 hours) and then pre-incubated with or without 100 nmol/L rapamycin 
(LC Laboratories, Woburn, MA) for 1 hour in order to inhibit mTORC1 activity. 
Experimental groups were as follows: [1] no treatment (control), [2] 1-hour SCF and 
insulin co-stimulation (SCF+Ins), [3] 1-hour rapamycin pre-treatment, [4] 1-hour 
rapamycin pre-treatment with subsequent 1-hour SCF and insulin co-stimulation. Cells 
were harvested for western blot analysis following treatment. 
Immunofluorescence staining of cells: INS-1 cells treated for 24 hours with ligands were 
harvested and fixed in 4% paraformaldehyde, embedded in 2% agarose gel, and 
processed to create paraffinized cell samples. Cell samples were sectioned and stained 
with antibodies against PCNA, C-peptide, and insulin (information can be found in Table 
2.2). Representative images were captured using the Nikon Eclipse Ti2 confocal 
microscope (Nikon). Additional details can be found in Section 2.8. 
Western blot analysis: INS-1 cells from the time-dependent study (15 mins, 1 and 24 
hours) and from the rapamycin pre-treatment study were analyzed for phosphorylated (p-
) c-KitY719, p-IRS-1Y608, p-IRY1146, p-AktS473, p-P70S6K1T389, p-ERK 1/2Y202/T204, p-IRS-
1S612, and Cyclin D1 (further information can be found in Table 2.2). Bands were 
normalized to reference proteins -tubulin or -actin or to total protein for 
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phosphorylated signalling proteins Akt, P70S6K1, and ERK (detailed protocol can be 
found in section 2.9).  
Statistical analysis: All data presented are represented as mean  SEM and were analyzed 
using a one-way ANOVA test with a Tukey’s post hoc. Statistical significance was 
obtained when p < 0.05. 
5.3 Results 
5.3.1 c-Kit and IR co-activation promoted phosphorylation of c-KitY719, 
IRS-1Y608, and IRY1146 sites 
INS-1 cells stimulated for 15 minutes with SCF, insulin, or SCF+Ins were analyzed for 
phosphorylation of the c-Kit receptor at tyrosine site (Y) 719 and IRS-1/2 tyrosine site 
(Y) 608, both representing sites that associate with the p85 subunit of PI3K (7,12). 
SCF+Ins-treated cells demonstrated increased phosphorylation of c-KitY719 compared to 
untreated controls (Figure 5.1a). However, no differences were noted between SCF+Ins 
and single ligand exposure. At 1 hour post-stimulation, SCF-treated cells demonstrated 
modestly elevated levels of c-KitY719 phosphorylation but statistical significance was not 
reached due to high variation within treatment groups (Figure 5.1b). There was no 
significant difference in c-Kit phosphorylation between insulin- or SCF+Ins-treated cells 
and control cells. Phosphorylation of c-KitY719 was also not enhanced by any ligand 
treatment after 24 hours of culture (Figure 5.1c). At 15 minutes following ligand 
treatments, IRS-1/2Y608 phosphorylation was elevated in SCF+Ins-treated groups 
compared to untreated controls (Figure 5.2a). However, no change in p-IRS-1/2Y608 
levels for any of the treatment groups was detected at 1 hour or 24 hours following 
stimulation (Figure 5.2bc). Phosphorylation of IR at tyrosine (Y) 1146 was also analyzed 
at 24 hours of culture and demonstrated that that insulin-treated cells had increased 
phosphorylation of IRY1146 (Figure 5.2d). SCF+Ins-treated cells did not show increased 
IR phosphorylation (Figure 5.2d). These results show that SCF+Ins ligand treatment was 
able to induce c-Kit receptor and IRS-1 tyrosine phosphorylation shortly following 
stimulation, and that insulin only ligand stimulation induced long-term receptor 
activation in INS-1 cells.  
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Figure 5.1: c-KitY719 phosphorylation was increased after short-term stimulation 
with SCF+Ins treatment. 
(a) INS-1 cells co-stimulated for 15 minutes with SCF+Ins demonstrated increased p-c-
KitY719 phosphorylation compared to untreated control cells (n=4). c-KitY719 
phosphorylation was unchanged from control for all treatment groups at (b) 1 hour (n= 3) 
and (c) 24 hours (n= 4) following stimulation. Representative western blots and 
quantification by densitometry are shown. Untreated control (Ctrl): closed circles; SCF: 
open squares; Insulin (Ins): open triangles; SCF+Ins (S+I): open circles. Data were 
normalised to untreated controls and expressed as mean ± SEM. *p < 0.05 vs control; 
analyzed using a one-way ANOVA with a Tukey’s post hoc test. 
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Figure 5.2: IRS-1/2Y608 phosphorylation was increased after short-term treatment 
with SCF+Ins and IRY1146 phosphorylation was increased only after long-term 
treatment with insulin. 
(a) Representative western blots and quantification by densitometry for IRS-1 
phosphorylation demonstrated an increase in IRS-1/2Y608 phosphorylation at 15 minutes 
in SCF+Ins-treated cells compared to untreated control cells (n=3). IRS-1/2Y608 
phosphorylation was similar between treatment groups at (b) 1 hour (n=6) and (c) 24 
hours (n=4) following stimulation. (d) Phosphorylation of IRY1146 was increased in 
insulin-treated cells only at 24 hours compared to control cells (n=4). Untreated control 
(Ctrl): closed circles; SCF: open squares; Insulin (Ins): open triangles; SCF+Ins (S+I): 
open circles. Data were normalised to untreated controls and expressed as mean ± SEM. 
*p < 0.05, **p < 0.01 vs control; analyzed using a one-way ANOVA with a Tukey’s post 
hoc test. 
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5.3.2 SCF and insulin co-administration did not enhance Akt 
phosphorylation at 24 hours over single ligand treatments 
To determine the effects of SCF and insulin co-stimulation downstream of receptor 
activation, intracellular signalling proteins Akt and P70S6K1, which are phosphorylated 
along the PI3K−Akt−mTOR−P70S6K1 pathway axis, were examined. At 1 hour 
following ligand stimulation, Akt phosphorylation at serine (S) 473 was not significantly 
different between untreated controls and any of the ligand-treated cell groups (Figure 
5.3a). Interestingly, AktS473 phosphorylation levels were significantly increased in all 
ligand-treated groups when compared to control cells 24 hours following ligand 
stimulation (Figure 5.3b). AktS473 phosphorylation in the SCF+Ins-treated cells was 
similar to levels observed with SCF or insulin treatment alone, indicating that co-
stimulation did not lead to a synergistic effect on intracellular Akt signalling. P70S6K1 
phosphorylation of threonine (T) 389, which is downstream from mTOR activation, was 
increased in insulin-treated and SCF+Ins-treated cells at 15 minutes compared to 
untreated control cells (Figure 5.4a). However, P70S6K1T389 phosphorylation levels 
were unchanged between control and treatment cell groups at 1 hour (Figure 5.4b). 
Although increased Akt phosphorylation was observed at 24 hours, p-P70S6K1T389 levels 
were similar throughout all groups at this time-point (Figure 5.4c). MAPK−ERK 
signalling was examined in treated cells to determine if other intracellular signalling 
pathways were active. At 24 hours, ERK phosphorylation was similar between all 
treatment groups (Figure 5.4d). The findings indicate that phosphorylation of P70S6K1 
was achieved in insulin-treated and SCF+Ins-treated cells shortly after ligand stimulation 
and Akt phosphorylation was achieved in all ligand stimulated groups after 24 hours 
compared to untreated controls. Importantly, SCF+Ins treatment did not enhance 
signalling compared to single ligand treatments. 
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Figure 5.3: AktS473 phosphorylation was increased 24 hours after SCF or insulin 
treatment.  
(a) AktS473 phosphorylation in INS-1 cells after treatment with SCF, insulin, or SCF+Ins 
for 1 hour was not increased compared to untreated control cells (n=3). (b) AktS473 
phosphorylation levels were increased for all treatments groups at 24 hours compared to 
untreated control cells. Co-stimulation with SCF and insulin did not increase 
phosphorylation compared to SCF or insulin alone (n=4). Representative western blot 
images are shown with quantification. Untreated control (Ctrl): closed circles; SCF: open 
squares; Insulin (Ins): open triangles; SCF+Ins (S+I): open circles. Data are normalised to 
untreated controls and expressed as mean ± SEM. *p < 0.05 vs control; analyzed using a 
one-way ANOVA with a Tukey’s post hoc test. 
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Figure 5.4: P70S6K1T389 phosphorylation was increased rapidly after insulin or 
SCF+Ins treatment, but phosphorylated P70S6K1T389 and ERK levels were 
unchanged at 24 hours. 
(a) 15 minutes following stimulation, P70S6K1T389 phosphorylation was found to be 
elevated in insulin and SCF+Ins treatments compared to untreated control cells (n=4). 
P70S6K1T389 phosphorylation levels were unchanged between treatment groups and 
untreated control groups at (b) 1 hour and (c) 24 hours following stimulation (n=4). (d) 
ERK phosphorylation was unchanged between treatment groups and untreated control 
cells at 24 hours (n=4). Representative western blot images are shown with densitometry 
quantification. Control (Ctrl): closed circles; SCF: open squares; Insulin (Ins): open 
triangles; SCF+Ins (S+I): open circles. Data are normalised to untreated controls and 
expressed as mean ± SEM. *p < 0.05 vs control; analyzed using a one-way ANOVA with 
a Tukey’s post hoc test.  
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5.3.3 SCF and insulin co-administration increased inhibitory IRS-1S612 
phosphorylation at 1 hour post-treatment 
The phosphorylation of serine residues on IRS-1 was examined to determine if SCF+Ins 
treatment induced serine phosphorylation at sites associated with intracellular negative 
feedback. At 15 minutes post-treatment, IRS-1S612 phosphorylation was similar between 
all treatment groups and the untreated control cells (Figure 5.5a). However, the 
phosphorylation of IRS-1S612 in SCF+Ins-treated cells was increased compared to 
untreated controls at 1 hour post-treatment (Figure 5.5b). Single ligand exposure failed 
to induce significant IRS-1S612 phosphorylation. Increased IRS-1S612 phosphorylation in 
SCF+Ins-treated cells was not observed after 24 hours of treatment, and IRS-1S612 
phosphorylation levels in all treatment groups were unchanged compared to untreated 
controls (Figure 5.5c). These results indicate that IRS-1S612 phosphorylation occurred 
after short-term SCF+Ins co-treatment, suggesting the potential for negative feedback on 
the Akt−P70S6K1 signalling axis in co-stimulated cells.  
  
  
 
165 
 
  
  
 
166 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: IRS-1S612 phosphorylation was increased at 1 hour following SCF+Ins 
treatment. 
(a) IRS-1S612 phosphorylation was unchanged in all treatment groups compared to 
untreated control cells 15 minutes following stimulation (n=4). (b) At 1 hour following 
stimulation, IRS-1S612 phosphorylation was increased in the SCF+Ins treatment compared 
to the untreated cells (n=6). (c) IRS-1S612 phosphorylation in all treatment groups was 
similar to untreated control cells 24 hours following treatment (n=4). Representative 
western blot images with densitometry are shown. Untreated control (Ctrl): closed 
circles; SCF: open squares; Insulin (Ins): open triangles; SCF+Ins (S+I): open circles. 
Data were normalised to untreated controls and expressed as mean ± SEM. *p < 0.05 vs 
control; analyzed using a one-way ANOVA with a Tukey’s post hoc test.  
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5.3.4 Rapamycin pre-treatment decreased IRS-1S612 phosphorylation and 
increased AktS473 phosphorylation induced by SCF and insulin co-
treatment 
Since the potential inhibitory IRS-1S612 phosphorylation residue was detected after 
SCF+Ins treatment, rapamycin, an inhibitor of mTORC1, was used to determine if 
phosphorylation of this IRS-1 serine site could be inhibited. Rapamycin pre-treatment did 
not significantly change IRS-1/2Y608 phosphorylation at 1 hour in SCF+Ins-treated cells 
compared to untreated control cells (Figure 5.6a). Interestingly, SCF+Ins treatment 
showed an increase in IRS-1S612 phosphorylation that was prevented with rapamycin pre-
treatment (Figure 5.6b), implicating mTOR pathway activation in IRS-1S612 –induced 
negative feedback. Akt phosphorylation was examined to determine if rapamycin pre-
treatment increased signalling through this axis. Pre-treatment with rapamycin was able 
to increase AktS473 phosphorylation in SCF+Ins-treated cells 1 hour following co-
stimulation compared to untreated controls, although it did not reach statistical 
significance (p = 0.0726) (Figure 5.6c). ERK phosphorylation was also examined to 
determine if alternate pathways were affected by rapamycin pre-treatment. ERK 
phosphorylation was not changed with SCF+Ins treatment with or without rapamycin 
pre-treatment (Figure 5.6d). Findings from this study indicated that mTORC1 signalling 
increased IRS-1S612 phosphorylation, and that inhibition of mTORC1 reduced IRS-1S612 
phosphorylation while potentially increasing AktS473 phosphorylation. 
. 
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Figure 5.6: Rapamycin pre-treatment reduced IRS-1S612 phosphorylation by 
SCF+Ins treatment. 
(a) At 1 hour, rapamycin pre-treatment had no effect on IRS-1/2Y608 phosphorylation 
(n=4). (b) IRS-1S612 phosphorylation induced by 1 hour SCF+Ins treatment was 
prevented with rapamycin pre-treatment (n=5). (c) AktS473 phosphorylation induced by 1 
hour SCF+Ins appeared to be increased with rapamycin pre-treatment (p = 0.0726 with 
one-way ANOVA) (n=3). (d) ERK phosphorylation was not changed with SCF+Ins 
treatment with or without rapamycin pre-treatment (n=4). Representative western blot 
images and densitometry are shown. Untreated control (Ctrl): closed circles; SCF+Ins 
(S+I): closed squares; Control with rapamycin pre-treatment (Ctrl+R): open circles; 
SCF+Ins with rapamycin pre-treatment (S+I+R): open squares. Data were normalised to 
untreated controls and expressed as mean ± SEM. *p < 0.05 vs control; analyzed using a 
one-way ANOVA with a Tukey’s post hoc test. 
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5.3.5 SCF and insulin co-administration did not stimulate INS-1 cell 
proliferation or C-peptide production 
To examine if ligand stimulation was able to induce cell proliferation or insulin 
production, SCF, insulin, and SCF+Ins treatment groups were assessed for Cyclin D1 
expression, proliferating cell nuclear antigen (PCNA), and C-peptide levels at 24 hours 
following ligand treatments. Cyclin D1 expression was unchanged between all treatment 
groups compared to untreated control cells (Figure 5.7a). Similar PCNA+ cell expression 
was observed in insulin+ cells from all treated groups when compared to untreated 
controls (Figure 5.7b). Finally, C-peptide levels were similar between all treatment 
groups and the untreated control groups after 24 hours (Figure 5.7c). Results from these 
experiments indicate that SCF+Ins co-treatment did not contribute to cell proliferation or 
C-peptide production after 24 hours of stimulation.  
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Figure 5.7: SCF+Ins treatment did not increase INS-1 cell proliferation or C-
peptide levels at 24 hours following treatment. 
(a) Cyclin D1 expression was similar at 24 hours for all treatment groups compared to 
untreated control cells (n=4). (b) Representative images of PCNA (green) in insulin+ 
(red) INS-1 cells showed similar PCNA+/insulin+ expression between cell treatments 
(n=3). (c) Representative immunofluorescence images of C-peptide (green) staining in 
insulin+ (red) cells of the INS-1 cell line demonstrated unchanged C-peptide levels 
between treatment groups and untreated control cells. Nuclei were stained with DAPI 
(blue). Scale bar: 25 m. Untreated control (Ctrl): closed circles; SCF: open squares; 
Insulin (Ins): open triangles; SCF+Ins (S+I): open circles. Data were normalised to 
untreated control and expressed as mean ± SEM. Analyzed using a one-way ANOVA 
with a Tukey’s post hoc test. 
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5.4 Discussion 
This study demonstrated that c-KitY719 and IRS-1/2Y608 phosphorylation was increased 
rapidly (15 minutes) following SCF+Ins treatment. This was accompanied by increased 
P70S6K1T389 phosphorylation. After 1 hour of ligand stimulation, increased 
phosphorylation of IRS-1S612 was observed in SCF+Ins-treated cells, suggesting that 
negative feedback on Akt−P70S6K1 signalling may have occurred. No synergistic 
increase in AktS473 phosphorylation was detected after SCF+Ins treatments at 24 hours 
when compared to single SCF or insulin treatments. INS-1 cell proliferation and C-
peptide levels were unaltered after 24 hours of SCF+Ins treatment. This study 
demonstrated that c-Kit and IR co-stimulation did not produce sustained synergistic 
signalling, potentially due to short-term IRS-1S612 phosphorylation and negative feedback 
on the Akt signalling pathway (Figure 5.8a-c). IRS-1S612 phosphorylation was prevented 
through inhibition of mTORC1 activity with rapamycin pre-treatment, which led to 
increased AktS473 phosphorylation in SCF+Ins treatments compared to untreated controls 
(Figure 5.8d).   
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Figure 5.8: Proposed mechanism of SCF + Insulin co-stimulation in INS-1 cells. 
(a) 15 minutes following SCF+Ins co-stimulation, c-KitY719, IRS-1/2Y608, and 
P70S6K1T389 phosphorylation was rapidly increased in INS-1 cells. (b) At 1 hour, 
however, increased IRS-1S612 phosphorylation from P70S6K1T389 activation at 15 minutes 
led to reduced signalling through the Akt/P70S6K1 pathway. (c) 24 hours following co-
stimulation, SCF+Ins-treated cells demonstrated Akt phosphorylation but no change in C-
peptide production or cell proliferation. This may be due to the IRS-1S612 phosphorylation 
that occurred following co-stimulation. (d) Rapamycin pre-treatment prevented 
phosphorylation of the negative feedback loop and IRS-1S612 phosphorylation, leading to 
increased signalling via the Akt pathway. The red star denotes a hypothesized result of 
increased Akt phosphorylation with rapamycin phosphorylation where beta cell function 
would be increased. However, this needs to be further investigated and confirmed. 
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The INS-1 cell line was selected for this study due to its co-expression of the receptors c-
Kit and IR (Appendix C). The dose of SCF required to stimulate beta cell proliferation 
and increased insulin production was validated previously in our laboratory using in vitro 
cell lines. The treatment of the PANC-1 cell line with 50 ng/mL SCF for one week 
induced cell proliferation (13). In addition, we have previously demonstrated that 
treatment of INS-1 cells with 50 ng/mL SCF for 24 hours increased Akt phosphorylation, 
indicating that this dosage was adequate for co-stimulation experiments (1). The 
concentration of insulin used for these experiments must be carefully considered due to 
potential detrimental effects observed using high insulin concentrations. A previous 
report examining both primary murine and human islets showed that culturing these cells 
in low insulin (0.2 nmol/L) and serum-free conditions resulted in decreased cleaved 
Caspase-3 levels and increased PDX-1 co-localization in insulin+ cells (14). However, 
long-term (7 days) exposure of islets to high insulin (200 nmol/L) increased cleaved 
Caspase-3 levels. Furthermore, INS-1E cells pre-treated with increasing insulin levels 
(from 10 nmol/L up to 1000 nmol/L) for prolonged periods (up to 48 hours) showed 
impaired AktS473 phosphorylation when re-stimulated with an additional 10 nmol/L 
insulin, suggesting that INS-1 cells can lose sensitivity to insulin stimulation if already 
exposed to a hyperinsulinemic environment (15). This may be reflected in the unchanged 
IR phosphorylation in SCF+Ins-treated cells, where prolonged stimulation of the 
receptors can reduce the impact of receptor co-activation and result in inhibitory 
signalling. It should be noted that there were variations within the INS-1 cell co-
treatments when examining c-KitY719 and IRS-1Y608 phosphorylation. Additional cell 
lines, like the PANC-1 pancreatic epithelial cell line or the MIN6 mouse beta cell line, 
could be used to verify the mechanisms observed with c-Kit and IR stimulation provided 
that these cell lines also demonstrate c-Kit and IR expression.  
Although SCF+Ins co-stimulation of INS-1 cells appeared to result in increased AktS473 
phosphorylation at 24 hours, the levels were comparable to SCF or insulin treatments 
alone. Short-term analyses, selected at 15 minutes and 1 hour following ligand 
stimulation, were also investigated to determine whether co-stimulation rapidly altered 
intracellular signalling. Two interesting changes were noted after INS-1 co-stimulation: 
[1] increased c-Kit and IRS-1 tyrosine phosphorylation at 15 minutes were reduced 1 
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hour following ligand stimulation; and [2] IRS-1S612 phosphorylation occurred in the 
SCF+Ins-treated cells at 1 hour post-stimulation. RTK transphosphorylation has been 
previously reported for receptor co-activation after ligand stimulation. FGFR3 and 
EphA4 receptors were able to phosphorylate tyrosine residues on the opposing receptor in 
HEK293 cells in vitro, while the RTKs EGFR and Axl have also demonstrated similar 
transphosphorylation after EGF stimulation in SNB-19 cells (16,17). Although no studies 
to date have examined c-Kit and IR co-stimulation in beta cells in vitro, there have been a 
number of studies that have analyzed the activity of platelet derived growth factor 
receptor (PDGFR) and insulin receptor co-activation. PDGFR is a member of the c-Kit-
containing class III RTK family and shares both structural and functional homology with 
c-Kit (18). When stimulating NIH-3T3-IR fibroblast cells or C2C12 myoblast cells with 
PDGF and insulin, co-activation led to rapid dephosphorylation of PDGFR and reduced 
proliferation in these cells compared to PDGF treatment alone (19). It is possible that a 
similar mechanism of receptor dephosphorylation occurred with SCF and insulin co-
stimulation in INS-1 cells since c-Kit phosphorylation, while increased at 15 minutes, 
was normalized at 1 hour following stimulation.  
PDGFR studies have also examined the regulation of IRS-1 serine phosphorylation in 
insulin-sensitive cells. Studies conducted using 3T3-L1 adipocytes found that treating 
cells with both PDGF and insulin resulted in decreased IRS-1 tyrosine phosphorylation 
when compared to insulin alone (20). Increased serine phosphorylation of IRS-1 was also 
found in 3T3-L1 cells when stimulated with PDGF (21). Another key study exposed 
vascular smooth muscle cells to PDGF over a 48-hour period. In those cells, Akt and 
P70S6K1 phosphorylation were maintained when compared to untreated controls over a 
48-hour period (22). In the current study, the early P70S6K1 phosphorylation seen at 15 
minutes was not observed at 1 hour, which was likely due to the IRS-1S612 
phosphorylation seen in cells at 1 hour post-stimulation. The above study on vascular 
smooth muscle cells also found that IRS-1 serine phosphorylation was consistently 
increased in PDGF-treated cells throughout a 48-hour period (22). This is different than 
the findings in the current study, where IRS-1S612 phosphorylation at 24 hours was 
unchanged between the treatment groups and untreated controls. This may explain why 
Akt phosphorylation was increased in ligand-stimulated groups at 24 hours, since IRS-
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1S612 phosphorylation was no longer present to inhibit this signalling pathway. However, 
this mechanism must be fully investigated to test this notion. 
The PI3K−Akt−mTORC1−P70S6K1 signalling axis is an intracellular pathway that has 
been shown to contribute to beta cell function and insulin release. 8-week beta cell c-Kit 
overexpressing mice (c-KitβTg) demonstrated increased AktS473 phosphorylation and 
enhanced insulin secretion (1). However, as mentioned above, signalling through the Akt 
pathway has been shown to induce serine phosphorylation in adipocytes and vascular 
smooth muscle cells (21,22). Rapamycin administration, which inhibits mTORC1, was 
able to reduce IRS-1S612 phosphorylation and partially restore signalling through AktS473 
phosphorylation. This finding has been previously observed in other cell lines. IRS-1S612 
phosphorylation was present in 3T3-L1 cells after 1 hour of 100 nmol/L insulin 
stimulation, and the use of rapamycin pre-treatment in these cells inhibited serine 
phosphorylation at this residue (6). Rapamycin has also been shown to prevent the 
serine/threonine degradation of IRS-2 in the INS-1 cell line (23). The regulation of the 
Akt−mTORC1−P70S6K1 pathway is also of interest in maintaining insulin secretion and 
glucose homeostasis. The two complexes of mTOR, mTORC1 and mTORC2, were 
expressed at different levels in islets isolated from T2D patients. mTORC1 expression 
was elevated in T2D patients compared to non-diabetic controls, leading to enhanced 
P70S6K1T389 phosphorylation (24). mTORC2 was also reduced in these islets from T2D 
patients, which resulted in reduced AktS473 phosphorylation, and insulin secretion was 
improved from islets of HFD-fed mice and T2D patients with in vitro inhibition of 
P70S6K1. Similar results were reported in INS-1 cells treated with siRNA against either 
mTORC1 or mTORC2 (Raptor and Rictor), where Raptor siRNA transfection increased 
GSIS (25). This suggested that short-term mTOR inhibition can improve insulin release 
from beta cells and that rapamycin treatment can prevent IRS-1 serine phosphorylation 
and increase insulin secretion from beta cells. 
Overall, this study demonstrated that the activation of RTKs c-Kit or IR generated similar 
intracellular signalling, but co-stimulation of these pathways did not enhance or alter 
their signalling. Negative feedback during receptor co-stimulation resulted in IRS-1 
serine phosphorylation. Although improved islet function observed after RTK stimulation 
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should still be considered for islet treatments, optimization of the temporal and dose-
dependent stimulation range should be considered to avoid negative feedback signalling 
that limits improved beta cell function. By examining the effects of RTK co-activation on 
intracellular regulation of beta cells, RTK-based therapeutics can be designed to improve 
beta cell survival and function. 
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Chapter 6  
6 Summary, limitations, and future directions 
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6.1 Summary of Chapters  
6.1.1 Review of overall rationale and main hypothesis 
RTKs in the developing and mature beta cells are required to maintain cellular function 
under normal and diabetic conditions. Although c-KitβTg mice demonstrate an up-
regulation of IR along with improved insulin secretion, it is unclear what role c-Kit and 
IR activation play in insulin release and if co-activation of the two receptors is required 
for beta cell function. The projects in this thesis work aimed to determine the role of 
these two RTKs on maintaining adult beta-cell function. We hypothesized that the c-Kit 
and IR signalling in beta cells under normal and metabolic stresses affected beta cell 
function and insulin release.   
6.1.2 Prolonged c-Kit expression in beta cells impaired glucose tolerance 
due to reduced expression of exocytotic proteins and altered intracellular 
signalling activation 
The examination of 8-week c-KitβTg mice had identified enhanced insulin secretion 
through increased beta cell mass and signalling through the PI3K−Akt pathway. The aim 
of Chapter 3 sought to determine the effects of prolonged beta cell c-Kit overexpression 
in c-KitβTg mice. Analysis of 60-week c-KitβTg mice showed an impairment in insulin 
release that resulted in glucose intolerance. Although c-KitβTg mice maintained 
increased beta cell mass and proliferation at 60 weeks, increased FOXO1 nuclear 
expression and cleaved PARP were present and indicated beta cell dysfunction and 
apoptosis. The exocytotic SNARE proteins Syntaxin 1A and MUNC18-1 were also 
reduced in 60-week c-KitβTg mice, potentially contributing to their loss of insulin 
secretion. The IR−IRS signalling axis was impaired in 60-week c-KitβTg mice and 
resulted in a loss of insulin-stimulated intracellular signalling. Generation of the c-
KitβTg;βIRKO mouse model showed partially improved fasting glucose and glucose 
tolerance with challenge. 60-week c-KitβTg;βIRKO mice also demonstrated normalized 
beta cell mass similar in levels to control mice. In addition, c-KitβTg;βIRKO mice had 
increased nuclear MAFA expression in beta cells. The results from this chapter 
demonstrated that long-term beta cell c-Kit over-expression induced dysfunctional 
glucose regulation in mice through impaired IR−IRS signalling, increased beta cell 
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dysfunction and apoptosis, and reduced expression of proteins required for insulin vesicle 
exocytosis.  
6.1.3 The loss of IR in postnatal beta cells led to reduced insulin release and 
PI3K−Akt−P70S6K1 intracellular signalling under high-fat diet 
conditions 
Mice with a beta cell-specific loss of IR had been previously generated in our laboratory 
to examine the effects of IR signalling. This loss was induced during prenatal 
development when the immature beta cell first emerged. The aim of Chapter 4 was to 
examine the effects of postnatal beta cell IR loss in MIP-βIRKO mice after exposure to 
normal (ND) and high-fat diet (HFD). MIP-βIRKO ND mice maintained comparable 
fasting glucose levels, glucose tolerance, insulin release, and islet morphology similar to 
control ND mice. Although MIP-βIRKO HFD mice did not demonstrate a difference in 
body weight or fasting glucose levels compared to control HFD mice, MIP-βIRKO HFD 
mice displayed glucose intolerance when challenged with a glucose load. This was linked 
to reduced insulin release, decreased beta cell GLUT2 expression, and down-regulation 
of SNARE proteins. AktS473−P70S6K1T389 signalling was also compromised in MIP-
βIRKO HFD mice. Although markers of insulin release were decreased in MIP-βIRKO 
HFD mice, beta cell mass and proliferation were unchanged between the two HFD 
groups. Taken together, these results indicated that normal postnatal beta cell IR 
expression was required in order to maintain GSIS when mice were exposed to high-fat 
diet stress.  
6.1.4 Synergistic signalling was not achieved with c-Kit and IR co-
stimulation   
Although c-KitβTg mice demonstrated increased IR expression concurrent with improved 
insulin release, increased Akt signalling, and beta cell expansion, it is not clear if these 
receptors act in tandem to improve beta cell function. The aim of Chapter 5 was to 
explore if c-Kit and IR co-activation enhanced intracellular signalling that would lead to 
beta cell proliferation. INS-1 cells were used to model beta cells and were stimulated 
with both SCF and insulin. The results demonstrated increased c-Kit receptor activation 
with heightened IRS-1Y608 and P70S6K1T389 phosphorylation occurring rapidly after 
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stimulation (15 minutes). However, IRS-1S612 phosphorylation was increased in SCF and 
insulin-treated cells at 1 hour, suggesting that there was negative feedback through the 
Akt−P70S6K1 signalling axis. At 24 hours, AktS473 phosphorylation was increased in all 
treatment groups but was not altered in the SCF+Ins co-treatment group. Rapamycin pre-
treatment reduced SCF+Ins-treated IRS-1S612 phosphorylation at 1 hour. INS-1 cell 
proliferation and C-peptide levels were unchanged at 24 hours between all treatment 
groups. The findings from these experiments indicated that c-Kit and IR co-stimulation 
did not alter signalling, possibly due to early negative feedback from IRS-1 serine 
phosphorylation. Inhibition of negative feedback through rapamycin may be a potential 
treatment to alleviate this axis. 
6.2 Limitations 
6.2.1 Chapter 3 
The c-KitβTg mouse model is unique in that it is currently the only available model for c-
Kit overexpression in beta cells. This mouse model was driven by the rat Insulin 
promoter (RIP), which transcribes Insulin 2. However, the use of RIP is associated with 
off-target gene transcription in other tissues that contain Insulin 2 transcription, notably 
in the hypothalamus (1,2). RIP-induced hypothalamic alterations have been associated 
with potentially inducing non-beta cell regulation of glucose homeostasis through 
influences on weight gain and feeding. However, studies that used a RIP-driven leptin 
receptor knockout found that food intake, weight gain, and body thermoregulation were 
not changed between control and RIP-driven mice (3,4). In our studies, there was no 
noticeable change in weight gain in c-KitβTg mice until 60 weeks of age. Even with these 
findings, other potential off-target effects from c-Kit expression in the hypothalamus 
should be considered. 
The mouse Insulin promoter (MIP), which transcribes Insulin 1, was created to 
circumvent the off-target gene expression in non-beta cells seen with RIP mouse models 
(5). Early studies that examined the MIP-Cre and MIP-CreERT mouse models identified 
high recombination rates in their beta cells (80-90%) (5,6). However, one study that had 
utilized the MIP-CreERT line to induce excision of floxed GLI-similar 3 (GLIS3) found 
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that beta cell-specific MIP-CreERT recombination of Glis3 was lower in isolated islets 
(66%) when compared to the recombination achieved through another promoter that is 
mostly beta cell-specific, PDX-1-CreERT (90%), even though both lines received similar 
tamoxifen treatments (i.p. dose of 3 mg per day for 7 consecutive days in 8-week male 
mice) (7). This may explain the low Cre recombination observed in the c-KitβTg;βIRKO 
mouse model used in our study. There has also been research that has reported MIP-
induced activity within the hypothalamus, which may result in the same confounding 
limitations presented with the RIP mouse model (8). This is still debated within the field 
but should be taken into consideration when interpreting results (6,9).    
A decisive drawback with the RIP and MIP mouse models that has emerged within the 
last few years involves the apparent translation and autocrine feedback effect from the 
human growth hormone (hGH) insert within the transgene. hGH is located downstream 
from the promoter and Cre recombinase gene (10). The translated hGH has been found to 
bind to prolactin receptor on beta cells, which induced reduced GLUT2 expression on 
beta cells, decreased GSIS, and increased beta cell mass and proliferation (10,11). In 
addition, mice producing the hGH transgene demonstrated increased resistance to 
diabetes induction through high-fat diet and streptozotocin treatments (10,12). We pooled 
the data from the control group in the c-KitβTg;βIRKO study from both MIP+ and MIP- 
mice. When examining the IPGTT results using only MIP+ controls, a similar response 
was observed to the one presented in Chapter 3 (Figure 3.11). In light of this recent 
information, future experiments that use the c-KitβTg or c-KitβTg;βIRKO mouse lines 
should ensure that only Cre-positive controls be used to account for hGH-driven beta cell 
changes. 
c-KitβTg mice demonstrated enhanced insulin release associated with receptor 
overexpression in beta cells. Although c-Kit overexpression in the beta cells of c-KitβTg 
mice was confirmed using western blot and immunofluorescence analysis, up-regulation 
of the receptor exclusively to the cell membrane of beta cells was not confirmed. It is 
possible that increased translation of c-Kit led to the accumulation of c-Kit in the ER, 
which promoted the unfolded protein response and ER stress in beta cells of c-KitβTg 
mice. Increased ER stress in diabetic rodent models has been linked to heightened beta 
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cell function and expansion as a method of beta cell compensation before the 
development of beta cell failure (13,14). Therefore, the effects of c-Kit overexpression in 
beta cells may not be solely due to receptor activation and can be due to off-target 
responses from the ER of beta cells.     
Although enhancing the presence of RTKs during pancreatic development has shown 
initial improvements in maintaining normoglycemia, detrimental effects that may develop 
from chronic RTK over-expression must be examined. Pancreatic samples from patients 
with pancreatic adenocarcinoma demonstrated high levels of c-Kit+ islet cells, which was 
different from the islets of control pancreata (15). Careful consideration must be taken 
when utilizing RTK overexpression in islets to avoid the development of insulinomas.   
6.2.2 Chapter 4 
Similar to the limitations reported in the Chapter 3 section, the beta cell IR knockout in 
MIP-βIRKO mice is controlled through the MIP promoter-dependent expression of Cre 
recombinase. As mentioned above, MIP-driven knockout models have been reported to 
be less effective than the PDX-1-driven knockout mouse model (7). This can account for 
the partial (50%) reduction of beta cell IR observed in MIP-βIRKO mice. Since the loss 
of IR in beta cells is only partial, the remaining beta cell IR population may be sufficient 
to compensate for the reduced signalling in MIP-βIRKO ND mice. One alternate 
experiment that could be designed to strengthen the results from this section would be to 
cross the IR floxed mouse line with a tamoxifen-inducible PDX-1-Cre mouse line, 
confirm the percentage of IR knockout in the islets of these mice after tamoxifen-induced 
knockout at 4 weeks of age, and compare their insulin release and beta cell function to 
MIP-βIRKO mice. Examining a mouse model with near complete beta cell IR deletion 
would be beneficial to confirm that IR signalling does not play a major role in glucose 
metabolism in mice fed a normal diet. 
The MIP-βIRKO mouse model is also subjected to potential confounding effects from 
hGH production. We had used both MIP-CreERT+ and MIP-CreERT- mice in our control 
groups for ND and HFD to increase our sample size. Although no change in proliferation 
was observed in our cohorts, it must be considered that hGH-driven proliferation may 
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mask any results seen between the two groups (10,11). Both control and MIP-βIRKO 
mice also received i.p. tamoxifen treatments to control for any effects from tamoxifen 
administration. However, tamoxifen administration has also been found to affect beta cell 
proliferation. C57BL/6 mice demonstrated reduced beta cell proliferation after tamoxifen 
administration (16,17). A separate report also noted improved glucose tolerance after 
tamoxifen administration in C57BL/6J mice (18). The potential estrogen receptor-
promoting effects of tamoxifen may be similar to the 17-estradiol protective effects 
observed in female mice on HFD, where both glucose tolerance and phosphorylated Akt 
levels in skeletal muscle were improved (19). The HFD feeding in both groups may 
therefore be subjected to hormone-mediated improvements in diet-induced obesity. 
Many studies using the high-fat mouse model have reported ‘characteristics’ associated 
with high-fat diet-induced obesity, including peripheral insulin resistance, 
hyperinsulinemia, and beta cell dysfunction that leads to hyperglycemia (20,21). The 
degree of ‘diabetic’ progression in mice fed HFD has been shown to vary based on the 
mouse background, with C57BL/6 HFD mice demonstrating increased first-phases GSIS 
response compared to DBA/2 HFD mice (22). This is important to keep in mind since the 
floxed IR mouse line (B6.129S4(FVB)-Insrtm1Khn/J) used in this project has been reported 
to be derived from a mixed background (129S4/SvJae, C57Bl/6J and /6N, and FVB). 
Careful interpretation of the data from this chapter, like the recorded body weight 
measurements and fasting blood glucose levels, must be made when comparing these 
HFD-associated changes from both control and MIP-βIRKO HFD mice to other studies 
that use a different mouse background. In addition, there have been reports of individual 
mouse variability within the C57BL6/J line. After the same amount of time on HFD, a 
subset of mice were obese and hyperinsulinemic with reduced glucose clearance while 
lean body weight litter-mates, which demonstrated glucose levels similar to their obese 
counterparts, had normal insulin levels and glucose reuptake (23). This should be 
discussed when examining the variability in HFD studies since subsets of mice may 
demonstrate a more severe phenotype due to heightened weight gain and may account for 
the varying reports within the literature.  
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Although there are multiple classes of PI3Ks expressed in beta cells, the effects that each 
class has on insulin exocytosis is still not fully understood. INS-1 cells transfected with 
class II PI3K shRNA demonstrated a similar phenotype to mice with a loss of class I 
PI3K, where a defect in insulin secretion was noted without any change in insulin gene 
expression or content. However, these cells did not demonstrate a reduction in SNARE 
protein expression (24). These findings demonstrated that further research must be 
conducted to establish a connection between PI3K−Akt signalling and exocytotic protein 
expression in beta cells. Identifying the select PI3K classes affected by IR knockout in 
islets and examining the activity of all PI3K classes and SNARE protein expression in IR 
knockout islets following glucose stimulation would provide an additional connection 
between IR stimulation and exocytotic SNARE proteins.  
6.2.3 Chapter 5 
The INS-1 832/13 cell line provided a suitable in vitro model for examining c-Kit and IR 
cross-talk in beta cells since both are expressed within the cell line. However, this is a 
trait inherent in cancer-derived cell lines and is not reflective of normal mature beta cell 
physiology. As mentioned earlier on in this thesis, the subset of c-Kit+ beta cells 
composed a small percentage within the adult islet and was therefore not highly 
expressed in unmodified islet cells (25). In addition, it has been reported that INS-1 cells 
express both IR-A and IR-B isoforms (26). Isolated islet cells from human donors express 
both isoforms, but a higher percentage of beta cells expressed IR-B (64%) over IR-A 
(18%) (27). Different intracellular mechanisms have been reported for activation of each 
isoform in beta cells. The IR-A isoform is associated with insulin-induced beta cell 
proliferation, while the IR-B isoform has been shown to initiate signalling through class 
II PI3K-C2 and Akt-1 (serine 473) for glucokinase up-regulation and insulin secretion 
(28,29). Since it is not known which isoform is predominately expressed with SCF and 
insulin treatments, this work cannot make conclusions as to what isoform-specific 
pathway is being activated.  
The INS-1 832/13 cell line is a rat insulinoma-derived line that is able to respond to 
glucose stimulation with insulin secretion, which is not present in all beta cell-derived 
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lines and provides a good model for studying beta cells in vitro (30,31). However, INS-1 
cells are cancer-derived cells that may display signalling mechanisms inherent to 
neoplastic cells. Gastrointestinal stromal tumours expressed both c-Kit and FGFR3 (32). 
These cells were able to induce c-Kit phosphorylation when under receptor inhibition 
(imatinib treatment) due to FGF2-induced signalling and direct FGFR3−c-Kit 
interactions. Mammary tumour cells expressing IR and IGF-1R displayed a similar 
mechanism to maintain signalling; IGF-1R inhibition led to increased phosphorylation 
and downstream signalling through IR (33). Therefore, it may be that modifications to 
either or both c-Kit and IR receptors, through stimulation or inhibition, may induce pro-
survival and pro-proliferative responses seen in other cancer cell experiments and not in 
primary beta cells. Although c-Kit expression in the adult mouse beta cell is low (10-
20%), the isolation and stimulation of c-Kit+ primary beta cells from mouse islets with 
SCF and insulin co-treatment would be ideal to further confirm the results observed in 
INS-1 cells (25).  
Rapamycin treatments of the INS-1 cell line should be taken into consideration due to the 
sensitive nature of mTOR inhibition in cells. As previously mentioned in Chapter 5, 
inhibition of the mTORC1−P70S6K1 signalling pathway has been shown to improve 
GSIS in both INS-1 cells and in islets from T2D patients (34,35). However, the use of 
mTOR inhibition through rapamycin treatment was also linked to the development of 
glucose intolerance. Although chronic Akt−mTOR−P70S6K1 signalling has been shown 
to lead to negative IRS-1 phosphorylation and the development of insulin resistance, the 
treatment of diabetic Psammomys obesus (desert gerbil) rodents with rapamycin 
worsened their hyperglycemia through reduced insulin release and beta cell mass through 
increased islet apoptosis (36). It has been found that maintaining transient mTOR 
signalling for a short period improved beta cell function while chronic mTOR activation 
reduced beta cell proliferation and led to high circulating glucose levels (37,38). In vivo 
rapamycin administration has also been reported to lead to both mTORC1 and mTORC2 
inhibition, which differs from the mTORC1-selective inhibition observed in cell 
treatments, and led to the development of glucose intolerance and insulin resistance in 
mice (39). These findings indicate that rapamycin treatment may not be suitable for the in 
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vivo potentiation of beta cell RTK intracellular signalling and that decreasing the negative 
feedback effects from RTK over-activation requires another approach in order to avoid 
the development of diabetic complications.   
6.3 Summarized conclusion 
The results from the presented studies indicate that beta cell c-Kit and IR signalling 
pathways are required for maintaining intracellular signalling, beta cell function, and 
glucose regulation using in vivo and in vitro models. c-KitβTg mice progressively 
developed insulin secretory defects and impaired insulin-IR signalling that resulted in 
glucose intolerance by 60 weeks of age. Down-regulating beta IR in c-KitβTg mice 
partially restored glucose tolerance, which suggests that over-activation of the IR−IRS 
pathway due to c-Kit-induced increased insulin can result in long-term impaired beta cell 
function. Maintained signalling through the beta cell IR pathway regulated insulin 
secretion, intracellular signalling, and exocytotic proteins under prolonged high-fat diet-
induced stress as seen in MIP-βIRKO mice. In vitro analyses of c-Kit and IR co-
stimulation showed that the intracellular signalling interplay between the two receptors 
was not synergistic 24 hours after stimulation and may be regulated through negative 
feedback from PI3K−Akt−P70S6K1-induced IRS-1 serine phosphorylation. Overall, the 
results featured in this thesis have shown that beta cell RTKs are important for the 
regulation of insulin secretion, and this is an important consideration when designing 
potential RTK-based islet therapies. 
6.4 Future directions 
The progressive loss of c-Kit expression during normal pancreas development in rodent 
models and in humans has shown that c-Kit is perhaps not a major RTK in the adult islet 
but continues to be expressed in a small population of beta cells (25,40). The effects of 
islet c-Kit stimulation with the use of controlled, short-term SCF treatment on beta cell 
proliferation, survival, and insulin secretion should be examined to determine if regulated 
RTK activation in beta cells can improve islet function. Inducing islet proliferation and 
survival through activated RTKs has already been examined as a potential therapeutic for 
improving islet transplantation. Both hepatocyte growth factor and nerve growth factor 
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treatments have been shown to improve islet survival and were able to restore euglycemia 
in diabetic rodent models (41-44). Increasing VEGF-A production in islets has been 
shown to improve their vascularization, islet survival, beta cell volume, and glucose 
tolerance (45-48). Although these studies have produced promising effects on improving 
beta cell survival for transplantation, the activation of RTKs have also been linked to 
exacerbating glucose intolerance in diabetic patients (49). Since no study to date has 
reported c-Kit expression in islets from diabetic patients, examining islets from normal 
and diabetic patients for changes in c-Kit expression or signalling would be ideal to 
determine if increased activation of this receptor in diabetic patients is linked to poor 
glucose tolerance. 
Many serine and threonine sites have been shown to be up-regulated after insulin 
treatment and through mTOR−P70S6K1 signalling (50,51). However, not all 
phosphorylated serine sites are linked to the development of intracellular negative 
feedback and insulin resistance. Although the phosphorylation of IRS-1S307 occurs with 
increased Akt−mTOR signalling, it has been found that this residue is required to prevent 
the development of glucose intolerance (52,53). Multiple reports have also found that the 
phosphorylation of different IRS serine and threonine sites are dependent on various 
pathways (mTOR, ERK1/2, c-Jun N-terminal kinase) and that this may differ based on 
the cell type analyzed (54-58). Screening islets from diabetic patients as well as from 
different experimental models of diabetes for phosphorylated serine/ threonine IRS 
residue would provide an appropriate reference for examining negative signalling on IRS 
proteins in the beta cell. Additional studies that perform residue-specific mutations would 
be useful to confirm their positive or negative regulatory roles on intracellular signalling.  
The results from this study have demonstrated that there is a potential link between 
insulin-induced intracellular signalling and the maintenance of the proteins required for 
exocytosis. Alterations in glucose levels and intracellular signalling have been linked to 
SNARE regulation (59-62). Promoting beta cell differentiation has also been shown to 
up-regulate SNARE proteins (63). However, the pathways that are responsible for beta 
cell SNARE production, and the direct role that RTK activation plays in SNARE 
transcription, are not well understood. Further studies examining the relationship between 
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receptor signalling, intracellular pathway regulation, and transcription of exocytotic 
proteins must be conducted to determine how RTK-based therapies can prime insulin 
granules for exocytosis. 
 
 
 
 
 
 
  
  
 
194 
6.5 References 
1. Aguayo-Mazzucato C, van Haaren M, Mruk M, Lee TB, Crawford C, Hollister-
Lock J, Sullivan BA, Johnson JW, Ebrahimi A, Dreyfuss JM, Van Deursen J, 
Weir GC, Bonner-Weir S. β Cell Aging Markers Have Heterogeneous 
Distribution and Are Induced by Insulin Resistance. Cell Metab. 2017;25(4):898-
910.e895. 
2. Deltour L, Leduque P, Blume N, Madsen O, Dubois P, Jami J, Bucchini D. 
Differential expression of the two nonallelic proinsulin genes in the developing 
mouse embryo. Proc Natl Acad Sci U S A. 1993;90(2):527-531. 
3. Covey SD, Wideman RD, McDonald C, Unniappan S, Huynh F, Asadi A, Speck 
M, Webber T, Chua SC, Kieffer TJ. The pancreatic beta cell is a key site for 
mediating the effects of leptin on glucose homeostasis. Cell Metab. 
2006;4(4):291-302. 
4. Mori H, Inoki K, Münzberg H, Opland D, Faouzi M, Villanueva EC, Ikenoue T, 
Kwiatkowski D, MacDougald OA, Myers MG, Guan KL. Critical role for 
hypothalamic mTOR activity in energy balance. Cell Metab. 2009;9(4):362-374. 
5. Wicksteed B, Brissova M, Yan W, Opland DM, Plank JL, Reinert RB, Dickson 
LM, Tamarina NA, Philipson LH, Shostak A, Bernal-Mizrachi E, Elghazi L, Roe 
MW, Labosky PA, Myers MG, Gannon M, Powers AC, Dempsey PJ. Conditional 
gene targeting in mouse pancreatic ß-Cells: analysis of ectopic Cre transgene 
expression in the brain. Diabetes. 2010;59(12):3090-3098. 
6. Tamarina NA, Roe MW, Philipson L. Characterization of mice expressing Ins1 
gene promoter driven CreERT recombinase for conditional gene deletion in 
pancreatic β-cells. Islets. 2014;6(1):e27685. 
7. Yang Y, Bush SP, Wen X, Cao W, Chan L. Differential Gene Dosage Effects of 
Diabetes-Associated Gene GLIS3 in Pancreatic β Cell Differentiation and 
Function. Endocrinology. 2017;158(1):9-20. 
8. Wang ZC, Wheeler MB, Belsham DD. Isolation and immortalization of MIP-GFP 
neurons from the hypothalamus. Endocrinology. 2014;155(6):2314-2319. 
9. Thorens B, Tarussio D, Maestro MA, Rovira M, Heikkilä E, Ferrer J. Ins1(Cre) 
knock-in mice for beta cell-specific gene recombination. Diabetologia. 
2015;58(3):558-565. 
10. Brouwers B, de Faudeur G, Osipovich AB, Goyvaerts L, Lemaire K, Boesmans L, 
Cauwelier EJ, Granvik M, Pruniau VP, Van Lommel L, Van Schoors J, Stancill 
JS, Smolders I, Goffin V, Binart N, in't Veld P, Declercq J, Magnuson MA, 
Creemers JW, Schuit F, Schraenen A. Impaired islet function in commonly used 
transgenic mouse lines due to human growth hormone minigene expression. Cell 
Metab. 2014;20(6):979-990. 
11. Baan M, Kibbe CR, Bushkofsky JR, Harris TW, Sherman DS, Davis DB. 
Transgenic expression of the human growth hormone minigene promotes 
pancreatic β-cell proliferation. Am J Physiol Regul Integr Comp Physiol. 
2015;309(7):R788-794. 
12. Oropeza D, Jouvet N, Budry L, Campbell JE, Bouyakdan K, Lacombe J, Perron 
G, Bergeron V, Neuman JC, Brar HK, Fenske RJ, Meunier C, Sczelecki S, 
Kimple ME, Drucker DJ, Screaton RA, Poitout V, Ferron M, Alquier T, Estall JL. 
  
 
195 
Phenotypic Characterization of MIP-CreERT1Lphi Mice With Transgene-Driven 
Islet Expression of Human Growth Hormone. Diabetes. 2015;64(11):3798-3807. 
13. Omikorede O, Qi C, Gorman T, Chapman P, Yu A, Smith DM, Herbert TP. ER 
stress in rodent islets of Langerhans is concomitant with obesity and β-cell 
compensation but not with β-cell dysfunction and diabetes. Nutr Diabetes. 
2013;3:e93. 
14. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Méneur C, Bernal-Mizrachi 
E. Natural history of β-cell adaptation and failure in type 2 diabetes. Mol Aspects 
Med. 2015;42:19-41. 
15. Amsterdam A, Raanan C, Polin N, Melzer E, Givol D, Schreiber L. Modulation 
of c-kit expression in pancreatic adenocarcinoma: a novel stem cell marker 
responsible for the progression of the disease. Acta Histochem. 2014;116(1):197-
203. 
16. Ahn S-H, Granger A, Rankin MM, Lam CJ, Cox AR, Kushner JA. Tamoxifen 
Suppresses Pancreatic β-Cell Proliferation in Mice. BioRxiv. 2019:586602. 
17. Carboneau BA, Le TD, Dunn JC, Gannon M. Unexpected effects of the MIP-
CreER transgene and tamoxifen on β-cell growth in C57Bl6/J male mice. Physiol 
Rep. 2016;4(18). 
18. Ceasrine AM, Ruiz-Otero N, Lin EE, Lumelsky DN, Boehm ED, Kuruvilla R. 
Tamoxifen Improves Glucose Tolerance in a Delivery-, Sex-, and Strain-
Dependent Manner in Mice. Endocrinology. 2019;160(4):782-790. 
19. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P. Estrogens protect 
against high-fat diet-induced insulin resistance and glucose intolerance in mice. 
Endocrinology. 2009;150(5):2109-2117. 
20. Winzell MS, Ahrén B. The high-fat diet-fed mouse: a model for studying 
mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. 
Diabetes. 2004;53 Suppl 3:S215-219. 
21. Reimer MK, Ahrén B. Altered beta-cell distribution of pdx-1 and GLUT-2 after a 
short-term challenge with a high-fat diet in C57BL/6J mice. Diabetes. 2002;51 
Suppl 1:S138-143. 
22. Andrikopoulos S, Massa CM, Aston-Mourney K, Funkat A, Fam BC, Hull RL, 
Kahn SE, Proietto J. Differential effect of inbred mouse strain (C57BL/6, DBA/2, 
129T2) on insulin secretory function in response to a high fat diet. J Endocrinol. 
2005;187(1):45-53. 
23. Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B. Heterogeneous 
metabolic adaptation of C57BL/6J mice to high-fat diet. Am J Physiol Endocrinol 
Metab. 2002;282(4):E834-842. 
24. Dominguez V, Raimondi C, Somanath S, Bugliani M, Loder MK, Edling CE, 
Divecha N, da Silva-Xavier G, Marselli L, Persaud SJ, Turner MD, Rutter GA, 
Marchetti P, Falasca M, Maffucci T. Class II phosphoinositide 3-kinase regulates 
exocytosis of insulin granules in pancreatic beta cells. J Biol Chem. 
2011;286(6):4216-4225. 
25. Rachdi L, El Ghazi L, Bernex F, Panthier JJ, Czernichow P, Scharfmann R. 
Expression of the receptor tyrosine kinase KIT in mature beta-cells and in the 
pancreas in development. Diabetes. 2001;50(9):2021-2028. 
  
 
196 
26. Uhles S, Moede T, Leibiger B, Berggren PO, Leibiger IB. Selective gene 
activation by spatial segregation of insulin receptor B signaling. FASEB J. 
2007;21(7):1609-1621. 
27. Muller D, Huang GC, Amiel S, Jones PM, Persaud SJ. Gene expression 
heterogeneity in human islet endocrine cells in vitro: the insulin signalling 
cascade. Diabetologia. 2007;50(6):1239-1242. 
28. Escribano O, Guillén C, Nevado C, Gómez-Hernández A, Kahn CR, Benito M. 
Beta-Cell hyperplasia induced by hepatic insulin resistance: role of a liver-
pancreas endocrine axis through insulin receptor A isoform. Diabetes. 
2009;58(4):820-828. 
29. Leibiger B, Moede T, Uhles S, Barker CJ, Creveaux M, Domin J, Berggren PO, 
Leibiger IB. Insulin-feedback via PI3K-C2alpha activated PKBalpha/Akt1 is 
required for glucose-stimulated insulin secretion. FASEB J. 2010;24(6):1824-
1837. 
30. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. 
Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-
dependent and -independent glucose-stimulated insulin secretion. Diabetes. 
2000;49(3):424-430. 
31. Skelin M, Rupnik M, Cencic A. Pancreatic beta cell lines and their applications in 
diabetes mellitus research. ALTEX. 2010;27(2):105-113. 
32. Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich 
MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and 
FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug 
Resistance. Cancer Res. 2015;75(5):880-891. 
33. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-
Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR. 
Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth 
factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. 
Mol Cancer Ther. 2010;9(10):2652-2664. 
34. Le Bacquer O, Queniat G, Gmyr V, Kerr-Conte J, Lefebvre B, Pattou F. 
mTORC1 and mTORC2 regulate insulin secretion through Akt in INS-1 cells. J 
Endocrinol. 2013;216(1):21-29. 
35. Yuan T, Rafizadeh S, Gorrepati KD, Lupse B, Oberholzer J, Maedler K, 
Ardestani A. Reciprocal regulation of mTOR complexes in pancreatic islets from 
humans with type 2 diabetes. Diabetologia. 2017;60(4):668-678. 
36. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault 
MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G. mTOR inhibition by rapamycin 
prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic 
state in type 2 diabetes. Diabetes. 2008;57(4):945-957. 
37. Ardestani A, Lupse B, Kido Y, Leibowitz G, Maedler K. mTORC1 Signaling: A 
Double-Edged Sword in Diabetic β Cells. Cell Metab. 2017. 
38. Bartolomé A, Kimura-Koyanagi M, Asahara S, Guillén C, Inoue H, Teruyama K, 
Shimizu S, Kanno A, García-Aguilar A, Koike M, Uchiyama Y, Benito M, Noda 
T, Kido Y. Pancreatic β-cell failure mediated by mTORC1 hyperactivity and 
autophagic impairment. Diabetes. 2014;63(9):2996-3008. 
  
 
197 
39. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis 
JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA. 
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and 
uncoupled from longevity. Science. 2012;335(6076):1638-1643. 
40. Li J, Quirt J, Do HQ, Lyte K, Fellows F, Goodyer CG, Wang R. Expression of c-
Kit receptor tyrosine kinase and effect on beta-cell development in the human 
fetal pancreas. Am J Physiol Endocrinol Metab. 2007;293(2):E475-483. 
41. Garcia-Ocana A, Takane KK, Reddy VT, Lopez-Talavera JC, Vasavada RC, 
Stewart AF. Adenovirus-mediated hepatocyte growth factor expression in mouse 
islets improves pancreatic islet transplant performance and reduces beta cell 
death. J Biol Chem. 2003;278(1):343-351. 
42. Lopez-Talavera JC, Garcia-Ocaña A, Sipula I, Takane KK, Cozar-Castellano I, 
Stewart AF. Hepatocyte growth factor gene therapy for pancreatic islets in 
diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-
free rat model of allogeneic portal vein islet transplantation. Endocrinology. 
2004;145(2):467-474. 
43. Fiaschi-Taesch NM, Berman DM, Sicari BM, Takane KK, Garcia-Ocaña A, 
Ricordi C, Kenyon NS, Stewart AF. Hepatocyte growth factor enhances 
engraftment and function of nonhuman primate islets. Diabetes. 
2008;57(10):2745-2754. 
44. Miao G, Mace J, Kirby M, Hopper A, Peverini R, Chinnock R, Shapiro J, Hathout 
E. In vitro and in vivo improvement of islet survival following treatment with 
nerve growth factor. Transplantation. 2006;81(4):519-524. 
45. Shimoda M, Chen S, Noguchi H, Matsumoto S, Grayburn PA. In vivo non-viral 
gene delivery of human vascular endothelial growth factor improves 
revascularisation and restoration of euglycaemia after human islet transplantation 
into mouse liver. Diabetologia. 2010;53(8):1669-1679. 
46. Cross SE, Richards SK, Clark A, Benest AV, Bates DO, Mathieson PW, Johnson 
PR, Harper SJ, Smith RM. Vascular endothelial growth factor as a survival factor 
for human islets: effect of immunosuppressive drugs. Diabetologia. 
2007;50(7):1423-1432. 
47. Staels W, Verdonck Y, Heremans Y, Leuckx G, De Groef S, Heirman C, de 
Koning E, Gysemans C, Thielemans K, Baeyens L, Heimberg H, De Leu N. 
Vegf-A mRNA transfection as a novel approach to improve mouse and human 
islet graft revascularisation. Diabetologia. 2018;61(8):1804-1810. 
48. Gebe JA, Preisinger A, Gooden MD, D'Amico LA, Vernon RB. Local, Controlled 
Release In Vivo of Vascular Endothelial Growth Factor Within a Subcutaneous 
Scaffolded Islet Implant Reduces Early Islet Necrosis and Improves Performance 
of the Graft. Cell Transplant. 2018;27(3):531-541. 
49. Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine Kinase Inhibitors and 
Diabetes: A Novel Treatment Paradigm? Trends Endocrinol Metab. 
2015;26(11):643-656. 
50. Copps KD, White MF. Regulation of insulin sensitivity by serine/threonine 
phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. 
Diabetologia. 2012;55(10):2565-2582. 
  
 
198 
51. Hançer NJ, Qiu W, Cherella C, Li Y, Copps KD, White MF. Insulin and 
metabolic stress stimulate multisite serine/threonine phosphorylation of insulin 
receptor substrate 1 and inhibit tyrosine phosphorylation. J Biol Chem. 
2014;289(18):12467-12484. 
52. Copps KD, Hancer NJ, Opare-Ado L, Qiu W, Walsh C, White MF. Irs1 serine 
307 promotes insulin sensitivity in mice. Cell Metab. 2010;11(1):84-92. 
53. Herrema H, Lee J, Zhou Y, Copps KD, White MF, Ozcan U. IRS1Ser³⁰⁷ 
phosphorylation does not mediate mTORC1-induced insulin resistance. Biochem 
Biophys Res Commun. 2014;443(2):689-693. 
54. Fritsche L, Neukamm SS, Lehmann R, Kremmer E, Hennige AM, Hunder-Gugel 
A, Schenk M, Häring HU, Schleicher ED, Weigert C. Insulin-induced serine 
phosphorylation of IRS-2 via ERK1/2 and mTOR: studies on the function of 
Ser675 and Ser907. Am J Physiol Endocrinol Metab. 2011;300(5):E824-836. 
55. Zhang J, Gao Z, Yin J, Quon MJ, Ye J. S6K directly phosphorylates IRS-1 on 
Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling 
through IKK2. J Biol Chem. 2008;283(51):35375-35382. 
56. Ueno M, Carvalheira JB, Tambascia RC, Bezerra RM, Amaral ME, Carneiro EM, 
Folli F, Franchini KG, Saad MJ. Regulation of insulin signalling by 
hyperinsulinaemia: role of IRS-1/2 serine phosphorylation and the mTOR/p70 
S6K pathway. Diabetologia. 2005;48(3):506-518. 
57. Gual P, Grémeaux T, Gonzalez T, Le Marchand-Brustel Y, Tanti JF. MAP 
kinases and mTOR mediate insulin-induced phosphorylation of insulin receptor 
substrate-1 on serine residues 307, 612 and 632. Diabetologia. 2003;46(11):1532-
1542. 
58. Andreozzi F, D'Alessandris C, Federici M, Laratta E, Del Guerra S, Del Prato S, 
Marchetti P, Lauro R, Perticone F, Sesti G. Activation of the hexosamine pathway 
leads to phosphorylation of insulin receptor substrate-1 on Ser307 and Ser612 and 
impairs the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin 
insulin biosynthetic pathway in RIN pancreatic beta-cells. Endocrinology. 
2004;145(6):2845-2857. 
59. Cheng KK, Lam KS, Wu D, Wang Y, Sweeney G, Hoo RL, Zhang J, Xu A. 
APPL1 potentiates insulin secretion in pancreatic β cells by enhancing protein 
kinase Akt-dependent expression of SNARE proteins in mice. Proc Natl Acad Sci 
U S A. 2012;109(23):8919-8924. 
60. Do OH, Low JT, Gaisano HY, Thorn P. The secretory deficit in islets from db/db 
mice is mainly due to a loss of responding beta cells. Diabetologia. 
2014;57(7):1400-1409. 
61. Torrejón-Escribano B, Escoriza J, Montanya E, Blasi J. Glucose-dependent 
changes in SNARE protein levels in pancreatic β-cells. Endocrinology. 
2011;152(4):1290-1299. 
62. Kaneko K, Ueki K, Takahashi N, Hashimoto S, Okamoto M, Awazawa M, 
Okazaki Y, Ohsugi M, Inabe K, Umehara T, Yoshida M, Kakei M, Kitamura T, 
Luo J, Kulkarni RN, Kahn CR, Kasai H, Cantley LC, Kadowaki T. Class IA 
phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by 
multiple mechanisms. Cell Metab. 2010;12(6):619-632. 
  
 
199 
63. Fox JE, Seeberger K, Dai XQ, Lyon J, Spigelman AF, Kolic J, Hajmrle C, Joseph 
JW, Kin T, Shapiro AM, Korbutt G, MacDonald PE. Functional plasticity of the 
human infant β-cell exocytotic phenotype. Endocrinology. 2013;154(4):1392-
1399. 
  
  
 
200 
Appendices  
Appendix A: 2017 Animal Use Protocol (AUP) 
  
 
 
 
AUP Number: 2017-007 
PI Name: Wang, Rennian 
AUP Title: Pancreatic Beta Cell Development: The Role Of The C-kit And Integrin 
Receptors 
 
Approval Date: 01/16/2017 
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use 
Protocol (AUP) entitled "Pancreatic Beta Cell Development: The Role Of The C-kit And 
Integrin Receptors 
" has been APPROVED by the Animal Use Subcommittee of the University Council on 
Animal Care. This approval, although valid for four years, and is subject to annual 
Protocol Renewal.2017-007::1 
1. This AUP number must be indicated when ordering animals for this project. 
2. Animals for other projects may not be ordered under this AUP number. 
3. Purchases of animals other than through this system must be cleared through 
the ACVS office. Health certificates will be required. 
The holder of this Animal Use Protocol is responsible to ensure that all associated safety 
components (biosafety, radiation safety, general laboratory safety) comply with 
institutional safety standards and have received all necessary approvals. Please consult 
directly with your institutional safety officers. 
 
 
 
 
 
Submitted by: Copeman, Laura  
on behalf of the Animal Use Subcommittee 
University Council on Animal Care 
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Appendix B: Biosafety Approval Form 
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Appendix C: Confirmation of c-Kit and IR expression in the INS-1 832/13 cell line 
 
 
 
 
 
 
 
 
 
INS-1 832/13 cells were probed with rabbit anti-c-Kit (1:100, Santa Cruz Biotechnology) 
and rabbit anti-insulin receptor (1:50, Santa Cruz) antibodies (green) to confirm receptor 
expression within the cell line. Nuclei were counterstained with DAPI (blue). Scale bar, 
10 m. Staining was performed by R.Wang and J. Li. 
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Appendix D: License for Chapter 1 
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